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Over the last century, the United States has experienced a shift from 
underweight malnutrition maladies to obesity-associated complications. Today, over 
70% of US adults are overweight and are at increased risk for various chronic diseases 
including diabetes, cardiovascular disease and cancer. The ubiquitous nature of obesity 
and its costs on the individual and societal level have elevated it to one of the most 
impactful diseases of the 21st century. The adipokine leptin is produced in proportion to 
the body’s triglyceride content and binds to its receptor (LepRb) in the CNS to provide a 
snapshot of energy stores, resulting in the regulation of energy balance. Due to leptin’s 
role in communicating fat stores and the hyperphagic obesity that results from its 
absence, leptin is clearly central to the homeostatic systems that regulate energy 
balance. And, while leptin replacement is an effective anti-obesity treatment in the few 
cases of obesity from leptin-deficiency, it fails to produce weight loss in diet-induced 
obese (DIO) individuals who express high levels of leptin (hyperleptinemia) 
commensurate with their elevated adipose content. Despite this, recent advances in 
genetic and sequencing technologies have allowed for a closer examination of DIO. 
xi 
	
We first examined the hypothalamic transcriptome of LepRb neurons and 
characterized DIO as a state of leptin activity. Additional region-specific analyses 
confirm this understanding of DIO, and when coupled to immunohistochemical and 
phenotypic findings, broaden our understanding of the role DIO-hyperleptinemia plays in 
LepRb neurons and neighboring glial cells. These transcriptome findings additionally 
revealed STAT1 to be not only another LepRb-dependent signal, but to also significantly 
increase when STAT3 was ablated in neurons. This increase in Stat1, however, did not 
functionally compensate for the absence of STAT3. Moreover, we found STAT3 to be 
both necessary and sufficient in LepRb neurons for energy balance. However, while 
increased STAT3 activity does decrease weight in normoleptinemic mice (mimicking 
hyperleptinemia in lean animals) it does not produce weight loss in already 
hyperleptinemic DIO animals. Thus, the diminishing returns of additional STAT3/leptin 
action with increasing endogenous leptin levels were demonstrated transcriptionally, 
phenotypically and genetically. Our further investigation into the overlap between leptin 
and other metabolic hormones like calcitonin and amylin has broadened our 
understanding of leptin action and has identified potential molecular targets and 
locations for the already-proven synergistic amylin-leptin weight loss therapy. Together, 
these varied approaches underscore the complexity and importance of leptin action and 













Chapter Summary   
Obesity represents the single most important risk factor for early disability and death in 
developed societies, and the incidence of obesity remains at staggering levels.  CNS 
systems that modulate energy intake and expenditure in response to changes in body 
energy stores serve to maintain constant body adiposity; the adipocyte-derived 
hormone, leptin, represents a crucial regulator of these systems.  A variety of 
mechanisms (including feedback inhibition, inflammation, gliosis, and ER stress) have 
been proposed to impede the systems that control body energy homeostasis to promote 
or maintain obesity, although the relative importance and contribution of each of these 
remain unclear.  Here, we review the state of the field regarding these processes and 
synthesize a framework for understanding potential mechanisms that may lead to or 





Obesity, generally defined by a body mass index (BMI) ≥30kg/m2, results from 
the accumulation of adiposity due to the storage of consumed calories that exceed 
metabolic needs.  While obesity has always existed in humans, malnutrition and 
disease dictated that even developed countries struggled primarily with the problem of 
underweight (BMI < 18.5 kg/m2) (rather than obesity) up through the late 19th and early 
20th centuries.1 The increasing production and availability of inexpensive high-calorie 
foods, coupled with the move from an agrarian society to a more sedentary working 
environment resulted in a steady rise in BMI over the 20th century, with an obesity 
prevalence of 15 percent in the United States by 1970.1  Over the subsequent decades, 
obesity has exploded in incidence and impact: Today, 70% of the US adult population is 
overweight (BMI >25kg/m2) and 37.7% is obese.1  
This obesity epidemic has far-reaching consequences in health, medical care 
and economics. Obese individuals are more likely to develop chronic diseases like 
diabetes, cardiovascular disease and cancer; indeed, obese individuals have a shorter 
life expectancy and incur $2741 higher annual healthcare costs than normal-weight 
individuals.2 On the societal level, obesity-related illnesses account for 20.6% of all US 
national health expenditures.2  
Any change in adipose mass must reflect an imbalance between the intake (by 
feeding) and expenditure (on a combination of overall metabolic rate and voluntary 
locomotion) of energy.3  Individuals (even if weight-stable and within the normal BMI 




furthermore, for each individual, each of these parameters also varies on a daily basis.  
Despite these differences, most people maintain relatively stable body weight and 
adiposity over the long term as a consequence of homeostatic systems that serve to 
counter fluctuations in energy consumption and expenditure.  When energy stores (i.e., 
adipose mass) decrease, hunger increases and energy expenditure decreases due to 
the activation of an anabolic system that tends to increase energy stores to previous 
levels. This anabolic pathway works in opposition to a catabolic pathway that decreases 
hunger and augments energy utilization in response to increased energy stores.  
Together, these two pathways compose a homeostatic system that opposes energy 
surpluses or deficits, thus maintaining stable body energy (adipose) stores over the long 
term.3 
While the control of energy expenditure is tightly coupled to adiposity in most 
instances, food intake more commonly becomes uncoupled from its appropriate control 
by energy stores.  Thus, although individuals with very low adiposity due to anorexia 
nervosa demonstrate appropriately decreased energy expenditure compared to normal-
weight people, they restrain food intake and resist gaining weight into the normal 
range.4  More commonly, most obese individuals demonstrate increased basal 
metabolic rate compared to lean controls, but fail to suppress food intake to restore 
energy stores to within the normal range.3  Indeed, even modest weight loss in obese 
individuals (to adiposity levels well above the norm) promotes the anabolic response 
(increasing hunger and decreasing energy expenditure) in a manner similar to that 
observed with weight loss in normal weight subjects.5 Hence, this response opposes the 




who lose weight by dieting and exercise tend to regain the weight within a relatively 
short time, as recently highlighted for former contestants on The Biggest Loser 
television show.6 
Thus, we require therapies that can countermand the anabolic response to 
weight loss to help patients lose weight and sustain weight loss.  The development of 
such drugs will likely require an understanding of the systems that control energy 
balance and how they may be dysregulated in obesity.   
II. MONOGENIC OBESITY SYNDROMES REVEAL CRUCIAL PLAYERS IN ENERGY 
BALANCE 
Over the past 25 years, the elucidation of the molecular basis for some 
monogenic obesity syndromes in both human patients and rodent models has begun to 
define the systems that control energy homeostasis.7  These findings have generally 
revealed the importance of specialized central nervous system (CNS) neurons for the 
control of food intake, energy expenditure, and overall body energy balance. 
Importantly, the finding that similar genetic systems mediate energy homeostasis in 
humans and rodents reveals the conservation of these systems across mammals and 
suggests the utility of rodent models for understanding the human systems that 
participate in the control of feeding.   
A. The Melanocortin System.   
The elucidation of the molecular basis for the agouti (Ay) autosomal dominant 
obesity phenotype revealed the importance of the hypothalamic melanocortin system in 




body in Ay mice, binds to and antagonizes melanocortin (MC) receptors, a class of 
guanine nucleotide binding protein (G protein)-coupled receptors that are activated by 
ligands derived from proopiomelanocortin (POMC).8 Of the five MC receptors, MC3R 
and MC4R are primarily expressed in the hypothalamus, suggesting a role for these 
receptors in the control of body weight.8 Indeed, mice null for MC4R demonstrate 
severe, early-onset, hyperphagic obesity.9 MC3R-null mice develop late-onset obesity 
with a more modest 50% increase in fat mass 10; mice null for both MC3R and MC4R 
are significantly heavier than mice with either mutation alone, suggesting that MC4R 
and MC3R each play independent roles in the regulation of energy balance.10 
POMC-producing neurons of the hypothalamic arcuate (ARC) nucleus produce 
the ligand for these hypothalamic MCRs11; these project widely to CNS MC3R- and 
MC4R-containing neurons, but MC4R in the hypothalamic paraventricular nucleus 
(PVN) plays a particularly crucial role in the control of food intake.11 
As in mice, humans with mutations in POMC or MC4R demonstrate severe early-
onset obesity.7 Indeed, coding mutations in MC4R represent the leading cause of 
monogenic obesity in humans: MC4R deficiency is estimated to be responsible for 5.8% 
of obesity in children, who display severe early-onset hyperphagic obesity, enhanced 
linear growth, and increased lean mass and bone mineral density.12 The similarity of the 
melanocortin deficiency syndromes between humans and mice demonstrates the 
conserved role for this system in the control of feeding and overall energy balance. 
B. Leptin plays essential roles in homeostatic systems that control energy 




The 1949 discovery of the autosomal recessive obese (ob) allele in mice (ob/ob 
mice are hyperphagic, obese, diabetic and sterile) revealed the existence of a gene 
crucial for the control of feeding, metabolism, and body weight.13 Positional cloning of 
the ob allele in 1994 revealed the presence of a nonsense mutation in the coding region 
for a peptide hormone (termed, “leptin”) that is secreted by adipocytes.14  Adipocytes 
produce leptin in approximate proportion to their triglyceride stores; leptin thus 
represents a hormonal signal that circulates in proportion to body energy stores (Figure 
1.1).15 
Like ob/ob mice, rare humans lacking leptin due to genetic mutations display 
hyperphagic obesity, depressed energy expenditure and hyperinsulinemia.16  
Exogenous leptin decreases food intake, increases energy expenditure, and normalizes 
body weight in leptin-deficiency.16 
The diabetic (db/db) mouse, which is phenotypically similar to the ob/ob mouse 
but arises from a different genetic locus is due to a splicing mutation that truncates the 
long isoform of the leptin receptor (LepRb).17 LepRb is most highly expressed in 
hypothalamic nuclei known to be important for the control of feeding and energy 
expenditure (Figure 1.1).18 
The hyperphagia and low energy expenditure exhibited by ob/ob and db/db mice, 
together with the ability of exogenous leptin to ameliorate these defects in ob/ob mice, 
suggest the importance of leptin as a regulator of energy balance.18 Leptin and LepRb-
deficient animal models and humans display other defects (high glucocorticoid levels, 
hypothalamic infertility, and decreased growth, thyroid, and immune function) that speak 




action mimics the response to starvation, suggesting that the withdrawal of leptin action 
plays a crucial role in the anabolic response to decreased fat stores.19  Consistently, 
exogenous leptin not only ameliorates these defects in leptin deficiency, but also blunts 
these responses to nutritional deficiency in humans and rodent models.19  Furthermore, 
exogenous leptin blunts many of the metabolic and neuroendocrine defects (hunger, 
high lipids, diabetes, and infertility) in humans and mice with lipodystrophy syndromes 
(which cause low body fat and thus very low leptin).20 Thus, leptin plays a crucial role in 
modulating the pathways that maintain energy homeostasis, and low leptin represents a 
powerful signal to promote the anabolic response to negative energy balance .19 
C. Molecular and neural mediators of leptin action.   
LepRb is a type I cytokine receptor, which signals via an associated tyrosine 
kinase, Janus kinase 2 (JAK2).18,21 Leptin binding to LepRb activates JAK2, which 
phosphorylates three conserved tyrosine residues (Tyr985, Tyr1077, and Tyr1138) on the 
LepRb intracellular domain (Figure 1.2).21 When phosphorylated, each of these tyrosine 
residues recruits distinct downstream signaling proteins: Tyr985 binds to SHP2 and 
SOCS3 to mediate ERK signaling and feedback inhibition of LepRb signaling, 
respectively.21 Tyr1077 recruits the signal transducer and activator of transcription (STAT) 
5, while Tyr1138 recruits STAT3; these STAT proteins represent latent transcription 
factors that become tyrosine phosphorylated upon their recruitment to the receptor, 
permitting their nuclear translocation and modulation of gene expression.21 
Not only does the tyrosine phosphorylation of STAT3 (pSTAT3) during leptin 
action provide a convenient and sensitive histochemical marker for the activation of 




lacking STAT3 in LepRb neurons display a dramatic hyperphagic obese phenotype22,23; 
this phenotype is not identical to that of ob/ob or db/db mice, however, suggesting that 
additional physiologically-important leptin/LepRb signals must exist.  Mutational analysis 
reveals that Tyr985 and Tyr1077 (and their binding partners) do not mediate such a signal, 
however, suggesting that there must exist another signal, independent of LepRb 
tyrosine phosphorylation, by which LepRb controls energy balance.24  Leptin also 
controls phosphatidylinositol 3’-kinase (PI 3-kinase), and it is possible that the currently 
undefined LepRb moiety that recruits the putative SH2B-insulin receptor substrate-PI 3-
kinase pathway could represent the missing LepRb signal.25 
Most leptin-responsive (i.e., LepRb-expressing) neurons lie in hypothalamic 
nuclei that have known roles in the control of energy balance, and hypothalamic LepRb 
is required for the control of energy homeostasis by leptin18; the midbrain and hindbrain 
also contain some substantial populations of LepRb neurons, however (Figure 1.3).  Of 
the populations of LepRb neurons, those of the ARC (which lies adjacent to the median 
eminence (ME), a circumventricular organ with fenestrated capillaries that permit the 
passage of circulating factors, like leptin) are best known.  Many ARC LepRb neurons 
express the MC precursor, POMC.11 Others express agouti-related protein (AgRP), the 
endogenous antagonist to CNS MCRs, along with the inhibitory neuropeptide Y (NPY) 
and the inhibitory neurotransmitter GABA.26 POMC neurons decrease food intake and 
increase energy expenditure, while the so-called “NAG” (NPY, AgRP and GABA) 
neurons act oppositely.18 Not surprisingly, leptin plays crucial roles in modulating the 
function of POMC and NAG neurons, increasing the activity of POMC neurons and the 




orexigenic peptides (e.g., neuropeptide Y (NPY)).18 Interestingly, however, deletion of 
LepRb from POMC and/or NAG neurons only modestly alters food intake and body 
weight,27 and leptin mediates a substantial component of its control on POMC and NAG 
neurons indirectly, including via non-POMC/non-NAG LepRb neurons elsewhere in the 
hypothalamus.28–30 Furthermore, recent single-cell sequencing analysis of ARC cells 
reveals the existence of additional, non-POMC, non-NAG ARC LepRb neurons of 
unknown functional relevance.26  
III. Common obesity and the notion of leptin resistance 
In contrast to the monogenetic rodent models of obesity, above, most obesity in 
humans does not result from a single genetic lesion, but rather appears to represent a 
common response to the availability of inexpensive, plentiful, tasty calories and the 
sedentary nature of modern society.1  Furthermore, most obese humans, as well as 
“diet-induced obese” (DIO) rodents made obese by the provision of palatable, high-
calorie diet (HCD), exhibit high circulating leptin concentrations, commensurate with 
their elevated adiposity.15  This observation, coupled with the failure of treatment with 
exogenous leptin to decrease food intake and provoke weight loss in obese humans 
and DIO animals,31 has led to the promulgation of the notion of “leptin resistance” 
(Figure 1.4).  Classical hormone resistance syndromes result from impaired receptor 
signaling stemming from genetic lesions, circulating antagonists (e.g., anti-receptor 
antibodies), or uncoupling of the receptor from its intracellular signaling system (as in 
the case of most insulin resistance, which also accompanies obesity).32  Since there is 




humans, any failure of leptin signaling presumably derives from the uncoupling of 
LepRb from its intracellular signaling mediators (as in insulin resistance).   
Due to the relatively low expression of LepRb on relatively few neurons, the 
detection and quantification of most LepRb signals in vivo remains problematic.  The 
detection of pSTAT3 represents a notable exception to this rule; most, if not all, 
hypothalamic pSTAT3 results from direct leptin action via LepRb.21 Thus, given the 
importance of STAT3 signaling to leptin action and the relatively facile detection of 
leptin-stimulated pSTAT3 in vivo, most studies treat pSTAT3 detection as tantamount to 
the detection of LepRb intracellular signaling.  Importantly, high-dose exogenous leptin 
not only fails to decrease food intake and body weight in obese humans and DIO 
animals,31 but also poorly increases hypothalamic pSTAT3,33 potentially consistent with 
an uncoupling of LepRb from its intracellular signaling cascade in common obesity. 
Since pSTAT3 may be detected immunohistochemically, as well as by 
immunoblot, it is possible to examine the detailed anatomic distribution of leptin-
stimulated pSTAT3 throughout the hypothalamus.  Studies in lean mice reveal that 
exogenous leptin stimulates pSTAT3 in the ARC before it does in deeper CNS 
structures.  The pSTAT3 response to exogenous leptin in DIO animals is most impaired 
in the ARC.33  Hence, many consider the ARC to be the major site affected by leptin 
resistance.   
A. Negative regulators of leptin/LepRb signaling 
Many potential mechanisms have been proposed to explain the limited response 




LepRb signaling (Figure 1.2).  During leptin/LepRb signaling, pSTAT3 translocates into 
the nucleus to modulate the expression of target genes, including the suppressor of 
cytokine signaling 3 (Socs3).34,35 SOCS3 binds to JAK2 and to phosphorylated Tyr985 on 
LepRb, thereby inhibiting JAK2 activity and LepRb signaling.36 Consequently, mice 
mutated for LepRb Tyr985 or ablated for Socs3 in the brain exhibit increased leptin-
stimulated pSTAT3 and anorectic signaling by leptin, resulting in a mildly lean 
phenotype in chow-fed mice.37,38  While mutation of LepRb Tyr985 or CNS ablation of 
Socs3 tends to decrease body weight, these animals still gain substantial weight on 
high-fat diet.  Furthermore, for reasons that are unclear, overexpression of Socs3 in 
LepRb neurons results in a lean phenotype.39  Thus, while Socs3 limits the maximum 
amplitude of leptin action and interference with Socs3 function decreases body weight, 
increased Socs3 expression cannot explain leptin resistance.  
The action of protein tyrosine phosphatases (PTPases) also limits leptin signaling 
by dephosphorylating LepRb, JAK2, and STAT3.40  In particular, PTP1B 
dephosphorylates and deactivates JAK2 to suppress leptin/LepRb signaling in vitro, and 
mice null for Ptpn1 (which encodes PTP1B) exhibit exaggerated responsiveness to 
leptin.40  Furthermore, as for Socs3, HCD increases the expression of Ptpn1 in the 
ARC, suggesting that PTP1B might play a role in the leptin resistance observed in 
DIO.41  Indeed, mice lacking Ptpn1 in the brain, like whole-body null animals, are lean 
and gain less weight than controls on high-fat diet (HFD).42  These mice still gain a 
substantial amount of weight on HFD,42 however, suggesting that increased PTP1B 




In addition to PTP1B, the tyrosine phosphatase, TCPTP, which directly 
dephosphorylates STAT3, contributes to the attenuation of LepRb signaling.  
Furthermore, obesity and elevated leptin increase the expression of Ptpn2 (which 
encodes TCPTP), and the deletion of neuronal Ptpn2 decreases body weight, increases 
leptin sensitivity, and blunts weight gain in DIO animals.43  Moreover, the combined 
deletion of Ptpn1 and Ptpn2 in the brain augments leanness and further attenuates 
weight gain in DIO mice.43 However, these mice still gain a substantial amount of weight 
on high-calorie diet.43 
The finding that high-calorie diet increases body weight and adiposity in mice 
lacking Socs3 or Ptpn1 and Ptpn2 in the brain suggest that none of these mediators of 
LepRb signal attenuation suffice to explain leptin resistance.38,42,43 Furthermore, leptin 
itself promotes the expression of Socs3 and Ptpn2,21,43 suggesting that the increased 
expression of these genes in obese animals reflects an increase in LepRb signaling 
(presumably in response to the increased circulating leptin that accompanies increased 
adiposity), rather than any reduction in LepRb signaling.  Thus, while the action of these 
LepRb signaling inhibitors may limit the maximal signaling response to high levels of 
leptin, they cannot diminish the LepRb signaling response to elevated endogenous 
leptin in DIO to below the level of signaling observed in response to endogenous leptin 
in lean mice.  Hence, it is difficult to propose that these attenuators of LepRb signaling 
cause obesity by decreasing overall leptin action; they may limit the ability of elevated 
leptin to reduce adiposity in obese mice, however, by attenuating the increase in LepRb 
signaling that would otherwise be observed in response to elevated leptin levels in the 




IV. Other processes that may interfere with leptin action and/or energy balance 
In addition to the systems that directly inhibit LepRb signaling, a variety of 
hypothalamic responses to high-fat feeding/DIO have been proposed to limit 
leptin/LepRb action. These include hypothalamic inflammation (including the activation 
of “proinflammatory” cellular signaling pathways and the production of cytokines), 
inflammatory-appearing alterations in glia surrounding ARC LepRb neurons, and 
alterations of endoplasmic reticulum (ER) and/or oxidative stress in LepRb neurons.   
A. Hypothalamic inflammation 
DIO is associated with a state of low grade inflammation (so-called “metabolic 
inflammation”) in peripheral tissues (such as adipose tissue), including the production 
and secretion of pro-inflammatory cytokines, such as tumor necrosis factor alpha 
(TNFa) and interferons (IFNs), and by the recruitment and activation of immune cells 
including macrophages and various subtypes of T cells.44 It makes teleologic sense that 
this metabolic inflammation might cause insulin resistance, since pathological 
inflammatory insults (such as infection) interfere with insulin action, and a variety of data 
support the notion that inflammatory cytokines and cellular signals associated with 
inflammation play roles in metabolic dysfunction in obesity.44  
As in peripheral tissues, exposure to high-calorie diet and the onset of positive 
energy balance promotes the expression of inflammatory cytokines in the 
hypothalamus.45  DIO has also been reported to activate intracellular signaling 
cascades associated with inflammation within the hypothalamus, including the NFkB 
pathway (which promotes cytokine expression), c-Jun Kinases (JNKs) and protein 




Thus, DIO-associated hypothalamic inflammatory signaling might play a role in 
promoting positive energy balance and/or attenuating leptin action (much as it is 
proposed to promote peripheral insulin resistance).  Indeed, intracerebroventricular 
(ICV) TNF-alpha promotes food intake, decreases energy expenditure and increases 
body weight.48 Furthermore, anti-TNF-alpha antibody treatment reduces weight gain 
during HFD feeding and mice without TNFR1 are resistant to DIO.49  Also, viral 
approaches that block NFkB signaling throughout the hypothalamus reduce food intake 
and body weight.46 Similarly, deletion of JNK throughout the brain blunts DIO, while the 
constitutive activation of JNK in NAG neurons results in hyperphagic obesity.50,51 And, 
ARC-specific knockdown of PKCθ attenuates DIO.47 
In contrast, however, the genetic activation of NFkB in hypothalamic neurons in 
mice does not increase hypothalamic cytokine levels, and mice null for IKKb in the 
arcuate nucleus (the inhibitor of NFkB signaling) are not obese or hyperphagic.52,53 
Thus, while the complete ablation of the NFkB pathway in the hypothalamus produces 
weight loss, the activation of this pathway is not sufficient to promote obesity.   
Further confusing the picture of how inflammatory hypothalamic signals impact 
energy balance is the role many cytokines (e.g., IL-4, IL-6) play in the brain to reduce 
food intake.54,55  Moreover, genetic and pharmacological interventions that block various 
inflammatory cytokine signals and proinflammatory signals result in increased 
susceptibility to DIO.56 Indeed, systemic inflammation (e.g., infection or cancer) 
promotes cachexia, a state of negative energy balance characterized by decreased 




Thus, strong inflammatory stimuli in the hypothalamus can decrease food intake, 
increase energy expenditure, and decrease body weight.  Conversely, manipulations of 
some cytokines and/or cellular signaling pathways involved in the response to 
inflammation suggest an anabolic role for such pathways.  Multiple mechanisms could 
underlie this apparent contradiction—including that milder inflammatory stimuli 
(associated with chronic, low-grade cytokine production and inflammatory signaling 
pathway activation) could act oppositely to stronger signals.  It is also possible that 
certain cytokines or signaling pathways promote anabolic responses, while others 
promote catabolic responses.  However, many cytokines can be both proinflammatory 
and anti-inflammatory depending on the source, target and other aspects of the immune 
response.58 It is then perhaps unsurprising that work studying different cytokines, 
concentrations, sources, targets, and backgrounds have resulted in inconsistent 
findings. 
Also, cytokines in the CNS regularly participate in normal physiological 
processes that regulate energy balance.59  Similarly, it is possible that some 
manipulations of the various signaling pathways that are activated by inflammatory 
stimuli (e.g., NFkB, JNKs, PKCθ) interfere with the roles that these signals play in 
normal cellular physiology at baseline, rather than in the response to inflammation.  
Additionally, many of the manipulations undertaken to examine the function of 
inflammatory signals within the hypothalamus do not target particular cell types, but 
rather affect multiple types of neurons, and in some cases non-neuronal cells (e.g., 




each cytokine and signaling pathway that may participate in the hypothalamic control of 
energy balance.   
B. Hypothalamic gliosis 
In addition to the observed induction of cytokine expression in the hypothalamus 
with DIO, the onset of obesity also increases the number and histologic activation state 
of microglia (the resident macrophage-like cells of the brain) in the ARC.45,60 While it is 
possible that these microglia represent the source of the increased cytokine expression 
observed in the hypothalamus of DIO animals: the proliferation and histological 
activation of ARC microglia with DIO requires the production of fractalkine (CXCL1) by 
neurons.61  It is not clear whether neurons produce the other cytokines that have been 
observed in DIO hypothalami, as well.   
Increased numbers of activated-appearing astrocytes (increased size and 
reactive morphology) in the ARC accompany the microgliosis observed in DIO (Figure 
1.4); these glial changes are observed in humans, as well as rodents.45,53  The 
microgliosis and astrocytosis observed in the ARC of DIO animals might play a role in 
hypothalamic inflammation or otherwise limit the function of hypothalamic neurons 
involved in energy balance (e.g., LepRb neurons).  Alternative interpretations exist, 
however: Microglia play important physiologic roles in remodeling neurological 
circuits/synaptic pruning and otherwise modulating neurons.62  Similarly, reactive 
astrocytes play key roles in maintaining synaptic plasticity and supplying neurons with 
nutrients.63  Thus, the gliosis observed in DIO could mediate changes in synaptic 
function and plasticity during DIO (and/or with chronic leptin administration), and could 




the macrophage and immune cell infiltration into adipose tissue in obese animals were 
initially hypothesized to represent a pathophysiologic process tied to insulin resistance, 
a variety of data now suggest the importance of these cells for adipocyte remodeling to 
maintain metabolic homeostasis during positive energy balance.64 
C. Endoplasmic reticulum stress 
Concomitant with the increased cytokine production, activation of inflammatory 
signals, and immune infiltration observed in adipose and other peripheral tissues in DIO 
mice, endoplasmic reticulum (ER) stress is also increased in these tissues.  Similarly, a 
variety of observations suggest that hypothalamic neurons experience ER stress during 
DIO.65 ER stress occurs when protein or lipid synthesis in the ER outstrips the ability of 
the organelle to complete the processing and export of fully functional molecules.  This 
can occur due to environmental (e.g., heat, infection) or other alterations associated 
with increased misfolding of proteins, or due to elevated rates of synthesis that augment 
demand on the ER. The misfolding of proteins in the ER activates the unfolded protein 
response (UPR) by activating IRE1 and the IRE1-dependent transcription factor, X-box 
binding protein 1 (XBP1); these limit protein synthesis and increase the expression of 
proteins (such as heat shock proteins) that enhance the protein folding capacity of the 
ER.66 The failure of cells to mitigate ER stress effectively can impair cellular function 
and even induce apoptosis.66,67 
Consistent with a potential role for hypothalamic ER stress in obesity, 
pharmacologic induction of ER stress in the brain promotes obesity, and mice that lack 
XBP1 in nestin+ neurons experience increased neuronal ER stress, dramatic 




that decrease ER stress or constitutive expression of XBP1 in POMC neurons protects 
against DIO.65,68 Furthermore, two compounds identified in a transcriptional screen to 
discover molecules that diminish ER stress decrease feeding and promote weight loss 
in DIO animals.69,70  Thus, a variety of data are consistent with the notion that 
decreasing ER stress in the hypothalamus promotes the activity of the catabolic arm of 
the energy balance system, potentially by augmenting leptin action. 
D. Potential roles for reactive oxygen species in energy balance 
Given the immense energetic needs of neurons for maintaining membrane 
potential and supporting neurotransmitter synthesis and release (the brain accounts for 
2% of body weight but uses 20% of the oxygen and calories consumed by the body), it 
is not surprising that neurons contain a large number of mitochondria and that their 
status plays a crucial role in neuronal function.  The increased mitochondrial activity that 
accompanies increased neuronal activity not only produces ATP, but also increases the 
production of reactive oxygen species (ROS). In addition to hypothetical roles for ROS-
induced oxidative stress in the activation of inflammatory pathways and/or gliosis, a 
variety of data suggest important regulatory roles for ROS in circuits that control energy 
balance.71  ROS promotes the activity of POMC neurons, while decreasing the activity 
of NAG neurons.71,72  Importantly, ARC ROS production may be diminished by the 
increased number of peroxisomes in POMC and NAG neurons during DIO, potentially 
limiting the activity of POMC cells and augmenting the activity of NAG neurons.72 





Processes that are altered in the hypothalamus (especially the ARC) during DIO 
include the production of inhibitors (SOCS3, PTP1B, TCPTP) relatively selective for 
LepRb signaling, the activation of signaling pathways associated with inflammatory 
stimuli (e.g., NFkB) and the production of pro-inflammatory cytokines (such as TNFa).  
ARC gliosis (microglia and astrocytes) and ER stress are also observed, along with 
peroxisome proliferation and the decreased production of ROS.  What process or 
processes might underlie these changes?   
One mechanism that has received a great deal of attention is the influx of lipids, 
especially those that contain saturated fatty acids (SFAs) during HFD feeding.  SFAs 
have been shown to increase inflammatory signaling pathways and increase cytokine 
production, as well as activate JNKs and PKCθ.47,60,73–75 In contrast, however, 
unsaturated fatty acids lower inflammation.60,76 Moreover, while free fatty acid levels do 
rise in obesity, they are more elevated after fasting, which sensitizes the hypothalamus 
to exogenous leptin.15,19  Furthermore, brain-specific deletion of lipoprotein lipase 
decreases FA uptake into the brain and increases food intake and body weight, 
consistent with the notion that FAs in the brain mediate anorectic signaling.77 
Some studies also suggest a potential role for the gut microbiome, which is 
altered by HFD and obesity, in the genesis and/or maintenance of obesity.78  It is 
theoretically possible that the amount or type of circulating endotoxin might be elevated 
during HFD feeding and/or obesity, and that this could augment inflammatory signaling 
and cytokine production systemically and in the hypothalamus.  To date, the observed 
changes in food intake and body weight with manipulations of the microbiome have 




Hyperleptinemia and endogenous leptin signaling 
With the exception of rare cases of leptin deficiency, obese patients and most 
animal models of obesity exhibit appropriately elevated circulating leptin for their 
adipose mass.15  Their failure to mount a catabolic response to this elevated 
endogenous leptin represents one line of evidence in favor of leptin resistance.15  
Treatment of DIO mice with a leptin/LepRb antagonist increases food intake and body 
weight, demonstrating that leptin action continues to restrain food intake and body 
weight in obesity, however.80 Furthermore, DIO animals and most models of obesity 
(except for animals mutant for leptin, LepRb, or STAT3) actually exhibit elevated 
pSTAT3 at baseline (especially in the ARC), 33 suggesting that LepRbàSTAT3 
signaling is augmented as expected in response to the increased endogenous leptin 
(Figure 1.4). Thus, endogenous leptin appropriately accesses hypothalamic LepRb and 
activates pSTAT3 in obesity, suggesting that obesity does not result from decreased 
leptin/LepRb signaling.  (Note that this also argues against a causative role for defective 
leptin transport in obesity).  Thus, obesity occurs not because of decreased 
leptin/LepRb signaling, but rather in spite of increased leptin/LepRb signaling.   
It is therefore possible that increased leptin/LepRb signaling could underlie some 
of the hypothalamic changes associated with obesity.  For instance, leptin is a cytokine 
of the IL-6 superfamily (and LepRb is a member of the IL-6R superfamily), and leptin 
increases inflammatory immune function (Figure 1.1).21,81 Hence, increased 
leptin/LepRb signaling in the hypothalamus might promote local cytokine production, 
secondarily increasing inflammatory signaling pathways in local cells.  Such a 




Since most data suggest that LepRb is not expressed by microglia and astrocytes,82 this 
would imply that leptin-induced changes in LepRb neurons would elaborate signals to 
neighboring glia.  Consistent with this notion, the proliferation and histological activation 
of ARC microglia with DIO requires the production of fractalkine (CXCL1) by non-
microglial cells.61  
Similarly, increased leptin/LepRb signaling could augment hypothalamic ER 
stress in obesity as the result of increased demand for the production of anorexigenic 
peptides (e.g., by POMC neurons and/or other LepRb-expressing cells).83,84  Indeed, 
fasting (which increases the production of AgRP and NPY and augments the activity of 
NAG neurons) produces a cell-autonomous transcriptional signature consistent with ER 
stress in these cells.85  
Thus, while this hypothesis requires extensive testing, many of the hypothalamic 
perturbations observed in DIO are consistent with the theoretical consequences of 
increased LepRb signaling due to elevated leptin levels.  If this is the case, how, then do 
we explain the modest anorectic and pSTAT3 responses to exogenous leptin in DIO 
and other obese models, and how do we explain the persistence of obesity in the face 
of hyperleptinemia?   
In addition to the changes (inflammatory cytokines/signals, gliosis, ER stress, 
etc.) noted above, leptin/LepRb signaling increases the expression of Socs3 and Ptpn2, 
which increase feedback inhibition on LepRb; PTP1B is also reportedly increased with 
DIO.  These inhibitors (potentially in concert with other processes), while unable to 




animals with normal leptin levels, could nonetheless limit the maximal amplitude of 
leptin signaling so that further increases in pSTAT3 and leptin-mediated anorexia are 
effectively blunted.   
This model thus proposes that elevated leptin limits the magnitude of the 
signaling and catabolic responses to further increases in leptin concentrations.  Indeed, 
Knight et al. demonstrated that DIO mice whose leptin levels were clamped to those 
observed in lean animals responded normally to exogenous leptin- exhibiting both an 
appropriately robust acute induction of pSTAT3 and decreased food intake and body 
weight, consistent with the notion that chronically elevated leptin concentrations and 
consequent LepRb signaling, rather than obesity per se, limit further increases in the 
amplitude of LepRb signaling and action.84  This finding also highlights an important 
limitation of many publications that propose “leptin resistance” as a mechanism by 
which a manipulated pathway promotes obesity- the analysis of leptin responsiveness is 
often carried out in obese (hyperleptinemic) animals.  Rather, this analysis must be 
carried out in pre-obese animals with demonstrably normal leptin levels to understand 
whether the pathway in question directly alters LepRb signaling, rather than promoting 
obesity and secondary leptin insensitivity. 
Putting aside for a moment the limited response to pharmacologic levels of leptin 
in obesity,31 the problem remains as to why obesity occurs in the face not only of 
increased endogenous leptin, but also in the face of increased baseline LepRb 
signaling.33,80 Explanations include the potential inability to sufficiently increase LepRb 
signaling to promote long-term catabolic signaling.33  If this were true, we would predict 




signaling. A thoughtful and thought-provoking recent perspective argued persuasively in 
favor of this notion, and suggested that we have not sufficiently tested this possibility 
(especially in humans).86  Testing this will be difficult, however, since it presumably 
requires promoting LepRb signaling without increasing the activity of feedback inhibitors 
(or other potential leptin-stimulated processes that limit leptin action).   
It is also possible that maximal LepRb signaling cannot mediate a sufficiently 
strong signal to the correct neurons to counteract the augmentation of feeding by 
palatable, high-calorie foods.  Indeed, leptin/LepRb signaling promotes changes in 
neuronal gene expression more powerfully than it activates (or inactivates) neurons.  
Thus, this theory would predict that stronger activators of specific LepRb-regulated 
pathways might reverse obesity.  Furthermore, many of the currently-available CNS-
acting molecules that produce weight loss (e.g., agonists of the GLP1 receptor, the 
amylin receptor, and the serotonin 2c receptor) tend to directly activate neurons or 
circuits that overlap with those controlled by LepRb.87–89 
Note that it is also possible (even likely) that mechanisms that limit maximal 
leptin action and the relatively modest modulation of neuronal function by leptin both 
contribute. The existence of mechanisms to limit the catabolic function makes 
evolutionary sense.  While there was selective pressure during evolutionary times to 
permit adipose accrual when food was plentiful (to permit survival during periods of 
caloric insufficiency), there was likely little to no selective pressure for leptin (or other 
signals) to strongly limit food intake and body weight, since there was not enough 
palatable, high-calorie, readily available food in the environment to promote obesity.  




demise, limiting the amplitude of LepRb signaling and the potential anorectic potency of 
leptin likely provided a long-term survival benefit.  
VI. Summary and conclusions 
The ongoing worldwide epidemic of obesity represents a serious threat to human 
health and economic productivity; current obesity therapies are inadequate and new 
medicines are required to combat this disease.  Identifying such therapies will require a 
detailed understanding of the mechanisms that maintain adipose stores relatively 
constant over the long term, and how these may be dysregulated to permit the 
establishment and maintenance of elevated adiposity.  Leptin, which is produced by 
adipose tissue in approximate proportion to triglyceride stores, controls the major 
hypothalamic systems that modulate food intake and energy expenditure and plays an 
important role in maintaining constant energy stores; low leptin augments food intake 
and suppresses energy expenditure, both of which tend to restore depleted energy 
stores.  Conversely, adequate leptin suppresses feeding and normalizes energy 
expenditure.   
Because obesity is defined by elevated adipose mass, leptin concentrations are 
increased in obesity.  The failure of this high endogenous leptin (and even exogenous 
leptin) to normalize body weight in obese individuals has suggested the possibility of 
leptin resistance in obesity, spurring a great deal of research aimed at understanding 
this failure.  A number of potential mechanisms that limit leptin/LepRb signaling in 
obesity (e.g., obesity-induced inhibitors of the LepRb signaling pathway, the activation 
of inflammatory signaling pathways and cytokines or ER stress in the hypothalamus, 




thus permit positive energy balance.  Proposed stimuli for these processes include the 
inundation of the hypothalamus with SFAs and/or low levels of endotoxin during obesity, 
but more compelling evidence exists for the notion that elevated leptin concentrations in 
obesity play a crucial role in limiting leptin action.  Indeed, hypothalamic LepRb 
signaling is elevated in obesity, as would be expected given increased endogenous 
leptin, and increased LepRb signaling augments the expression of a variety of inhibitors 
of LepRb signaling; it is possible that increased LepRb signaling mediates some or all of 
the other changes in hypothalamic processes suggested to attenuate LepRb signaling, 
as well.  This would imply that increased leptin/LepRb signaling limits the potential 
maximal amplitude of LepRb signaling, such that the strength of the leptin signal in 
hyperleptinemic obesity is less than it would be otherwise, and that the response to 
exogenous leptin would also be blunted (as is observed).  Thus, important questions for 
future research include not only the mechanisms and relative roles for each potential 
process proposed to limit leptin action, but also the roles for leptin/LepRb signaling in 
the genesis of each process.  Furthermore, it will be crucial to understand whether 
augmenting the leptin/LepRb signal and/or whether other means of more strongly 












Figure 1.1: Leptin action. White adipose cells secrete leptin in approximate proportion 
to their triglyceride content.  Leptin binds to the long form of the leptin receptor (LepRb) 
in the hypothalamus and brainstem to promote growth, energy expenditure, glycemic 
control, and reproduction. Leptin also suppresses food intake and the production of 




















Figure 1.2: Leptin signaling and mechanisms that mediate its inhibition. (A) In 
individuals with normal body weight, circulating leptin binds to its receptor, which 
activates Jak2 tyrosine kinase activity, resulting in the phosphorylation of LepRb 
tyrosine residues Y985, Y1077, and Y1138. Phosphorylated Y985 recruits and permits the 
phosphorylation of SHP-2, which recruits GRB2 and activates the ERK pathway in 
cultured cells. Phosphorylated Y1077 recruits STAT5, which could contribute to aspects 
of leptin-regulated gene expression. Phosphorylated Y1138 engages STAT3, resulting in 
its phosphorylation and translocation into the nucleus to mediate important aspects of 
gene expression.  In addition to mediating changes in gene expression that contribute to 
the control of energy balance by leptin, STAT3 mediates the expression of SOCS3, 
which binds to phosphorylated Y985 and blunts leptin signaling. The tyrosine 
phosphatases PTP1B and TCPTP dephosphorylate Jak2 and STAT3, respectively. 
While LepRb→STAT3 represents a major means by which leptin regulates energy 
balance, leptin also recruits IRS proteins and SH2B1 by a poorly-defined mechanism.  
LepRb also mediates important, but not mechanistically understood, signals that 
operate independently of LepRb tyrosine phosphorylation. (B) In obesity, increased 
adipose mass increases leptin production and thus circulating leptin concentrations.  
The consequent increase in LepRb signaling promotes increased expression of SOCS3 
and TCPTP; obesity also increases PTP1B expression.  These mechanisms blunt the 





Figure 1.3: CNS leptin action. Leptin acts on its receptor in various discrete nuclei to 
regulate a variety of actions. Leptin promotes the function of arcuate nucleus (ARC) 
POMC-expressing cells to increase energy expenditure and decrease feeding, as well 
as attenuates the activity of oppositely-acting ARC NPY, AgRP and GABA (NAG)-
containing neurons.  Other (as yet molecularly undefined) ARC LepRb neurons 
presumably also modulate energy expenditure and food intake in response to leptin. 
Outside of the ARC, roles for LepRb neurons have been examined in a variety of 
regions.  In the ventromedial hypothalamic nucleus (VMH), LepRb deletion decreases 
basal metabolic rate and other determinants of energy expenditure, resulting in mild 
obesity independently of leptin action in the ARC.90  LepRb neurons in the large and 
dispersed dorsomedial hypothalamic nucleus (DMH) play roles in the control of 
thermogenesis and feeding,91 and poorly-characterized subpopulations of DMH LepRb 
neurons play important roles in the control of POMC and NAG neurons.29  The ventral 
premammilary nucleus (PMv) has been shown to be involved in the hypothalamic 
control of reproduction. Lateral hypothalamic area (LHA) LepRb neurons directly 
innervate the ventral tegmental area (VTA) to modulate the mesolimbic dopamine 
system and motivation; these cells play a modest role in energy balance 92; other LepRb 
neurons in the VTA may play distinct roles in modulating the mesolimbic dopamine 
system and/or anxiety.93  In the brainstem, leptin acts on LepRb neurons in the nucleus 
of the solitary tract (NTS) to modulate gastrointestinal satiety signals,94 while LepRb 
neurons in the parabrachial nucleus (PBN) and nearby periaqueductal gray (PAG) 
modulate the sympathetic response to metabolic emergencies appropriately for the 











Figure 1.4: Hypothalamic leptin action and changes during DIO. In lean individuals 
(A, B), white adipose tissue (WAT) produces leptin in proportion to triglyceride content 
and binds to LepRb in the arcuate nucleus (ARC) resulting in a baseline level of 
pSTAT3 activation and quiescent microglia and astrocytes. (B) Acute exogenous leptin 
injection adds to the endogenous leptin from WAT, augmenting LepRbàSTAT3 
signaling. (C, D) In DIO, high-calorie feeding increases WAT and leptin production; 
saturated fatty acids (SFAs) and circulating LPS are also hypothesized to be increased. 
(C) The increased endogenous leptin production increases baseline LepRb activation, 
leading to increased pSTAT3 and other changes in neuronal and function activity. This 
increased LepRb signaling also increases the expression of feedback inhibitors (FIs) 
including SOCS3 and TCPTP.  DIO also increases PTP1B expression.  Increased leptin 




parameters in specific subsets of LepRb neurons; this could result in the activation of 
neighboring microglia and astrocytes. Additionally (or alternatively), SFAs, LPS, or other 
responses to high-calories diet may also contribute to the alterations in neuron and glia 
in the ARC. (D) The presence of feedback inhibitors or other modifiers of LepRb 
signaling limits the further amplification of LepRb signaling following the administration 
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THE PRESERVATION OF LEPTIN ACTION IN DIET-INDUCED OBESITY 
 
Chapter Summary 
Leptin controls the body’s homeostatic systems that regulate energy balance by acting 
through its receptors (LepRb) primarily in the hypothalamus. The arcuate nucleus of the 
hypothalamus (ARC) is the most populous LepRb neuronal region and is unique for the 
presence of leptin-responsive transcripts not made in any other LepRb population. 
Additionally, diet-induced obesity (DIO) coincides with the development of gliosis and 
leptin resistance, both of which are attributed primarily to the ARC. Here, we examine 
the transcriptional regulation, glial activation, and phenotypic consequence of the many 
aspects of DIO. RNA isolated by Translating Ribosome Affinity Purification (TRAP) in 
hypothalamic and ARC cells into the LepRb-expressing cell fraction and the non-LepRb 
fraction identified DIO as a leptin-active state. Furthermore, the increased leptin 
signaling that defines DIO drives the gliosis typically observed in obese animals. Thus, 
we characterized the state of DIO in LepRb neurons and neighboring cells 




 Diet-induced obesity (DIO) is the defining ailment of the 21st century. And as 
technological advances continue to transform the World, calorically dense foods will 
only become increasingly affordable and omnipresent.1 Obesity results when an 
individual’s homeostatic systems are unable to maintain energy balance and instead, in 
the face of the obesogenic environment, continued positive energy surpluses result in 
the accumulation of more and more adipose tissue.2 At the center of these homeostatic 
systems evolved to maintain energy balance is the adipocyte hormone leptin, which is 
produced in proportion to the body’s fat content and circulates in the blood to bind to its 
receptor (LepRb), located primarily in the hypothalamus of the brain, to provide a 
snapshot of energy stores and a commensurate response.3–5 The most important leptin 
signaling pathway is LepRb→STAT3, such that when STAT3 is phosphorylated 
(pSTAT3) and translocates into the nucleus, pSTAT3 is responsible for the majority of 
leptin’s negative energy balance effects to decrease food intake and increase energy 
expenditure.6,7 
 LepRb-expressing neurons in the arcuate nucleus of the hypothalamus (ARC) 
account for one-quarter of all hypothalamic LepRb neurons and uniquely express a 
number of leptin-regulated transcripts known to modulate energy balance (e.g. Pomc, 
AgRP, Npy).8–11 The ARC lies adjacent to the median eminence, a circumventricular 
organ, and is exposed to a number of circulating factors, like leptin. In DIO, individuals 
exhibit high levels of circulating leptin (hyperleptinemia) consistent with their elevated 
adiposity.12,13 Additionally, exogenous leptin treatment not only fails to provoke weight 
loss in DIO patients and rodents, but it also immunohistochemically fails to elicit an 
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increase in ARC pSTAT3 (in contrast to other LepRb hypothalamic populations that are 
responsive).14–16 Thus, the ARC is considered to be the major site of “leptin resistance”, 
or the state of leptin unresponsiveness/deficiency in DIO. Another histochemical finding 
localized to the ARC that may limit LepRb neuronal function and explain leptin 
resistance is the gliosis observed in male DIO humans and rodents.17–19 This gliosis, 
which can result from elevated cytokine and endotoxin levels in DIO individuals, may 
then contribute to the genesis of obesity and be a target of future anti-obesity 
therapies.20,21 However, complicating this is the finding that female rodents on high-fat 
diets (HFD) do not experience gliosis, even when obese/DIO.22 
There are a number of metabolically significant phenomena that impact only the 
ARC that hold clues to treating DIO. And, given the heterogeneous nature of LepRb 
neurons, particularly within the ARC LepRb neuronal population, and the differences 
observed between male and female mice, a careful examination of metabolism, 
transcriptional regulation and histochemical manifestations is necessary to clarify our 
understanding of DIO. Our hypotheses are that DIO is a leptin active, rather than 
impaired, state and that the hyperleptinemia (and not obesity per se) as a consequence 
of DIO drives the reactive gliosis observed. 
Results 
Regulation of the hypothalamic LepRb transcriptome reveal similarities among 
conditions 
Using LepReGFP mice previously described,23 we were able to perform anti-eGFP 
TRAP-seq on dissected hypothalami from mice under a variety of conditions: 1. 
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LepReGFP mice treated with PBS 10-hours prior to sacrifice, 2. LepReGFP mice treated 
with leptin 10-hours prior to sacrifice, 3. LepReGFP mice treated with PASylated 
superactive mouse leptin antagonist (SMLA) 20-hours prior to sacrifice, 4. LepReGFP 
mice weaned onto a high-fat diet, and 5. LepReGFP mice bred onto the ob/ob 
background to generate LepReGFP;ob/ob mice. From the analyses performed, we 
identified over 300 genes that were enriched in LepRb neurons (FPKM in TRAP/FPKM 
in TRAP-depleted >1.5) and whose fold changes differentially changed from the 10-hour 
PBS treated condition to at least one of the four other conditions (10-hour leptin treated, 
SMLA treated, high-fat diet-induced obese (DIO) or ob/ob). These genes underwent 
Clustered Image Map (CIM) generation to determine the similarities between these four 
conditions (when compared to the same baseline of PBS-treated LepReGFP mice) 
(Figure 2.1A). Two groups clearly form: 10h leptin and DIO, and SMLA and ob/ob. 
SMLA is a transient form of leptin deficiency; therefore, it is not unexpected that it would 
mimic ob/ob genetic leptin deficiency. However, it is unexpected that DIO is most similar 
to 10-hour leptin treated mice, given the notion of leptin resistance. To better 
characterize the relationships, we plotted the fold changes for all genes of the various 
conditions and, through linear regression, found the coupling between DIO and 10-hour 
leptin treatment to be the tightest (Figure 2.1B-G). 
A curated list of these 341 genes whose fold changes under the four conditions 
move in opposing directions based on their coupling (i.e. fold changes that moves in 
one direction for the 10h-leptin and DIO coupling and not in the same direction for the 
SMLA and ob/ob coupling, and vice versa) defined in Figure 2.1 is detailed in Table 2.1. 
Using fold change cutoffs of 1.5 and 0.667, there are clearly a number of genes that are 
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significantly changed in all four conditions (Group I), in three conditions (Group II) and in 
two conditions (Group III) (Table 2.1). Next, to determine whether these groups are 
transcriptionally regulated together, we performed Enrichr analyses to identify 
transcription factor protein-protein interactions (TF-PPI) and found that the most 
significant transcription factor for Group I to be STAT3, the key leptin signal (Table 2.2). 
The resemblance of DIO to 10h leptin treated mice and the identification of STAT3 as 
the transcription factor responsible for the most significant gene fold changes 
demonstrate that DIO is a leptin active state like treatment with leptin. 
Regulation of the arcuate-specific LepRb transcriptome 
 To further explore the relationship of DIO and states of leptin action, arcuate-
specific anti-eGFP TRAP-seq was performed in male mice under a number of 
conditions: 1. 10-hour PBS treated chow-fed LepRbeGFP mice, 2. 10-hour leptin treated 
chow-fed LepRbeGFP mice, 3. 10-hour PBS treated high-fat diet fed LepRbeGFP mice, 4. 
10-hour PBS treated high-fat diet fed LepRbeGFP mice, 5. PBS-filled osmotic minipump 
implanted LepRbeGFP mice, and 6. leptin-filled osmotic minipump implanted LepRbeGFP 
mice. Genes enriched (FPKM in TRAP/FPKM in TRAP-depleted) at baseline (10-hour 
PBS treated LepRbeGFP mice or PBS minipump implanted LepRbeGFP mice) or that 
became enriched under any of the other conditions were included. We further sifted the 
gene list to only include those enriched genes that had differentially expressed fold 
changes under the five comparisons from baseline (1. Leptin-treated DIO vs PBS-
treated DIO, 2. Leptin minipump vs PBS minipump, 3. 10-hour leptin treated vs 10-hour 
PBS treated, 4. PBS-treated DIO vs PBS treated, and 5. Leptin treated DIO vs PBS 
treated) and arrived at 148 genes. These genes underwent CIM analyses and 
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similarities between the conditions were identified (Figure 2.2A).  Next, we, like in the 
hypothalamus-specific TRAP-seq analyses, plotted the 10-hour leptin treatment 
condition against the DIO condition and a similar, if not stronger, relationship exists in 
the ARC (Figure 2.2B). Clearly, the leptin action relationship first identified in the 
hypothalamus between DIO and 10h-leptin treated mice is maintained in the ARC. 
Effect of exogenous leptin on the setting of hyperleptinemic diet-induced obesity 
 We examined relationship between the two most similar conditions in Figure 2.2A 
(PBS-treated DIO and leptin-treated DIO, both versus the baseline of 10-hour PBS-
treated chow-fed mice) by plotting their fold change gene values (Figure 2.3A). The 
close coupling suggests that DIO mice treated with exogenous leptin are 
physiologically, immunohistochemically,15,16 and transcriptionally similar to DIO mice 
given vehicle. We further parsed this exogenous leptin treatment in the setting of DIO 
condition by using the 10-hour PBS treated DIO condition as the baseline for the 10-
hour leptin treated DIO condition (DIO leptin vs DIO PBS) and plotted the gene fold 
changes values against the PBS DIO condition (which is versus PBS treated chow 
mice) (Figure 2.3 B). Clearly, the regulation of genes with the extra leptin do not 
resemble the regulation of genes under DIO (Figure 2.3 B). This exogenous leptin 
condition (DIO leptin vs DIO PBS) was also plotted against 10-hour leptin treatment in 
chow-fed mice and was found to have a weak positive relationship (Figure 2.3 C). Last, 
we compared 10-hour leptin treated chow-fed animals and 10-hour leptin treated DIO 
animals and found the relationship to be a strong positive one (Figure 2.3D). In fact, this 
relationship was stronger than that between DIO and 10-hour leptin treated mice, 
suggesting that while exogenous leptin does marginally less in the context of 
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endogenous hyperleptinemia in DIO, it is still effective in regulating genes 
transcriptionally like that of 10-hour leptin treatment in normoleptinemic (leptin levels 
expected of lean animals) chow-fed mice. 
ARC-specific regulation of LepRb transcriptome in leptin minipump implanted 
mice 
 Chow-fed male LepReGFP mice were implanted with minipumps containing PBS 
or leptin for two weeks. Leptin minipump infused animals weighed significantly less than 
PBS minipump implanted littermates (Figure 2.5A). Indeed, over the two-week span, 
leptin minipump implanted mice lost over 10% of their body weight, most of which was 
adipose tissue (Figure 2.5B, 2.5C). One set of these mice underwent anti-LepRb TRAP-
seq and gene fold change values are plotted against the other conditions (Figure 2.4). 
The strongest relationship is between leptin minipump implanted mice and the 10-hour 
leptin injected animals (Figure 2.4A). And, while there exist trending relationships 
between leptin minipump implanted animals and DIO (+/- leptin) animals, they are quite 
weak (Figure 2.4B, 2.4D). Because the leptin levels of these leptin minipump infused 
mice are comparable to high-fat diet fed animals, the adipose loss versus gain in leptin 
minipump animals versus in DIO animals, respectively, may be counterbalancing the 
leptin-driven relationships between the conditions (Figure 2.5D). 
Gliosis in leptin active and deficient states 
 An area of intense interest is the manner by which gliosis in the ARC contributes 
to obesity. Here, we explored gliosis with many of the same groups we performed ARC-
specific TRAP-seq analyses: 1. Chow fed mice, 2. High-fat diet fed mice, 3. PBS 
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osmotic minipump implanted mice, and 4. Leptin minipump implanted mice. As 
expected, high-fat DIO mice are significantly heavier, have more adipose tissue and are 
hyperleptinemic compared to chow-fed littermate controls (Figure 2.5A, 2.5B, 2.5D). 
Over the two-week period of minipump implantation, leptin minipump animals lost a 
significant amount of weight (while PBS minipump animals had unchanged weights) 
from fat due presumably to the increased leptin levels (Figure 2.5A-D). We therefore are 
able to study mice of comparable hyperleptinemic levels that are either obese (HFD) or 
extra-lean (leptin minipump) (Figure 2.5A-D). 
 Then, using immunohistochemical methods to detect Iba1 (microglia marker) and 
GFAP (astrocyte marker), we found the number of microglia/astrocyte and average area 
per microglia/astrocyte to indeed be increased in the high-fat diet fed male mice 
(compared to chow controls) as described by other researchers (Figure 2.5E-G).17,22 
Additionally, we detected a comparable increase in both microglia/astrocyte number and 
area in leptin minipump implanted mice (compared to PBS minipump implanted mice) 
(Figure 2.5E, 2.5H, 2.5I). 
 Because we found gliosis to occur in extra-lean leptin minipump animals, the 
gliosis may be driven by the hyperleptinemia experienced in DIO (and not the obesity). 
To investigate this, we employed three obese mouse models with varying degrees of 
leptin deficiency. It is worth differentiating between these three models of obesity: 1. 
The ob/ob leptin deficient animal is hypoleptinemic (no baseline leptin) and has largely 
absent LepRb signaling; 2. the db/db LepRb truncated mutant is hyperleptinemic and 
has completely absent LepRb signaling; and 3. the mouse with STAT3 conditionally 
deleted in LepRb neurons (STAT3LepRKO) is hyperleptinemic and possesses intact 
46 
 
leptin action outside of leptin→STAT3 activity. Immunohistochemical analyses of Iba1 
and GFAP reveal not only the absence of gliosis, but also a decrease in the number and 
average size of glia in ob/ob mice, db/db mice, and STAT3LepRKO mice (Figure 2.6). 
Therefore, gliosis is not directly linked to obesity; instead, gliosis is a consequence of 
hyperleptinemia and increased leptin action in neighboring LepRb neurons. 
Endotoxemia and diet-induced obesity 
 DIO mice are hyperleptinemic and obese; they also experience elevated 
endotoxin levels in their blood.20 We implanted male mice with osmotic minipumps filled 
with low-dose lipopolysaccharide (using the same LPS concentration as the previous 
publication), high-dose LPS, or vehicle control. Body weights across the three groups 
were comparable (Figure 2.7A, 2.7B). Immunohistochemical analysis of Iba1 and GFAP 
revealed significant gliosis in both LPS minipump conditions when compared to PBS 
minipump control (Figure 2.7C-2.7H). 
 Whole hypothalamus TRAP-seq was then performed in male mice treated with 
LPS 10-hours before sacrifice and compared to DIO animals (both using 10-hour PBS 
injected chow-fed animals as a baseline). We plotted genes that were enriched (FPKM 
in TRAP/FPKM in TRAP-depleted > 1.5) in any of the three conditions and differentially 
expressed in the LPS treated or DIO conditions (Figure 2.7I). Here, genes that are 
positively regulated with both DIO and LPS are identified; the majority of the genes, 
however, crowd the two axes, suggesting that LPS and DIO are different conditions. 
Next, we plotted those genes that were differentially expressed in the non-LepRb cell 
(TRAP-depleted) fraction and similarly see genes crowding the axes (Figure 2.7J). All 
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together, while DIO animals may experience endotoxemia that can cause gliosis, the 
state of DIO is not comparable to one of endotoxin-driven inflammation. 
Sex differences in gliosis 
 Female mice were placed into the same groups as their male counterparts: 1. 
Chow-fed, 2. High fat-diet fed, 3. PBS minipump, 4. Leptin minipump, 5. Low-dose LPS 
minipump, and 6. High-dose LPS minipump. Similar to male mice, females on high-fat 
diet weighed more from increased adipose tissue and were hyperleptinemic (Figure 
2.8A, 2.8C, 2.8D). Female mice implanted with leptin minipumps lost a significant 
amount of weight over the two-week period due to decreased adipose tissue and were 
hyperleptinemic (Figure 2.8A-D). LPS minipump implanted females had comparable 
weights (the high-dose LPS minipump mice even unexpectedly gained weight) 
compared to PBS minipump control mice (Figure 2.8A, 2.8B). These similarities to their 
male littermates underscore the diet- and treatment-driven phenotypic similarities 
regardless of sex. 
 As others have demonstrated,22 the gliosis associated with diet-induced obesity 
is absent in female mice (Figure 2.8E-I). Likewise, the gliosis we observed in leptin 
minipump implanted male mice disappeared in females (we found microglia/astrocytes 
to instead decrease in number) (Figure 2.8E-I). In contrast, female mice implanted with 
LPS minipumps (both concentrations) did experience gliosis like their male littermates 
(Figure 2.8E-I). 
 Because leptin action may be mediating DIO-induced gliosis, we employed anti-
LepRb TRAP-seq in ARC-specific dissections of male and female mice in four 
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conditions: 10-hour PBS injected chow-fed mice, 10-hour PBS injected high-fat diet fed 
mice, PBS minipump implanted mice, and leptin minipump implanted mice. There are 
77 genes that were enriched (FPKM in TRAP/FPKM in TRAP-depleted) and 
differentially expressed in at least one of the four conditions when compared to baseline 
controls (1. Male mice implanted with leptin minipumps vs male mice implanted with 
PBS minipumps, 2. Female mice implanted with leptin minipumps vs female mice 
implanted with PBS minipumps, 3. Male DIO mice vs male chow-fed mice, and 4. 
Female DIO mice vs female chow-fed mice) (Table 2.3). The CIM generated from these 
gene fold change values reveals a relationship not based on presence/absence of 
gliosis (i.e. both male DIO and male leptin minipump conditions have gliosis, but female 
DIO and female leptin minipump conditions do not); rather, there is clear coupling based 
on treatment type regardless of sex (Figure 2.8J). Upon plotting the fold change values 
of each treatment comparing gene regulation in male mice versus female mice, the 
genes are generally coordinately regulated by both male and female conditions (Figure 
2.8K, 2.8L). 
Regulation of non-LepRb cells transcriptome in the hypothalamus and ARC 
 Using our LepReGFP mice, the LepRb pull-down fraction of TRAP does not include 
microglia or astrocytes; therefore, transcriptional changes in glia should exist in the 
LepRb-depleted cell fraction. Here, we examined our TRAP-depleted fold change 
values for the aforementioned hypothalamic- and arcuate-specific TRAP-seq conditions. 
Interestingly, we find that the non-LepRb hypothalamic cell transcriptome of DIO mice 
most resembles that of 10-hour leptin treated mice; therefore, the transcriptional 
changes in DIO (whether in LepRb neurons or not) is markedly similar to that of 10-hour 
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leptin treated mice (Figure 2.9A, 2.9B). In contrast, analyses of our ARC-specific TRAP-
seq data demonstrates that DIO is very different from the other conditions of leptin 
action (Figure 2.9C). Plotting the fold changes of genes in the non-LepRb cells in DIO 
condition versus those in the 10-hour leptin treated condition (both with the baseline of 
PBS-treated chow-fed mice) reveals no relationship (Figure 2.9D). In addition, despite 
the difference noted in the regulation of the LepRb transcriptome of 10-hour leptin 
treated condition compared to the leptin minipump condition, the regulation of the non-
LepRb transcriptome of these two conditions are consistent (Figure 2.9C, 2.9E). 
Discussion 
 The rise of diet-induced obesity (DIO) is a particularly concerning development, 
given its profound impact on other diseases, overall health, and the well-fare of 
nations.1,24–26 Hence, there is a clear need to develop effective anti-obesity therapies, 
which may hinge on the understanding of homeostatic systems that control energy 
balance and their dysregulation in DIO. Indeed, DIO-induced leptin resistance and 
gliosis in the ARC are particularly interesting phenomena worth exploring as part of 
homeostatic dysregulation. 
 We found the ARC-specific gliosis described in male DIO mice to exist in lean 
hyperleptinemic mice, but absent in obese leptin deficient mice. In contrast to the 
interpretation that gliosis may drive the development of obesity,17 we instead find it to be 
a consequence of LepRb action. Additionally, we explored the gliosis that results from 
chronically elevated endotoxemia (another characterization of DIO) with translational 
profiling of LepRb and non-LepRb cells to find that DIO is not at all transcriptionally 
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similar to a state of endotoxin exposure. Therefore, while DIO can be characterized as a 
state of hyperleptinemia, obesity and endotoxemia, the gliosis observed appears to be 
driven by the hyperleptinemia. Furthermore, the bidirectional nature we observe in 
number and area of glia and the correlated level of leptin action suggest that gliosis is a 
sensitive marker for neighboring LepRb neuronal activity. Indeed, our analyses of 
transcriptional regulation of non-LepRb neurons suggests concordant changes based 
on leptin levels and actions. So, while glia may not respond directly to leptin, leptin-
driven neuronal activity may affect nearby glial activity.  
This relationship, however, does not appear to extend to female mice. DIO 
female mice do not experience gliosis like their male counterparts. Further supporting 
hyperleptinemia driven gliosis, lean hyperleptinemic female mice similarly do not display 
gliosis, while mice with varying degrees of endotoxemia do still experience gliosis. Our 
sex- and ARC-specific TRAP analyses also reveal that the presence or absence of 
gliosis does not define LepRb neurons transcriptionally, for genes are largely 
coordinately regulated between sexes. Truly, DIO is not an exclusively male condition, 
in fact the prevalence of obesity is higher for females in the United States;27 therefore, it 
would follow that DIO and leptin resistance are similar condition for males and females 
and the absence of female DIO gliosis may instead suggest that gliosis does not cause 
leptin resistance or obesity. 
If male gliosis is a measure of leptin action in neighboring LepRb neurons, our 
gliosis data would suggest that DIO is a state of increased leptin action, rather than one 
of leptin resistance or deficiency. Hypothalamus- and ARC-specific TRAP-seq analyses 
reveal that indeed DIO is a state of leptin action; this finding fits well with a recent 
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publication detailing continued leptin action from endogenous DIO-hyperleptinemia.28 
Upon further examination, we found the LepRb transcriptome of DIO mice and 
exogenous leptin-treated DIO mice to be remarkably similar. Additionally, while 
exogenous leptin treatment in DIO mice does not affect the transcription of LepRb 
neurons to the extent that exogenous leptin treatment in lean mice does, we did find a 
noticeable effect. In sum, our TRAP-seq analyses demonstrate the diminishing returns 
from the same marginal unit of exogenous leptin with increasing endogenous leptin 
levels. Therefore, future studies amplifying leptin action and augmenting marginal 
returns may hold the key to combating DIO by manually rebalancing the body’s 
homeostatic systems. 
Materials and Methods 
Mice. 
Mice were bred in our colony in the Unit for Laboratory Animal Medicine at the 
University of Michigan. All procedures were approved by the University of Michigan 
University Committee on the Use and Care of Animals in accordance with AAALAC and 
NIH guidelines.  Animals were bred at the University of Michigan and maintained in a 
12-hour light/12-hour dark cycle with ad libitum access to food and water.  We 
purchased male and female C57BL/6 mice (Jackson stock #000664), ob/ob mice 
(Jackson stock #000632), ob/+ mice (Jackson stock #000632), db/db mice (Jackson 
stock #000664), db/+ mice (Jackson stock stock #000664) for experiments and 
breeding studies from Jackson Labs. STAT3flox (Jackson stock #016923) mice were 
also from Jackson.  
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We generated LepReGFP mice by crossing LepRcre mice29 onto the eGFP-L10a 
background to generate LepRcre/+;Rosa26eGFP-10a/+ mice,30 which we then intercrossed to 
generate double homozygous LepRcre/cre;RosaeGFP-10a/eGFP-L10a (LepReGFP) study animals. 
LepReGFP mice were backcrossed to ob/ob mice until LepRcre/cre;RosaeGFP-L10a/eGFP-
L10a;ob/+ mice were obtained. These mice were subsequently intercrossed to generate 
LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;ob/ob (LepReGFPob/ob) and LepRcrecre;RosaeGFP-
L10a/eGFP-L10a;+/+ (LepReGFP) control mice for study. STAT3flox mice were backcrossed to 
LepReGFP mice to generate LepReGFP-L10a;STAT3flox/+ mice. These mice were then 
intercrossed to generate LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT3flox/flox (STAT3LepRKO) 
and LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT3+/+ (LepReGFP) control mice for study. 
High-fat diet, leptin treatment, LPS treatment and SMLA treatment 
For fold induction TRAP-seq experiments, mice were weaned onto either a 
standard chow diet (Purina Lab Diet 5001) or a 60% high-fat diet (Research Diets 
D12492, 60% kcal from fat) for at least 8 weeks and were dissected at 12-14 weeks of 
age. Mice were treated 10 hours prior to sacrifice with metreleptin (5mg/kg, i.p.) (a 
generous gift from AstraZenica, Inc.), 10 hours prior to sacrifice with lipopolysaccharide 
(Sigma escherichia coli 055:B5, St. Louis; 100ug/kg; i.p.), 10 hours prior to sacrifice with 
vehicle (0.9% saline; Hospira; i.p.), or 20 hours prior to sacrifice with PASylated 
superactive mouse leptin antagonist (SMLA; Protein Laboratories Rehovot; 100pmol/g; 
i.p.). A separate group of LepReGFP mice were implanted subcutaneously with osmotic 
minipumps (Alzet Model 1002; Alza, Palo Alto, CA) filled with either metreleptin 
(2.2mg/kgday), low-dose lipopolysaccharide (300ug/kgday), high-dose 
lipopolysaccharide (9.6mg/kgday), or vehicle (0.9% sodium chloride; Hospira; i.p.). All 
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conditions were compared to the control LepReGFP vehicle injected or minipump 
implanted animals raised on standard chow, except for the 10-hour leptin treated DIO 
condition, which was compared to the PBS-treated DIO condition.  
Hypothalamic and arcuate dissections for TRAP-seq 
At the midpoint of the light cycle, adult homozygous mice were anesthetized with 
isoflurane, had their brains removed and placed onto a mouse coronal brain matrix 
(1mm sections). For whole hypothalamic dissections, a 3x3x3mm block was dissected 
from the ventral diencephalon immediately caudal to the optic chiasm and then 
homogenized for TRAP-seq analysis. For arcuate specific dissections, 3 consecutive 
1mm sections were removed immediately caudal to the optic chiasm, and arcuate nuclei 
were dissected bilaterally by hand from the hypothalamus of each section, and pooled 
for TRAP-seq analysis. 
Translating ribosome affinity purification (TRAP). 
Messenger RNA was isolated from eGFP-tagged ribosomes, as well as from the 
eGFP-depleted fraction. RNA was assessed for quality using TapeStation (Agilent, 
Santa Clara, CA). Samples with RINs (RNA Integrity Numbers) of 8 or greater were 
prepped using the Illumina TruSeq mRNA Sample Prep v2 kit (Catalog #s RS-122-
2001, RS-122-2002) (Illumina, San Diego, CA), where 0.1-3ug of total RNA was 
converted to mRNA using a polyA purification. The mRNA was fragmented via chemical 
fragmentation and copied into first strand cDNA using reverse transcriptase and random 
primers. The 3’ ends of the cDNA were adenylated, and 6-nucleotide-barcoded 
adapters ligated.  The products were purified and enriched by PCR to create the final 
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cDNA library. Final libraries were checked for quality and quantity by 
TapeStation (Agilent) and qPCR using Kapa’s library quantification kit for Illumina 
Sequencing platforms (catalog # KK4835) (Kapa Biosystems, Wilmington MA).  They 
were clustered on the cBot (Illumina) and sequenced 4 samples per lane on a 50 cycle 
single end run on a HiSeq 2000 (Illumina) using version 2 reagents according to 
manufacturer’s protocols. 
RNA sequencing. 
50 base pair single end reads underwent QC analysis prior to alignment to 
mouse genome build mm10 using TopHat and Bowtie alignment software.31 Differential 
expression was determined using Cufflinks Cuffdiff analysis, with thresholds for 
differential expression set to fold change >1.5 or <0.66 and a false discovery rate of 
<0.05.32 Lists of differentially expressed genes were then queried against the Uniprot 
Database for gene ontology and protein class analysis.33 Lists of differentially expressed 
genes were run through One Matrix CIMminer (with log transformation) and Enrichr 
databases.34,35 
Immunohistochemistry. 
Prior to perfusion, mice were anesthetized with a lethal dose of pentobarbital and 
transcardially perfused with phosphate buffered saline (PBS) followed by 10% buffered 
formalin. Brains were removed, placed in 10% buffered formalin overnight, and 
dehydrated in 30% sucrose for one week. Using a freezing microtome (Leica), brains 
were cut into 30 um sections. Sections were treated sequentially with 1% hydrogen 
peroxide/0.5% sodium hydroxide, 0.3% glycine, 0.03% sodium dodecyl sulfate, and 
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blocking solution (PBS with 0.1% triton, 3% Normal Donkey Serum). Immunostaining 
was performed using primary antibodies for pSTAT3 (Cell Signaling #9145, 1:1000), 
Iba1 (Wako, 1:1000), and GFAP (Millipore, 1:500). All antibodies were processed with 
the avidin-biotin/diaminobenzidine (DAB) method (ABC kit, Vector Labs, 1:500; DAB 
reagents, Sigma). Images were collected on an Olympus BX53F microscope. 
Quantification was performed on anatomically matched brain regions with pre-set 
regions of interest using the Olympus BX53F software. Both sides of the arcuate 
nucleus were counted and groups means were determined (n=7-14 animals per group). 
Phenotyping studies. 
LepReGFP mice fed chow and high-fat diet had their body weights and body 
composition measured using an NMR-based analyzer (Minispec LF90II, Bruker Optics) 
(mice were 12-14 weeks old). Mice with implanted minipumps had their body weights 
measured the day of surgery and two weeks later at time of sacrifice. Body composition 
was also assessed at time of sacrifice (mice were 12-15 weeks old). Leptin was 
assayed by commercial ELISA (Crystal Chem) using serum of implanted mice one week 
after implantation and the day of sacrifice.  
Statistics. 
Physiological data are reported as mean +/- SEM. Statistical analysis of data was 
performed using Prism (version 7.0) software. Correlation analyses were also 
performed using Prism (version 7.0). Unpaired t-tests were used to assess significance; 




Figure 2.1: Fold change similarities in hypothalamic LepRb-enriched genes. 
Translating ribosome affinity purification (TRAP) was performed in LepReGFP and 
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LepReGFPob/ob mice fed either normal chow or high-fat diet and treated with either PBS 
, SMLA, or leptin. Fold change values for each group were calculated and compared to 
littermate control PBS-treated LepReGFP mice. (A) Heat map detailing the relationship 
via dendrogram between genes (left axis) and conditions (top axis). (B) Fold change in 
10-hour leptin treated mice versus fold change in DIO mice. (C) Fold change in DIO vs 
fold change in ob/ob mice. (D) Fold change in 10-hour leptin treated mice versus fold 
change in ob/ob mice. (E) Fold change in 10-hour leptin treated mice versus fold 
change in 20-hour SMLA treated mice. (F) Fold change in DIO mice versus fold change 
in 20-hour SMLA treated mice. (G) Fold change in 20-hour SMLA treated mice versus 
fold change in ob/ob mice. Genes enriched (FPKM in TRAP/FPKM in TRAP-depleted > 
1.5) at baseline or in any of the conditions were included in this analysis. Dashed lines 
are at FC=1.5 and FC=0.667 for axis in (B-G). Each sample comprised of pooled 






leptin DIO SMLA ob/ob Group 
C1qtnf7 1.74 2.02 0.32 0.44 
I 
Serpina3h 6.15 2.32 0.60 0.32 
Serpina3n 2.06 1.89 0.57 0.26 
Serpina3f 3.19 1.62 0.64 0.27 
Serpina3c 2.77 1.94 0.60 0.20 
Socs3 3.14 2.56 0.52 0.25 
Bcl3 1.75 1.92 0.63 0.43 
Traf3ip3 2.36 1.75 0.56 0.53 
Serpina3i 2.48 1.48 0.49 0.13 
Sprr1a 9.22 4.31 0.56 0.83 
II 
Atf3 4.58 6.26 0.64 1.02 
Serpina3m 3.92 2.14 0.84 0.52 
H2-Q6 1.60 2.85 0.86 0.34 
Serpina3k 3.37 1.99 1.47 0.18 
Pomc 1.56 2.17 0.82 0.16 
Cd44 1.98 1.74 0.87 0.61 
Prokr2 2.29 2.04 0.82 0.61 
Asb4 1.74 1.62 0.76 0.61 
Vwf 0.23 0.63 1.38 1.69 
Pglyrp1 0.34 0.54 1.63 1.11 
Ccnb1ip1 1.15 1.61 0.45 0.43 
Pecam1 0.56 1.12 1.51 1.53 
Ly6a 0.45 1.17 1.85 1.67 
Robo4 0.51 0.88 1.72 1.91 
Apol10b 3.97 2.28 0.93 0.87 
III 
Cd38 2.97 5.72 0.95 1.15 
Gpr151 2.30 2.15 0.97 0.77 
Gna14 2.03 1.69 0.91 0.72 
Crem 1.53 1.78 0.94 1.10 
Lamc2 1.78 1.53 0.72 1.07 
Gal 1.60 1.77 1.01 1.01 
Sdc1 1.59 1.51 1.07 0.98 
Rrad 1.59 1.84 1.01 1.24 
Tac2 2.25 1.65 1.29 0.99 
Nr5a2 2.26 1.51 1.03 1.00 
Gpc2 1.64 1.53 1.30 1.24 
Prr19 1.81 1.63 1.07 0.92 
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Slc39a4 0.28 0.63 0.75 0.77 
Lix1 0.67 0.60 0.80 0.76 
En2 0.45 0.55 0.80 0.78 
Sult5a1 0.42 0.50 1.03 1.06 
Bnc2 0.59 0.62 0.89 0.93 
Elovl3 0.52 0.66 1.06 1.04 
Th 0.59 0.66 0.82 0.78 
BC002163 0.23 0.11 1.27 1.32 
Rnase6 0.60 0.25 1.48 1.24 
H2-Aa 0.60 0.65 0.85 0.95 
Chrna3 0.47 0.62 1.15 1.02 
Hsd17b2 0.60 0.63 0.98 1.03 
Ntn1 0.50 0.63 0.98 0.87 
Ces1d 0.53 0.65 0.85 0.74 
Foxc2 0.55 0.54 1.23 1.44 
D830030K20Rik 0.62 0.56 1.12 1.40 
Col5a3 1.09 0.97 1.55 1.90 
Apoa1 1.22 1.40 1.60 2.25 
Mgp 0.69 1.43 1.78 2.14 
Krtap17-1 1.07 0.94 1.50 2.07 
Gbp9 1.04 1.39 0.60 0.51 
 
Table 2.1: Fold change in hypothalamic LepRb-enriched genes. Translating 
ribosome affinity purification (TRAP) was performed in LepReGFP and LepReGFPob/ob 
mice fed either normal chow or high-fat diet and treated with either PBS or leptin. Genes 
enriched (FPKM in TRAP/FPKM in TRAP-depleted >1.5) at baseline, or that became 
enriched in a condition in which they were also significantly changed, were included in 
this analysis. Per Figure 2.1, genes whose fold change moved in opposing directions 
based on coupling were included and grouped into 3 groups (Column 6). (I) Genes that 
were differentially regulated under all four conditions. (II) Genes whose fold change 
were significantly changed under three of the conditions. (III) Genes that were 
differentially regulated in two of the conditions. Each sample comprised of pooled 































































Table 2.2: Transcription factors responsible for TRAP-seq gene fold changes. The 
genes clustered into groups I-III in Table 2.1 were linked to the corresponding list of 
transcription factors, as determined by the Transcription Factors Protein-Protein 
Interactions database through Enrichr. Genes highlighted in red were significant for 





















Figure 2.2: Fold changes in LepRb-enriched genes in the arcuate nucleus. 
Translating ribosome affinity purification (TRAP) was performed in male LepReGFP mice 
fed either normal chow or high-fat diet and treated with either PBS or leptin (via 10h 
injection or 2-week minipump implantation) (leptin: 5mg/kg i.p. injection or 2.2mg/kgday 
minipump). Fold change values for each group were calculated and compared to 
littermate control PBS-treated LepReGFP mice. (A) Heat map detailing the relationship 
via dendrogram between genes (left axis) and conditions (top axis). (B) Fold change in 
10-hour leptin treated mice versus fold change in DIO mice. Genes enriched (FPKM in 
TRAP/FPKM in TRAP-depleted > 1.5) at baseline or in any of the conditions were 
included in this analysis. Dashed lines are at FC=1.5 and FC=0.667 for axis in (B). Each 






Figure 2.3: Fold changes in LepRb-enriched genes in the arcuate nucleus of DIO 
mice. Translating ribosome affinity purification (TRAP) was performed in male LepReGFP 
mice fed either normal chow or high-fat diet and treated with either PBS or leptin (via 
10h injection). Fold change values for each group were calculated and compared to 
littermate control PBS-treated LepReGFP mice. (A) Fold change in PBS-treated DIO mice 
versus fold change in 10h leptin-treated DIO mice. (B) Fold change in PBS-treated DIO 
mice versus fold change between 10h leptin-treated DIO mice and PBS-treated DIO 
mice. (C) Fold change in 10-hour leptin treated mice versus fold change between 10h 
leptin-treated DIO mice and PBS-treated DIO mice. (D) Fold change in 10h leptin-
treated mice versus fold change in 10h leptin-treated DIO mice. Genes enriched (FPKM 
in TRAP/FPKM in TRAP-depleted > 1.5) at baseline or in any of the conditions were 
included in this analysis. Dashed lines are at FC=1.5 and FC=0.667 for axis. Each 






Figure 2.4: Fold changes in arcuate LepRb-enriched genes of leptin minipump 
mice. Translating ribosome affinity purification (TRAP) was performed in male LepReGFP 
mice fed either normal chow or high-fat diet and treated with either PBS or leptin (via 
10h injection or 2-week minipump implantation) (leptin: 5mg/kg i.p. injection or 
2.2mg/kgday minipump). Fold change values for each group were calculated and 
compared to littermate control PBS-treated LepReGFP mice or PBS-treated DIO 
LepReGFP mice. (A) Fold change in 10h leptin-treated mice versus fold change in leptin 
minipump implanted mice. (B) Fold change in 10h leptin-treated DIO mice versus fold 
change in leptin minipump implanted mice. (C) Fold change between 10h leptin-treated 
DIO mice and PBS-treated DIO mice verses leptin minipump implanted mice. (D) Fold 
change in PBS-treated DIO mice and leptin minipump implanted mice. Genes enriched 
(FPKM in TRAP/FPKM in TRAP-depleted > 1.5) at baseline or in any of the conditions 
were included in this analysis. Dashed lines are at FC=1.5 and FC=0.667 for axis. Each 







Figure 2.5: Histochemical analysis of gliosis in the arcuate nucleus of male mice 
fed normal chow or high-fat diet (HFD), fasted, and implanted with PBS or leptin 
minipumps. Body weights (A) and body composition (B) of mice on day of sacrifice. (C) 
Percent change in body weight over the two-week span with PBS or leptin minipumps 
(leptin: 2.2mg/kgday) implanted. (D) Leptin levels of the various conditions from serum 
collected at time of sacrifice. (E) Immunohistochemical detection of microglia (via Iba1 
protein) and astrocytes (via GFAP protein) in mice fed chow, HFD, implanted with PBS 
minipumps for 2 weeks, and implanted with leptin minipumps for 2 weeks. Quantification 
of total ARC microglia (F) or ARC astrocyte (H) cell number and average area per 
microglia (G) or astrocyte (I). Immunohistochemical analyses (A-E) were performed in 
8-15 male mice per condition. Mean+/- SEM is shown for (B-I). *p<0.05, **p<0.01, 






Figure 2.6: Histochemical analysis of gliosis in the arcuate nucleus of male 
mouse models of leptin deficiency. (A) Immunohistochemical detection of Iba1 
protein (microglial marker) in leptin deficient ob/ob mice (with ob/+ littermate controls), 
LepRb deficient db/db mice (with db/+ littermate controls) and STAT3 null mice in 
LepRb neurons (STAT3LepRKO) with STAT3LepRWT littermate controls. Quantification of 
total ARC microglia (B) and average area per microglia (C). (D) Representative images 
of histochemical detection of GFAP protein (astrocyte marker) in ob/ob (with ob+ 
controls), db/db (with db/+ controls), and STAT3LepRKO (with STAT3LepRWT controls) 
mice. Quantification of total ARC astrocyte (E) and average area per astrocyte (F). 
Immunohistochemical analyses (A-E) were performed in 7-10 male mice per condition. 






Figure 2.7: ARC glial histochemical and TRAP-seq analyses of male mice treated 
with lipopolysaccharide. (A) Body weights of mice on day of sacrifice. (B) Percent 
change in body weight over the two-week span with PBS, low-dose LPS (300ug/kgday), 
or high-dose LPS (9.6mg/kgday) minipumps implanted. Immunohistochemical detection 
of (C) microglia (via Iba1 protein) and (D) astrocytes (via GFAP protein) in chow-fed 
mice implanted with PBS, low-dose LPS (300ug/kgday), or high-dose LPS 
(9.6mg/kgday) minipumps for 2 weeks. Quantification of total ARC microglia (E) or ARC 
astrocyte (G) cell number and average area per microglia (F) or astrocyte (H). (I) 
Translating ribosome affinity purification (TRAP) was performed in male LepReGFP mice 
fed either chow or high-fat diet and treated with LPS (100ug/kg) or PBS 10 hours prior 
to sacrifice, respectively. Fold change values for each group were calculated and 
compared to littermate control PBS-treated LepReGFP mice to generate the fold change 
in PBS-treated DIO mice versus fold change in 10h LPS-treated chow-fed mice. Genes 
enriched (FPKM in TRAP/FPKM in TRAP-depleted > 1.5) at baseline or in either 
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condition were included in this analysis. (J) Fold change values for the non-LepRb 
TRAP-depleted fraction are plotted here for PBS-treated DIO mice against 10h LPS-
treated chow-fed mice; genes that were differentially changed in either condition were 
included. (A-H) were performed in 7-12 male mice per condition. Mean+/- SEM is 
shown for (A,B,E-H). **p<0.01, ***p<0.001, ****p<0.0001 by t-test (A-B, E-H). Dashed 
lines are at FC=1.5 and FC=0.667 for axis in (I-J). Each sample comprised of pooled 



























Figure 2.8: ARC glial histochemical and TRAP-seq analyses of female mice. (A) 
Body weights of mice on day of sacrifice. (B) Percent change in body weight over the 
two-week span with PBS, leptin (2.2mg/kgday), low-dose LPS (300ug/kgday), or high-
dose LPS (9.6mg/kgday) implanted minipumps. (C) Body composition of animals on day 
of sacrifice. (D) Leptin levels assayed from serum collected on day of sacrifice. (E) 
Immunohistochemical detection of microglia (via Iba1 protein) and astrocytes (via GFAP 
protein) in mice fed either chow or high-fat diet (HFD), and mice implanted with PBS, 
leptin (2.2mg/kgday), low-dose LPS (300ug/kgday), or high-dose LPS (9.6mg/kgday) 
minipumps for 2 weeks. Quantification of total ARC microglia (F) or ARC astrocyte (H) 
cell number and average area per microglia (G) or astrocyte (I). (J) Translating 
ribosome affinity purification (TRAP) was performed in male and female LepReGFP mice 
fed either chow or HFD, and male and female mice implanted with PBS or leptin 
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(2.2mg/kgday) minipumps. Fold change values for each group were calculated and 
compared to littermate control PBS-treated LepReGFP mice (either PBS injected for HFD 
fed mice or PBS minipump for leptin minipump mice) of the same sex. (K) Fold change 
in PBS-treated male DIO mice versus fold change in PBS-treated female DIO mice. (L) 
Fold change in leptin minipump implanted male mice versus leptin minipump implanted 
female mice. (A-I) were performed in 7-15 female mice per condition. Mean+/- SEM is 
shown for (A-D, F-I). p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by t-test (A-D, F-I). 
Genes enriched (FPKM in TRAP/FPKM in TRAP-depleted > 1.5) at baseline or in any of 
the conditions were included in this analysis (J-L). Dashed lines are at FC=1.5 and 
FC=0.667 for axis in (K, L). Each sample comprised of pooled arcuate nuclei for 10-20 















































MP DIO M/F 
Leptin 
MP M/F 
Olfr1033 0.34 0.05 2.82 1.31 7.42 2.15 
A130040M12Ri
k 0.32 0.09 3.73 1.18 3.56 3.16 
Tac2 8.51 2.47 0.86 1.16 3.45 0.74 
Cd38 9.07 4.57 3.01 7.12 1.98 0.42 
Socs2 2.66 1.40 4.00 2.68 1.90 1.49 
Gbp9 4.45 2.44 3.37 8.32 1.82 0.40 
Arid5b 2.04 1.14 3.43 2.81 1.79 1.22 
Ifi47 5.61 3.19 3.18 7.79 1.76 0.41 
Sprr1a 25.78 16.18 4.67 2.87 1.59 1.62 
BC002163 1.16 0.73 0.47 2.04 1.59 0.23 
Gbp6 6.23 3.97 2.39 7.05 1.57 0.34 
Atf3 9.25 6.34 4.97 4.00 1.46 1.24 
Foxq1 0.93 0.64 4.99 2.84 1.46 1.76 
Psmb8 3.85 2.96 1.75 2.03 1.30 0.86 
Erg 6.24 4.86 3.71 4.23 1.29 0.88 
Cd24a 3.24 2.62 3.05 2.32 1.24 1.31 
Yeats2 0.99 0.80 1.53 2.68 1.24 0.57 
Prkar2b 3.01 2.59 2.50 3.00 1.16 0.83 
Fam163a 5.44 4.82 2.76 3.68 1.13 0.75 
Vwa5a 3.14 2.80 3.79 3.73 1.12 1.02 
Socs3 4.67 4.19 4.40 4.54 1.11 0.97 
2010011I20Rik 3.40 3.28 3.56 2.23 1.04 1.60 
Cxcl12 4.54 4.45 2.93 3.55 1.02 0.83 
Filip1 1.60 1.57 3.30 3.00 1.02 1.10 
St18 4.00 3.93 3.51 4.93 1.02 0.71 
Fgfr4 1.25 1.25 5.40 1.09 1.00 4.96 
Nhlh2 3.12 3.16 2.14 2.39 0.99 0.90 
Serpina3i 2.64 2.68 4.97 5.18 0.98 0.96 
Stat1 3.07 3.13 2.29 3.31 0.98 0.69 
Serpina3h 2.71 2.78 4.74 8.81 0.97 0.54 
Irf9 3.17 3.27 2.59 3.13 0.97 0.83 
Fgl2 3.91 4.15 4.44 1.70 0.94 2.62 
Rgs4 3.42 3.71 3.00 2.86 0.92 1.05 
Otp 1.23 1.34 2.58 2.56 0.92 1.01 
Bcl3 3.97 4.39 2.99 3.05 0.90 0.98 
Ddn 1.18 1.37 1.46 2.11 0.86 0.69 




k 1.50 1.77 1.09 0.96 0.85 1.13 
Bahcc1 1.21 1.56 2.97 2.86 0.78 1.04 
Heatr8 1.04 1.35 1.80 1.87 0.77 0.96 
Asb4 3.53 4.65 2.91 2.84 0.76 1.02 
Gna14 4.46 5.90 3.22 3.54 0.76 0.91 
B2m 3.90 5.31 2.38 2.23 0.73 1.07 
Hrh3 1.29 1.87 1.32 1.59 0.69 0.83 
Irs4 2.31 3.35 3.11 3.31 0.69 0.94 
Prr7 1.20 1.81 1.67 0.99 0.66 1.68 
Pcsk1n 1.06 1.68 1.75 1.30 0.63 1.35 
C1ql2 1.04 1.68 0.93 1.88 0.62 0.49 
Serpina3n 3.10 5.05 4.09 4.03 0.61 1.01 
Glp1r 2.56 4.22 4.03 3.51 0.61 1.15 
Kcnk12 1.07 1.79 1.74 1.87 0.60 0.93 
Lepr 2.31 4.26 4.28 4.24 0.54 1.01 
Cartpt 2.78 5.21 1.84 1.40 0.53 1.32 
BC018242 1.23 2.32 1.61 1.52 0.53 1.06 
Npdc1 1.25 2.39 1.64 1.26 0.52 1.31 
Ghsr 1.71 3.32 4.49 5.80 0.51 0.78 
Acvr1c 1.47 2.99 3.17 3.86 0.49 0.82 
Ccdc107 1.18 2.42 1.29 0.96 0.49 1.35 
Ghrh 1.40 2.90 1.17 0.95 0.48 1.23 
Pomc 1.33 2.78 1.02 1.35 0.48 0.76 
Agrp 0.75 1.60 2.40 1.79 0.47 1.35 
Spint2 1.21 2.63 1.59 1.27 0.46 1.25 
Rec8 0.94 2.19 1.40 0.66 0.43 2.12 
Npy 0.69 1.69 2.47 1.65 0.41 1.50 
Car12 3.44 8.81 3.06 1.22 0.39 2.51 
C130021I20Rik 2.69 8.32 2.75 0.86 0.32 3.21 
Slc6a3 1.70 5.29 3.70 1.75 0.32 2.12 
Irx5 2.16 6.81 2.43 0.97 0.32 2.51 
Ngfr 2.21 7.00 4.01 1.43 0.31 2.81 
Adamts2 1.66 5.60 3.20 2.79 0.30 1.15 
Foxa1 2.47 8.38 2.65 0.88 0.30 3.02 
Egflam 2.02 7.58 3.14 1.60 0.27 1.96 
Gucy2c 3.57 13.43 5.19 0.99 0.27 5.25 
Tac1 2.06 8.45 2.65 0.74 0.24 3.60 
Ret 1.55 7.98 3.21 1.66 0.19 1.93 
Pitx2 2.34 12.43 2.72 0.56 0.19 4.87 




Table 2.3: Fold change in ARC LepRb-enriched genes in male and female diet-
induced obese and chow-fed leptin minipump implanted mice. TRAP-seq was 
performed in male and female LepReGFP mice fed either normal chow or high-fat diet 
and treated with PBS 10 hours prior to sacrifice. A separate cohort of male and female 
LepReGFP mice mice had minipumps implanted for two weeks filled with leptin or vehicle. 
Genes enriched (FPKM in TRAP/FPKM in TRAP-depleted > 1.5) at baseline (or that 
became enriched in any of the conditions) and whose fold changes were differentially 
regulated compared to baseline (sex-specific PBS-treated chow fed mice or vehicle 
implanted mice) were included in this analysis. Column 6 calculates the fold change in 
the DIO conditions for male and female mice. Column 7 calculates the fold change in 
leptin minipump implanted male and female mice. Each sample comprised of pooled 
arcuate nuclei of 10-20 adult mice. N=3-4 per group. The last gene (Cxcl1) is italicized 
because it was not significantly enriched in any of the conditions but is included due to a 











Figure 2.9: Fold change similarities in non-LepRb genes in the hypothalamus and 
the arcuate nucleus. Translating ribosome affinity purification (TRAP) was performed 
in LepReGFP and LepReGFPob/ob mice fed either normal chow or high-fat diet and treated 
with either PBS or leptin by injection or 2-week minipump implantation (leptin: 5mg/kg 
i.p. injection or 2.2mg/kgday minipump). Fold change values for the non-LepRb fraction 
of each group were calculated and compared to littermate control PBS-treated LepReGFP 
mice. Those genes that were significantly changed and that were not enriched in the 
LepRb fraction were included. (A) Heat map detailing the relationship via dendrogram 
between genes (left axis) and conditions (top axis) in whole hypothalamic dissections. 
(B) Hypothalamic fold change in 10-hour leptin treated mice versus fold change in DIO 
mice. (C) Those genes from the arcuate nuclei dissections and were significantly 
changed are mapped here with the relationships revealed in the dendrograms on the 
top and left axis. (D) Arcuate specific fold change in 10-hour leptin treated mice vs fold 
change in DIO mice. (E) Arcuate specific fold change in 10-hour leptin treated mice vs 
fold change in leptin minipump implanted mice. Genes enriched (FPKM in TRAP/FPKM 
in TRAP-depleted > 1.5) at baseline or in any of the conditions were not included in this 
analysis. Dashed lines are at FC=1.5 and FC=0.667 for axis in (B, D-E). Each sample 
comprised of pooled hypothalami for 4-6 adult mice or pooled arcuate for 10-22 adult 
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 LACK OF STAT1 DOES NOT EXACERBATE LACK OF STAT3 
IN LEPTIN RECEPTOR NEURONS 
 
Chapter Summary 
Leptin is the key hormone responsible for regulating energy balance by signaling 
through its receptor (LepRb) in the brain an individual’s approximate energy stores. The 
majority of leptin’s anorectic action is mediated through the phosphorylation of Tyr1138 
on the intracellular tail of LepRb. In cell culture, Tyr1138 recruits and phosphorylates both 
STAT1 and STAT3, and while STAT3 is the transcription factor responsible for much of 
leptin action, leptin action through STAT1 has not been examined closely. Here, we 
employed LepRb specific TRAP-seq to identify the transcriptome of leptin-deficient 
ob/ob mice and STAT3 null (STAT3LepRKO) mice. Surprisingly, the transcriptional 
difference between the obese ob/ob and marginally less obese STAT3LepRKO mice 
involves genes known to be involved in STAT1 action. Furthermore, in STAT3LepRKO 
mice, STAT1 mRNA and protein both increase dramatically, suggesting a compensatory 
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mechanism consistent with the overlapping function of STAT proteins in other systems. 
To determine the role STAT1 plays on energy balance, we conditionally deleted STAT1 
in LepRb neurons and found metabolic parameters to be unchanged. Additionally, the 
further ablation of STAT1 on top of STAT3 null mice did not exacerbate the obesity. 
Thus, STAT1 does not appear to contribute to energy balance; however, it’s increase in 
neighboring glia when deleted in neurons highlights the importance of interactions 





Obesity is an ever-increasing problem in the United States. And as the rate of 
obesity increases, its costs rise proportionally: in addition to driving diabetes, 
cardiovascular disease and a variety of cancers, obesity is responsible over 20% of 
current US health care costs.1 
Leptin is produced in white adipocytes in proportion to the individual’s triglyceride 
content and travels through the circulation to the central nervous system, where it binds 
to its receptor (LepRb) to regulate energy balance.2–4 Bound LepRb results in the 
autophosphorylation and activation of Janus-activated Kinase 2 (JAK2) and consequent 
phosphorylation of the three tyrosine residues (Tyr985, Tyr1077, Tyr1138) on the 
intracellular tail of the receptor.5–8 Tyr985 recruits SHP2 and Socs3 to attenuate LepRb 
signaling, Tyr1077 recruits STAT5, and Tyr1138 recruits STAT3. Together, these tyrosines 
and downstream transcriptional signals are largely responsible for leptin action, for mice 
with these three tyrosine mutated (LepRb123F) or the receptor truncated (LepRbΔ65) are 
phenotypically similar to LepRb-deficient db/db animals.9,10 Furthermore, genetic 
mutation analysis revealed no phenotypic difference between mutation of all three 
tyrosines (LepRb123F) and of only Tyr1138 (LepRb3F), pointing to Tyr1138 as the tyrosine 
responsible for the majority of LepRb action.9 Importantly, phosphorylation of Tyr1138 
results in the recruitment and activation of STAT3.7,11 This JAK2-STAT3 pathway 
mediates the majority of leptin’s control of energy balance.12  
And while much of the Tyr1138-mediated control of energy balance is mediated by 
STAT3, recent transcriptome analysis of LepRb neurons revealed novel genes enriched 
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in LepRb neurons that may be separate from STAT3 action but part of Tyr1138 
signaling.13 Additionally, in cultured cells, Tyr1138 recruits and activates both STAT1 and 
STAT3.14 And, due to the overlapping function of STAT proteins, STAT1 may, like 
STAT3, mediate part of leptin action through Tyr1138.  
Results 
STAT3 in leptin receptor neurons is critical for energy balance 
LepReGFP mice (homozygous for Rosa26eGFP-L10a) were crossed to STAT3flox mice 
to generate LepRcre/creSTAT3flox/flox (STAT3LepRKO) and LepRcre/creSTAT3+/+ (LepReGFP) 
mice. In STAT3LepRKO mice, exons 18-20 of STAT3 (which encode the SH2 domain) 
are conditionally deleted in LepRb-expressing neurons (Figure 3.1A). To confirm the 
ablation of STAT3 in LepRb neurons, STAT3LepRKO and LepReGFP mice were treated 
with PBS vehicle or leptin (5mg/kg; i.p.) for 90 minutes and pSTAT3-IR in eGFP-labeled 
LepRb neurons was assessed (Figure 3.1B). As expected, in LepReGFP mice, leptin 
treatment strongly induces pSTAT3; however, in STAT3LepRKO mice, pSTAT3 is absent 
with leptin treatment (Figure 3.1B). Given the importance of LepRb→STAT3, 
STAT3LepRKO mice have expectedly more adiposity and decreased lean mass (Figure 
3.1C). In addition, these obese STAT3LepRKO mice have markedly elevated leptin and 
insulin levels (Figure 3.1D, 3.1E). 
Transcriptional profiling of leptin-active and leptin-deficient animals. 
Mice on the eGFP-L10a background were in one of seven conditions: 1. 
STAT3LepRKO , 2. LepReGFP treated with PBS 10 hours prior to sacrifice, 3. LepReGFP 
treated with leptin (5mg/kg, i.p.) 3 hours prior to sacrifice, 4. LepReGFP treated with leptin 
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(5mg/kg, i.p.) 10 hours prior to sacrifice, 5. LepReGFP mice fasted for 24 hours, 6. 
LepReGFPob/ob (on the ob/ob background) treated with PBS 10 hours prior to sacrifice, 
and 7. LepReGFPob/ob treated with leptin (5mg/kg, i.p.) 10 hours prior to sacrifice. 
Hypothalami from all groups were pooled, at least three independently pooled samples 
from each condition were sequenced and the differentially expressed genes were 
analyzed. Gene expression comparisons were analyzed between the LepRb neuron 
fraction (pull-down) and the non-LepRb cell fraction (supernatant) to generate a list of 
enriched genes. Then, further comparisons were performed between the gene 
expression values from the various conditions against the control PBS-treated LepReGFP 
condition to identify the genes that were differentially regulated (the leptin-treated 
LepReGFPob/ob condition was the only one not compared to the PBS-treated LepReGFP 
sample; rather, the PBS-treated LepReGFPob/ob condition was used as the baseline). 
From these six comparisons, over 150 genes were found to be differentially regulated 
and enriched in LepRb neurons and are displayed in the heatmap, which demonstrates 
the clear dichotomy of relationships between the conditions of leptin action (3h leptin, 
10h leptin, ob/ob leptin) and leptin deficiency (STAT3LepRKO and ob/ob) (Figure 3.2A). 
Due to the similar hyperphagic obesity experienced in STAT3LepRKO and 
LepReGFPob/ob mice, it is unsurprising that STAT3LepRKO and LepReGFPob/ob mice 
share a close transcriptional relationship, particularly given the importance of STAT3 in 
leptin action. Comparison of the fold expression changes observed in STAT3LepRKO and 
LepReGFPob/ob (versus LepReGFP PBS) would determine genes that are regulated by 
LepRb→STAT3, by LepRb action independent of STAT3, and by STAT3 signaling 
independent of LepRb (Figure 3.2B, Table 3.2). Genes that are coordinately regulated 
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by both STAT3 and leptin are labeled as I and I’ (red background in 2B) and include 
many of the neuropeptides known to be involved in leptin action, including Pomc, Agrp, 
Npy, Nts and Cartpt. However, when all these genes were analyzed, there were no 
significantly enriched terms that appeared through transcription factors protein-protein 
interactions (TF-PPIs) (data not shown). The genes with significant fold changes in 
ob/ob, but not in STAT3LepRKO mice, are denoted in green with II and II’ (Figure 3.2B, 
Table 3.2). Through TF-PPI analysis, these group II genes are most enriched for 
EP300, which has been implicated in leptin action (Figure 3.2C, Table 3.3).15,16 Last, 
fold change expression of the genes in group III is significantly altered in STAT3LepRKO 
mice, but not in LepReGFPob/ob mice, suggesting that these genes are leptin regulated 
but independent of STAT3 action (Figure 3.2, Table 3.2). Through TF-PPI, group III 
genes are highly significant for a number of pathways, including IRF3, STAT1 and 
STAT2 (Figure 3.2C, Table 3.3). This, together with the significantly increased Stat1 
transcript in STAT3LepRKO mice and participation of STAT1 in LepRb signaling in 
cultured cells,14 suggests that STAT1 may drive the expression of these group III genes 
in the absence of STAT3. It is important to note that  STAT1 activity disappears with 
complete leptin absence (ob/ob group), further confirming the existence of a 
leptin→STAT1 signal. 
RT-qPCR confirms TRAP-seq gene expression 
Previously, Allison et. al. demonstrated that differential expression of genes 
determined by TRAP-seq not only follows trends in quantitative RT-qPCR gene 
expression levels, but is also more specific for LepRb neurons.13 We similarly confirmed 
our LepRb transcriptome findings with RT-qPCR, and as expected, the discovered 
83 
 
changes in gene expression of target genes by RT-qPCR in ob/ob and STAT3LepRKO 
mice align with the observed changes by TRAP-seq (Table 3.1). Additionally, we 
employed RT-qPCR on LepRs/s mice (which contain a mutation in Tyr1138 that prevents 
recruitment of STAT3 to LepRb while leaving global STAT3 signaling intact) and found 
expression levels to be similar to either that of ob/ob mice or that of the STAT3LepRKO 
mice, depending on the gene (Table 3.1). All together, our analysis confirms the 
elevation of Stat1 and STAT1-induced transcripts (Irf1 and Psmb8) in STAT3LepRKO 
mice, but not in LepRs/s or ob/ob mice; thus, STAT1’s upregulation in the absence of 
STAT3 may be downstream of LepRb→Tyr1138. 
STAT3 absence results in increased STAT1 protein expression 
To explore this coupling of STAT1 and STAT3, the fold expression changes of 
Stat1 in LepRb neurons (LepRSTAT1) and of Stat3 in LepRb neurons (LepRSTAT3) under a 
number of conditions are plotted (Figure 3.3A). Excluding the STAT3LepRKO condition, 
the fold change relationship between LepRSTAT1 and LepRSTAT3 is remarkably linear 
(r2=0.9172) (Figure 3.3A). The outlier is the STAT3LepRKO condition, which is expected 
due to the deletion of Stat3 in LepRb neurons; although, perhaps more interesting is the 
3.49-fold change of Stat1. This dramatic increase of Stat1 is confirmed with 
immunohistochemical studies demonstrating a robust increase in STAT1 protein in 
LepRb neurons of STAT3LepRKO mice (Figure 3.3B-E). 
Conditional ablation of STAT1 in LepR neurons 
STAT3LepRKO mice, while obese, are not as obese as ob/ob mice, suggesting the 
presence of other LepRb-specific anorectic signals that contribute to the ob/ob 
84 
 
phenotype. Therefore, we conditionally deleted Stat1 in LepRb neurons to generate 
LepRcre/creSTAT1flox/flox (STAT1LepRKO) and LepRcre/creSTAT1+/+ (LepRcre) control mice 
(Figure 3.4A). Through in situ hybridization, we confirmed the deletion of Stat1 from 
LepRb neurons in STAT1LepRKO (Figure 3.4C). Interestingly, both 
immunohistochemistry and ISH suggest that STAT1 ablation in LepRb neurons results 
in the increase of STAT1 in neighboring tanycytes/glia (Figure 3.4B, 3.4C). In addition, 
we crossed these STAT1LepRKO to STAT3LepRKO to generate STAT3LepRKO single 
conditional knock-out mice and littermate STAT1STAT3LepRKO double knock-out mice, 
which lose the robust STAT1 expression seen in STAT3LepRKO (Figure 3.6). 
Absence of STAT1 in LepR neurons does not perturb energy balance 
Generally, male and female STAT1LepRKO have comparable body weights, food 
intake, body composition, blood glucose, serum leptin and serum insulin to littermate 
control LepReGFP mice (Figure 3.5, Figure 3.8). STAT1LepRKO mice also responded 
similarly to glucose and insulin tolerance tests when compared to LepReGFP controls 
(Figure 3.5, Figure 3.8, Figure 3.10). Moreover, the further deletion of STAT1 in 
STAT3LepRKO mice did not exacerbate the obesity experienced; indeed, 
STAT1STAT3LepRKO mice had similar body weights, food intake, body composition, 
blood glucose, serum leptin, serum insulin levels compared to STAT3LepRKO mice 
(Figure 3.7, Figure 3.9). Glucose and insulin tolerance were also comparable between 
STAT1STAT3LepRKO and STAT3LepRKO mice (Figure 3.6, 3.9, 3.10). 
Markers of gliosis present in STAT1LepRKO animal 
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Microglial activation and astrogliosis are markers of injury and have been 
postulated to play a role in obesity.17 In male STAT1LepRKO animals (compared to their 
LepReGFP littermate controls), the number of microglia are elevated in the ARC using 
immunohistochemical microglia specific marker Iba1 (Figure 3.11a, 3.11b, 3.11e). 
Additionally, the number of astrocytes is also higher in the ARC with a concomitant 
increase in the average area of each astrocyte (Figure 3.11c, 3.11d, 3.11g, 3.11h). 
These findings, when coupled to the increase of STAT1 in neighboring glia with its 
ablation in LepRb neurons may point to a new mechanism of DIO-induced gliosis 
(Figure 3.4B, Figure 3.4C). 
Discussion 
Tyr1138 is responsible for the majority of leptin’s actions and STAT3 is the main 
downstream signal that mediates those effects. Another STAT protein, STAT1, is also 
recruited by Tyr1138 and is tightly coupled to STAT3 activity under various metabolic 
conditions. Of particular interest is our data demonstrating the upregulation of STAT1 
when STAT3 is deleted in LepRb-expressing neurons (STAT3LepRKO), suggesting that 
at least part of Tyr1138 is preserved in STAT3 absence. Furthermore, the gene 
expression differences between STAT3LepRKO, LepRbs/s, and ob/ob mice point to the 
existence of leptin-dependent STAT1 signaling. 
 Our data, however, show that STAT1, although regulated by leptin→Tyr1138 and 
coupled to STAT3 signaling, does not provide a significant metabolic signal or 
exacerbate STAT3 deficiency when deleted in LepRb neurons. While its absence does 
not appear to have a metabolic consequence, it does result in increased gliosis in the 
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hypothalamus and STAT1 expression in neighboring non-LepRb neurons. 
STAT1LepRKO animals are then an example of lean mice that experiences gliosis and 
points to the importance of the LepRb neuronal interaction with neighboring cells. 
Therefore, the gliosis observed in diet-induced obesity (DIO) may not necessarily drive 
obesity but it may instead be a consequence of the cross-talk between LepRb neurons 
and microglia/astrocytes.17 
 Finally, DIO is at times considered a state of STAT3-deficiency; there are clear 
phenotypic similarities between DIO and STAT3LepRKO mice: both are obese, 
hyperleptinemic, and do not phenotypically or immunohistochemical (via pSTAT3-IR) 
respond to exogenous leptin treatment. However, our TRAP-seq analyses demonstrate 
that Stat1 and Stat3 fold change expression in LepRb neurons under DIO are dissimilar 
to those in STAT3LepRKO. While this body of work examined the metabolic consequence 
of deleting STAT proteins, future work should examine the interactions between STAT1 
and STAT3 during elevated states like DIO. 
Materials and Methods 
Mice. 
Mice were bred in our colony in the Unit for Laboratory Animal Medicine at the 
University of Michigan; these mice and the procedures performed were approved by the 
University of Michigan Committee on the Use and Care of Animals and in accordance 
with AALAC and NIH guidelines. We purchased male and female C57BL/6 mice 
(Jackson stock #000664) and ob/ob mice (Jackson stock #000632) for experiments and 
breeding studies from Jackson Labs. STAT1flox (Jackson stock #012901) and STAT3flox 
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(Jackson stock #016923) mice were also from Jackson. Mice were bred at the 
University of Michigan and provided with food and water ad libitum in temperature 
controlled rooms on a 12-hour light-dark cycle. 
We generated LepReGFP mice by crossing LepRcre mice18 onto the eGFP-L10a 
background to generate LepRcre/+;Rosa26eGFP-10a/+ mice,19 which we then intercrossed to 
generate double homozygous LepRcre/cre;RosaeGFP-10a/eGFP-L10a (LepReGFP) study animals. 
LepReGFP mice were backcrossed to ob/ob mice until LepRcre/cre;RosaeGFP-L10a/eGFP-
L10a;ob/+ mice were obtained. These mice were subsequently intercrossed to generate 
LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;ob/ob (LepReGFPob/ob) and LepRcrecre;RosaeGFP-
L10a/eGFP-L10a;+/+ (LepReGFP) control mice for study. STAT3flox mice were backcrossed to 
LepReGFP mice to generate LepReGFP-L10a;STAT3flox/+ mice. These mice were then 
intercrossed to generate LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT3flox/flox (STAT3LepRKO) 
and LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT3+/+ (LepReGFP) control mice for study. 
STAT1flox mice were then crossed to STAT3LepRKO mice to generate 
LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT3flox/+;STAT1flox/+, which were intercrossed to 
generate LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT3flox/flox (STAT3LepRKO), 
LepRcre/cre;RosaeGFP-L10a/eGFP-L10a;STAT1flox/flox;STAT3flox/flox (STAT1STAT3LepRKO) mice 
for study. LepRs/s mice and controls were generated as previously described.20 
Leptin treatment, high-fat diet, SMLA treatment, and fasting. 
For LepRSTAT1 and LepRSTAT3 fold induction TRAP-seq experiments, mice were 
weaned onto either a standard chow diet (Purina Lab Diet 5001) or a 60% high-fat diet 
(Research Diets D12492, 60% kcal from fat) for at least 8 weeks and were dissected at 
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12-14 weeks of age. Food was removed at the onset of the light cycle and mice were 
treated four hours later with metreleptin (5mg/kg, i.p.), PASylated superactive mouse 
leptin antagonist (SMLA; Protein Laboratories Rehovot; 100pmol/g; i.p.), vehicle (0.9% 
sodium chloride; Hospira; i.p.). For the fasting condition, mice were fasted for 24 hours. 
All conditions were compared to the control LepReGFP vehicle injected animals raised on 
standard chow. For immunohistochemistry, mice had food removed at the onset of the 
light cycle. Animals were treated four hours later with metreleptin (5mg/kg, i.p.) and 
subjected to perfusion 90 minutes after treatment. 
Immunohistochemistry. 
Prior to perfusion, mice were anesthetized with a lethal dose of pentobarbital and 
transcardially perfused with phosphate buffered saline (PBS) followed by 10% buffered 
formalin. Brains were removed, placed in 10% buffered formalin overnight, and 
dehydrated in 30% sucrose for one week. Using a freezing microtome (Leica), brains 
were cut into 30 um sections. Sections were treated sequentially with 1% hydrogen 
peroxide/0.5% sodium hydroxide, 0.3% glycine, 0.03% sodium dodecyl sulfate, and 
blocking solution (PBS with 0.1% triton, 3% Normal Donkey Serum). Immunostaining 
was performed using primary antibodies for pSTAT3 (Cell Signaling #9145, 1:1000), 
GFP (Aves Labs #GFP1020, 1:1000), STAT1 (Santa Cruz sc-346, 1:250), dsRed 
(Living Colors #632496, 1:1000), Iba1 (Wako, 1:1000), and GFAP (Millipore, 1:500). All 
antibodies were reacted with species-specific Alexa Fluor-488 or -568 conjugated 
secondary antibodies (Invitrogen, 1:200) or processed with the avidin-
biotin/diaminobenzidine (DAB) method (ABC kit, Vector Labs, 1:500; DAB reagents, 
Sigma). Images were collected on an Olympus BX53F microscope. DAB images were 
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pseudocolored using Photoshop software. Quantification was performed on 
anatomically matched brain regions with pre-set regions of interest using the Olympus 
BX53F software. Both sides of the arcuate nucleus were counted and groups means 
were determined (n=10-14 animals per group). 
In situ hybridization.   
For in situ hybridization (ISH), adult STAT1LepRKO, STAT3LepRKO, 
STAT1STAT3LepRKO and wildtype control mice were anesthetized with isoflurane and 
then euthanized by decapitation. Whole brains were dissected, flash frozen in 
isopentane, chilled on dry ice and stored at -80°C. 16 μm-thick coronal sections were 
cut on a cryostat (Leica), thaw-mounted to SuperFrost Plus slides, allowed to dry at -
20°C for one hour and then stored at -80°C. Slides were then processed for ISH using 
RNAScope technology per the manufacturer’s protocol (Advanced Cell Diagnostics). 
For all slides, the multiplex fluorescent assay (320850) was used to visualize Stat1 
(11ZZ) and Cre (312281-C3) probes using Amp 4 Alt-A. Images were obtained with an 
Olympus BX53F and QImaging Retiga 6000 monochrome camera under 40X objective. 
All images were processed identically in CellProfiler (Lamprecht MR 2007 
Biotechniques) to reduce nonspecific background. Serial images (16 per arcuate 
nucleus) were taken and stitched together using Photoshop (Adobe). 
Phenotyping of STAT-null mice and control mice.   
STAT1LepRKO, STAT3LepRKO, STAT1STAT3LepRKO and littermate control 
(LepRcre) mice were weaned into individual housing at 21 days and fed normal chow 
(Purina Lab Diet 5001). Weekly body weight and food intake were monitored. Unfasted 
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blood glucose sample was take every other week from 4-12 weeks of age. Glucose 
tolerance test (2g/kg body weight, i.p.) and insulin tolerance test (1 unit/kg body weight, 
Humulin (Eli Lilly), i.p.) were performed in 13 and 14 week old mice, respectively, after a 
5 hour fast three hours after the start of the light-cycle. Analysis of body fat and lean 
mass was performed at 15 weeks of age using NMR-based analyzer (Minispec LF90ll, 
Bruker Optics). Leptin and insulin were assayed by commercial ELISA (Crystal Chem). 
Hypothalamic and arcuate dissections for TRAP-seq and RT-PCR. 
At the midpoint of the light cycle, adult homozygous mice were anesthetized with 
isoflurane, had their brains removed and placed onto a mouse coronal brain matrix 
(1mm sections). For whole hypothalamic dissections, a 3x3x3mm block was dissected 
from the ventral diencephalon immediately caudal to the optic chiasm and immediately 
homogenized for TRAP-seq analysis. For arcuate specific dissections, 3 consecutive 
1mm sections were removed immediately caudal to the optic chiasm, and arcuate nuclei 
were dissected bilaterally by hand from the mediobasal hypothalamus of each section, 
pooled and snap frozen for later processing. 
Translating Ribosome Affinity Purification with deep sequencing (TRAP-seq). 
We employed anti-eGFP Translating Ribosome Affinity Purification (TRAP) using 
hypothalamic material from PBS and leptin treated LepReGFP, LepRLepRob/ob, and 
STAT3LepRKO mice (which all express an eGFP-tagged ribosomal subunit in LepR 
cells). Messenger RNA isolated from eGFP-tagged ribosomes and from the eGFP-
depleted fraction was assessed for quality using TapeStation (Agilent, Santa Clara, CA) 
and samples with RNA Integrity Numbers (RINs) of 8 or greater were prepared using 
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the Illumina TruSeq mRNA Sample Prep v2 kit (Catalog # RS-122-2001 and #RS-122-
2002) (Illumina, San Diego, CA), where 0.1-3ug of RNA was converted to mRNA using 
a polyA purification. The mRNA was chemically fragmented and copied into first strand 
cDNA using reverse transcriptase and random primers. The 3’ ends of the cDNA were 
adenylated and the 6-nucleotide-barcoded adapters ligated. These products were then 
purified and enriched by PCR to create the cDNA library, which were checked for quality 
and quantity by TapeStation (Agilent) and qPCR using Kapa’s library quantification kit 
for Illumina Sequencing platforms (catalog #KK4835) (Kapa Biosystems, Wilmington 
MA). They were clustered on cBot (Illumina) and sequenced 4 samples per lane on a 50 
cycle single end run on a HiSeq 2000 (Illumina) using version 2 reagents according to 
manufacturer’s protocols. 
RNA-seq analysis 
50 base pair single end reads underwent QC analysis prior to alignment to 
mouse genome build mm10 using TopHat and Bowtie alignment software.21 Differential 
expression was determined using Cufflinks Cuffdiff analysis, with thresholds for 
differential expression set to fold change >1.5 or <0.66 and a false discovery rate of 
</0.05 22. Lists of differentially expressed genes were then queried against the Uniprot 
Database for gene ontology and protein class analysis.23 
RNA extraction of arcuate nuclei and analysis by RT-qPCR. 
 RNA was extracted from microdissected hypothalamic using Trizol (Invitrogen) 
according to manufacturer’s protocol and subsequently converted to cDNA using iScript 
cDNA synthesis kit (Biorad #170-8891) for use in reverse transcription PCR. cDNA was 
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analyzed in triplicate by quantitative real time PCR on an Applied Biosystems 
StepOnePlus Real-Time PCR System for TBP (endogenous control) and the following: 
Socs3, Atf3, JunB, Arid5a, Etv6, Fos, Slco1a4, Ghrh, Agrp, Pomc, Serpina3h, Tbx19, 
Pltp, and Gdd45g. All Taqman assays were acquired from Applied Biosystems (Foster 
City, CA). We calculated relative mRNA expression values using the 2-ΔΔCt method with 
normalization of each sample ΔCt value to the average ΔCt value from the control mice. 
Statistics. 
Data are reported as mean +/- SEM. RT-qPCR data are reported as mean fold change 
compared to normalized vehicle. Statistical analysis of physiological data was 
performed with Prism software (version 7). Unpaired t-test was used to compare results 
between two groups. Body weight gain, cumulative food intake, body length, GTT and 





Figure 3.1: Deletion of STAT3 in LepRb neurons. (A) Schematic diagram showing 
the cross of LepRcre with STAT3flox mice to generate STAT3LepRKO mice through 
excision of exons 18 to 20 of the STAT3 gene. (B) Representative images showing 
colocalization of pSTAT3-IR (red) with GFP-IR (green) in the PMv of STAT3LepRKO and 
LepRcre control mice (both of which are on the Rosa26eGFP-L10a background) treated with 
leptin (5mg/kg; i.p.) or PBS vehicle for 90 minutes. Arrows denote dual labeled neurons. 
(C) STAT3LepRKO and LepRcre control mice underwent body composition analysis by 
NMR spectroscopy. Blood serum from mice were assayed for leptin (D) and insulin (E). 
n=15 per group. Mean +/- SEM; ***p<0.001 by unpaired t-test; ***p<0.0001 by unpaired 






Figure 3.2: LepRb-enriched genes regulated by STAT3 and leptin action. 
Translating ribosome affinity purification (TRAP) was performed in STAT3LepRKO, 
LepReGFPob/ob, and LepReGFP mice. (A) Fold change values for each of the groups 
were calculated and compared to littermate control PBS-treated LepReGFP or PBS-
treated LepReGFPob/ob mice. Each sample comprised of pooled hypothalamic for 5-8 
adult animals. n=3-4 pooled samples per condition. (B) Both fold change values for 
STAT3LepRKO mice and LepReGFP ob/ob mice were calculated compared to control 
LepReGFP mice; fold change values are plotted and dashed lines are at FC=1.5 and 
FC=0.667 for both axes. (C) The genes in groups II and III are detailed with their 
corresponding list of transcription factors, as determined by the Transcription Factors 






































  Fold Change in TRAP Fold Change in Arcuate  
Gene Enrichment  ob/ob STAT3LepRKO ob/ob STAT3LepRKO Leprs/s 
Agrp 75.34 5.55 3.73 1.75 3.28 3.87 
Stat1 1.43 0.56 3.49 0.73 1.46 0.96 
Stat3 2.61 0.52 0.87 0.79 0.94 0.89 
Psmb8 2.37 0.8 13.81 1.74 4.65 1.4 
Irf1 1.88 0.71 2.91 0.98 1.51* 0.78 
Irf9 2.19 0.38 2.2 0.66 1.2 0.67 
Gch1 8.99 0.51 0.81 0.57 1.04 1.03 
Socs3 2.51 0.25 1.05 0.48 0.76 1.34 
 
Table 3.1: Fold change in ob/ob, STAT3LepRKO, and Leprs/s mice as determined by 
TRAP or qPCR. TRAP-Seq was performed on STAT3LepRKO, LepRbeGFP and 
LepRbeGFPob/ob mice. Genes enriched (FPKM in TRAP/FPKM in TRAP-depleted >1.5) 
at baseline, or that became enriched in a condition in which they were also significantly 
changed, were included in this analysis. Enrichment and expression (FPKM) values 
displayed are from LepRbeGFP mice. Fold change values as determined by RNA-Seq for 
STAT3LepRKO mice were versus LepRbeGFP controls (Column 4), Fold change values 
as determined by RNA-Seq for LepRbeGFP-L10aob/ob (Column 3) are versus 10-hour 
vehicle treated LepRbeGFP. N=3-4 samples per treatment group. Each sample was 
comprised of pooled hypothalami of 4-6 adult animals. Whole RNA was also isolated 
from the arcuate nuclei of adult ob/ob and c57bl6 controls, Leprs/s and Lepr+/+ controls, 
and STAT3LepRKO and LepRbeGFP mice (n=8-10 mice per group). Changes in transcript 
expression were assayed by RT-qPCR using ABI Taqman assays for the listed genes, 












Figure 3.3:  STAT1 increases in STAT3 absence. (A) TRAP-seq was performed on 
STAT3LepRKO mice; LepReGFPob/ob mice treated with PBS or leptin; and LepReGFP mice 
treated with leptin, SMLA antagonist, HFD, or fasting; STAT1 and STAT3 fold changes 
values (compared against control LepReGFP STAT1 and STAT3 expression) are plotted 
and the line of best fit is shown for all conditions except the STAT3LepRKO outlier. (B-E) 
Representative images showing colocalization of STAT1-IR (red) and GFP-IR (green) in 






Figure 3.4: Deletion of STAT1 in LepRb neurons. (A) Schematic diagram showing 
the cross of LepRcre with STAT1flox mice to generate STAT1LepRKO mice through 
excision of exons 6 to 10 of the STAT1 gene. (B) Representative images showing 
colocalization of STAT1-IR (red) with GFP-IR (green) in the hypothalamus of 
STAT1LepRKO and LepRcre control mice (both of which are on the Rosa26eGFP-L10a 
background). (C) Representative ISH images showing Stat1 (brown) in the arcuate 







 does not regulate energy balance. (A) Male STAT1LepRKO and 
LepReGFP (littermate control) mice were placed on chow and body weight (A) measured 
weekly, and cumulative food intake (B) measured weekly. (C-D) At 14 weeks of age, 
animals underwent body composition by NMR spectroscopy. (E) Glucose concentration 
for male 12-week-old mice. Serum from 12-week-old mice were assayed for leptin (F) 
and insulin (G). Mice at weeks 12-14 of age were treated with (H) glucose (2g/kg; i.p.) 
and blood glucose concentrations were measured, and area under the curve analysis (I) 
was performed. N=10-15 for all genotypes. ANOVA analysis was performed for (A, B, 





Figure 3.6:  Deletion of STAT1 and STAT3 in LepRb expressing neurons. (A) 
Schematic diagram showing the cross of LepRcre with STAT1flox and STAT3flox mice to 
generate STAT3LepRKO and STAT1STAT3LepRKO mice. pA: polyadenylation signal. (B) 
Representative images showing colocalization of STAT1-IR (red) with GFP-IR (green) in 
the arcuate nucleus of STAT3LepRKO and STAT1STAT3LepRKO (both of which are on 
the Rosa26eGFP-L10a background) mice. (C) Representative ISH images showing Stat1 





Figure 3.7: Ablation of STAT1 does not exacerbate metabolic parameters in mice 
that lack STAT3 in LepRb-expressing neurons. Male STAT3LepRKO and 
STAT1STAT3LepRKO mice were placed on chow and body weight (A) and cumulative 
food intake (B) were measured weekly. (C, D) At 14-15 weeks of age, animals 
underwent body composition analysis by NMR spectroscopy. (E) Blood glucose 
concentrations for 12-week-old male STAT3LepRKO and STAT1STAT3LepRKO mice. 
Serum from 12-week-old mice were assayed for leptin (F) and insulin (G). (H) Mice at 
12-14 weeks of age were treated with glucose (2g/kg; i.p) and blood glucose 
concentrations were measured. (I) Area under the curve analysis for GTT was 
performed. N=8-14 per genotype. ANOVA analysis was performed for (A, B, H); 











KO Stat3/ob Group 
9230105E10Rik 0.40 0.34 1.61 4.28 4.97 
I 
Adrb2 0.86 0.34 2.07 3.08 1.34 
Agrp 75.34 229.60 5.55 3.73 0.73 
Apoa1 0.93 0.73 2.25 1.99 0.73 
Apol9a 1.87 0.14 1.75 8.08 6.57 
Ccl17 1.73 1.81 2.62 4.32 0.85 
Cdhr3 1.60 0.46 1.84 1.89 0.73 
Fam159a 4.79 6.09 2.94 2.25 0.88 
Fosl2 0.95 2.31 3.26 1.50 0.65 
Gdpd3 1.34 4.79 1.54 2.06 0.90 
Gm885 1.81 0.30 7.88 3.01 1.11 
Il18bp 0.32 0.65 2.28 5.62 4.37 
Isg20 0.34 0.20 2.64 7.83 1.90 
Krtap17-1 2.88 1.35 2.07 1.56 0.53 
Maff 1.47 1.37 1.88 2.18 0.83 
Nmb 0.93 3.45 4.14 1.73 0.54 
Npy 24.98 1152.79 4.17 3.39 0.86 
Rbp4 2.05 10.30 1.92 1.74 0.93 
Samd9l 0.65 0.34 1.51 4.44 5.80 
Spink8 0.59 0.56 3.50 5.07 1.55 
Cartpt 11.37 661.42 0.28 0.35 1.07 
I' 
Gm5779 1.71 2.17 0.52 0.11 0.14 
Npy2r 3.72 18.83 0.44 0.61 1.78 
Nts 5.39 113.14 0.41 0.37 0.93 
Pomc 37.76 539.53 0.16 0.28 1.39 
Serpina3n 13.18 69.85 0.26 0.51 1.97 
Tmem176a 3.92 32.57 0.40 0.57 1.38 
Tnfrsf11b 3.22 1.31 0.42 0.58 1.77 
Tuba1c 1.42 10.46 0.37 0.15 0.21 
Ucn 14.97 16.44 0.35 0.31 0.54 
Bahcc1 2.58 5.86 1.86 1.02 0.73 
II 
Brca2 1.22 1.26 1.56 1.27 0.85 
Btg1 1.39 11.68 1.55 1.29 0.88 
Camk1g 2.41 31.35 1.53 1.15 0.64 
Ctla2a 0.82 2.47 2.97 1.19 0.52 
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Cyp4v3 1.06 0.99 2.20 1.32 0.85 
Ezr 1.41 7.02 1.51 1.45 1.08 
Fam46a 1.73 5.37 1.73 1.11 0.80 
Fosb 1.32 1.05 3.20 1.31 0.38 
Gem 1.76 1.91 1.67 1.12 0.50 
Ghrh 11.83 56.26 2.66 1.08 0.36 
Ghsr 3.73 2.21 1.74 1.24 0.75 
Hs3st1 0.82 7.56 2.06 1.33 0.82 
N4bp2l1 1.83 49.33 1.50 1.37 0.96 
Rpl22l1 2.30 657.56 1.51 1.16 1.14 
Rplp2 1.92 941.48 1.51 1.24 0.86 
Snhg8 1.45 24.62 1.65 1.28 0.78 
Tnrc18 2.32 14.56 1.59 0.92 0.80 
Xist 2.91 1.92 2.47 1.48 2.22 
Anxa2 1.34 11.51 0.63 0.89 1.48 
II' 
Asb4 9.86 63.03 0.61 0.76 1.39 
Atg7 8.52 61.48 0.42 0.68 1.83 
Bcl3 1.86 0.71 0.43 0.90 1.45 
Chodl 2.01 4.61 0.62 0.79 1.49 
Fam179a 1.89 3.45 0.66 0.80 1.02 
Gch1 8.99 14.49 0.51 0.81 1.31 
Gstm6 3.04 45.54 0.62 0.83 1.03 
Gsx1 12.87 9.73 0.64 0.98 1.14 
Irs4 5.62 55.04 0.60 0.82 1.39 
Nr0b1 7.73 2.57 0.49 0.82 1.33 
Plagl1 2.97 33.71 0.55 0.85 1.54 
Serpina3i 31.59 0.58 0.13 1.37 6.18 
Socs3 2.51 1.94 0.25 1.05 3.65 
Stat3 2.61 31.53 0.52 0.87 1.63 
Tac1 4.55 301.96 0.57 0.83 1.72 
Tmem176b 2.79 57.43 0.55 0.71 1.29 
Tnfaip8l3 1.71 5.26 0.53 0.77 1.58 
Vwa5a 2.27 6.88 0.52 0.99 2.04 
Yeats2 5.46 37.38 0.62 0.78 1.51 
1500012F01Rik 1.70 137.17 1.34 1.69 1.06 
III 
Apol6 0.94 0.37 1.12 4.82 3.92 
B2m 1.77 60.49 0.82 6.09 10.66 
Bst2 1.11 1.45 1.30 49.14 47.84 
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Casp1 0.54 0.37 0.90 4.39 4.66 
Cd274 2.51 2.52 0.84 3.87 5.49 
Cish 1.25 3.78 0.67 1.78 2.06 
Cited1 8.86 122.41 1.22 1.59 1.09 
Ddx58 1.11 0.89 1.25 2.81 2.76 
Dhx58 0.68 0.51 0.83 3.26 3.13 
Dtx3l 1.28 0.96 0.85 3.33 5.22 
Eif2ak2 1.20 2.51 1.15 3.52 3.06 
Gbp2 1.24 0.51 1.00 5.41 9.18 
Gbp3 0.82 0.53 0.54 27.82 90.13 
Gbp4 1.58 0.21 0.38 14.57 48.45 
Gbp6 0.95 0.48 0.69 3.99 6.93 
Gbp9 2.58 0.46 0.51 5.45 17.25 
Gm12250 1.05 0.07 1.23 130.58 182.66 
Gm4841 0.54 0.12 1.03 11.99 13.57 
Gm4951 0.44 0.09 1.26 39.21 37.92 
Gm6548 1.33 2.75 1.13 2.06 1.91 
H2-Aa 0.44 0.76 0.95 3.32 5.27 
H2-Bl 1.48 2.64 1.27 3.23 0.65 
H2-D1 2.22 17.38 0.91 2.77 3.19 
H2-Gs10 1.31 1.53 0.98 9.50 11.07 
H2-K1 1.15 4.13 0.81 10.96 16.51 
H2-Q6 17.57 0.48 0.34 19.77 60.79 
H2-Q7 2.44 0.73 0.41 16.87 23.98 
H2-Q8 6.44 0.62 0.65 6.64 5.66 
H2-T23 1.90 6.47 1.31 3.65 2.87 
I830012O16Rik 0.60 0.95 0.87 3.42 3.76 
Ifi35 1.84 2.22 0.79 5.23 6.16 
Ifi44 1.70 0.13 0.91 15.12 28.50 
Ifi47 2.23 0.42 0.48 49.06 152.81 
Ifit1 0.72 0.67 0.92 29.69 39.38 
Ifit2 0.64 3.66 1.14 2.93 2.93 
Ifit3 0.51 1.43 1.07 6.37 6.49 
Igtp 1.83 1.76 0.64 15.40 25.13 
Iigp1 0.81 0.23 0.60 33.53 90.96 
Irf1 1.88 4.24 0.71 2.91 3.76 
Irf7 1.66 0.97 1.09 5.68 4.33 
Irf8 0.40 0.59 0.97 4.21 5.71 
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Irf9 2.19 7.68 0.38 2.20 5.69 
Irgm1 1.10 5.68 1.05 7.24 7.65 
Irgm2 0.98 0.65 0.59 22.91 51.99 
Isg15 0.42 1.03 0.53 31.03 51.26 
Lgals3bp 2.57 8.76 0.90 1.89 2.14 
Mpa2l 1.63 0.63 0.61 16.03 30.60 
Nmi 0.96 2.21 0.76 2.02 2.65 
Oas1b 1.73 0.45 1.06 4.66 5.14 
Oasl2 1.31 1.40 1.04 23.57 24.70 
Parp10 0.86 0.53 0.95 9.23 8.64 
Prlh 29.22 70.94 0.89 1.80 1.54 
Psmb10 1.48 45.60 1.02 1.93 1.56 
Psmb8 2.37 3.10 0.80 13.81 17.82 
Psmb9 1.11 1.50 0.61 11.95 15.98 
Psme2 2.11 102.53 0.87 1.59 1.79 
Rsad2 2.19 0.34 1.22 4.59 3.04 
Rtp4 0.64 0.68 1.02 25.99 21.21 
Samhd1 1.36 7.23 1.06 1.78 1.75 
Serpina3f 2.56 0.20 0.27 29.80 33.49 
Serpina3h 2.64 0.46 0.32 1.54 1.50 
Stat1 1.43 5.84 0.56 3.49 6.02 
Stat2 0.81 3.08 0.91 1.67 1.79 
Tap1 2.04 0.83 0.91 7.28 9.08 
Tapbp 1.75 10.48 0.95 1.63 1.82 
Trim21 1.30 1.35 0.68 4.08 4.67 
Trim25 1.59 1.68 1.00 1.82 1.78 
Uba7 1.87 0.28 0.55 5.31 12.35 
Ube2l6 1.33 6.04 1.05 2.96 2.84 
Usp18 1.32 0.48 0.57 13.53 20.30 
Xaf1 0.39 1.44 0.81 4.96 8.68 
Zbp1 0.43 0.06 0.66 127.49 200.15 
Zc3hav1 1.33 0.59 0.81 2.42 3.11 
Procr 4.30 1.18 2.45 0.42 0.20   
St8sia4 1.93 8.06 0.78 0.64 1.16   
Npy1r 1.66 7.93 0.72 0.57 0.96   
Npy5r 1.91 3.76 0.71 0.54 0.90   




Table 3.2: Fold change in LepRb enriched genes in STAT3
LepR
KO and ob/ob mice. 
TRAP-Seq was performed on STAT3LepRKO, LepRbeGFP and LepRbeGFPob/ob mice. 
Genes enriched (FPKM in TRAP/FPKM in TRAP-depleted >1.5) at baseline, or that 
became enriched in a condition in which they were also significantly changed, were 
included in this analysis. Enrichment and expression (FPKM) values displayed are from 
LepRbeGFP mice. Fold change values for STAT3LepRKO mice were versus LepRbeGFP 
controls (Column 5), or against LepRbeGFPob/ob (Column 6). Fold change values for 
LepRbeGFPob/ob (Column 4) are versus 10-hour vehicle treated LepRbeGFP. (Column 7) 
designates the corresponding section of Figure 2B. n=3-4 samples per treatment group. 
Each sample was comprised of pooled hypothalami of 4-6 adult animals. p<.05 for 











































SP1 1.67E-03 ANXA2;STAT3;NR0B1;BRCA2 
BRCA1 8.68E-03 STAT3;XIST;EZR;BRCA2 
JUN 1.24E-02 STAT3;BCL3;FOSB 
STAT1 6.54E-03 STAT3;BCL3;ATG7 
NFKB1 1.32E-02 SOCS3;STAT3;BCL3 
NCOA1 1.30E-02 STAT3;BCL3 
HNF1A 4.62E-03 ANXA2;STAT3 
STAT6 1.14E-02 ANXA2;STAT3 
STAT5A 1.51E-02 STAT3;BRCA2 
ESR1 2.62E-02 ANXA2;STAT3;BCL3;NR0B1;EZR 
NR4A1 2.11E-02 STAT3;NR0B1 
SMAD3 3.63E-02 SOCS3;PLAGL1;BRCA2 
HDAC2 3.93E-02 STAT3;FOSB;BRCA2 
CTNNB1 4.22E-02 BCL3;RPLP2;EZR 
PML 4.71E-02 PLAGL1;STAT3 
IRF3 3.43E-07 ZBP1;CITED1;DDX58;IRF7;ISG15;TRIM21 
III 
STAT1 8.06E-06 CISH;IRF1;STAT2;EIF2AK2;ISG15;NMI;IRF9 
STAT2 1.13E-06 LGALS3BP;CD274;CISH;STAT1;IRF9 
STAT3 3.00E-04 CISH;STAT1;STAT2;EIF2AK2;NMI;IRF9 
STAT6 2.54E-04 CISH;STAT2;NMI;IRF9 
STAT5B 2.32E-04 CISH;STAT1;NMI;IRF9 
STAT5A 4.44E-04 CISH;STAT1;NMI;IRF9 
STAT4 1.49E-04 CISH;NMI;IRF9 
IRF1 6.17E-04 STAT1;IRF8;IRF9 
SMAD4 1.30E-02 CITED1;STAT1;IRF7;ISG15 
EP300 3.08E-02 CITED1;STAT1;IRF1;STAT2;IRF7 
IRF8 6.23E-03 IRF1;TRIM21 
FOS 3.76E-02 STAT1;NMI;IRF9 
ILF2 3.08E-02 EIF2AK2;IFIT1;IFIT2 
SPI1 2.49E-02 IRF1;IRF8 
CHD1 2.42E-02 ISG15;GBP2 
SMARCA
4 4.76E-02 STAT1;IRF1;STAT2 




Table 3.3: Significantly enriched transcription factor pathways. The list of genes in 
groups II and III in Figure 2B were analyzed for terms that were signficiantly enriched 
through Transcription Factor Protein Protein Interaction by Enrichr. The enriched terms, 


















Figure 3.8:  LepR
STAT1
 does not regulate energy balance (females). (A) Female 
STAT1LepRKO and LepReGFP (littermate control) mice were placed on chow and body 
weight (A) measured weekly, and cumulative food intake (B) measured weekly. (C-D) 
At 14 weeks of age, animals underwent body composition by NMR spectroscopy. (E) 
Biweekly blood glucose concentrations for female STAT1LepRKO and LepReGFP mice at 
4-12 weeks of age. Mice at weeks 12-14 of age were treated with (F) glucose (2g/kg; 
i.p.) or (G) insulin (1 U/kg; i.p.) and blood glucose concentrations were measured. 10-
week old mice had their serum assayed for (H) leptin and (I) insulin. N=10-18 per 
condition. ANOVA analysis was performed for (A-B, E-G); unpaired t-test analysis was 









KO does not exaggerate energy 
imbalance (females). Female STAT1STAT3LepRKO and STAT3LepRKO mice were 
placed on chow and body weight (A) measured weekly, and cumulative food intake (B) 
measured weekly. (C-D) At 14 weeks of age, animals underwent body composition by 
NMR spectroscopy. (E) Biweekly blood glucose concentrations for female 
STAT1STAT3LepRKO and STAT3LepRKO mice at 4-12 weeks of age. Mice at weeks 12-
14 of age were treated with (F) glucose (2g/kg; i.p.) or (G) insulin (1 U/kg; i.p.) and 
blood glucose concentrations were measured. 10-week-old mice had their serum 
assayed for (H) leptin and (I) insulin. N=7-10 per condition. ANOVA analysis was 








 does not cause hypoglycemia. (A-D) At 12-14 weeks of age, 
male LepReGFP, STAT1LepRKO, STAT3LepRKO, and STAT1STAT3LepRKO mice were 
treated with insulin (1U/kg; i.p.) and blood glucose concentrations were measured; area 
under the curve analysis was performed for insulin tolerance test. ANOVA analysis was 











Figure 3.11: Histochemical analysis of hypothalamic microglia and astrocytes in 
STAT1 deficient animals. Representative images of microglial distribution in the 
medial basal hypothalamus in (A) LepReGFP and (B) STAT1LepRKO mice. Representative 
sections of astrocytes in (C) LepReGFP and (D) STAT1LepRKO mice. Quantification of 
microglia numbers (E) and average area per microglia (F) in the ARC; quantification of 
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CONSTITUTIVE STAT3 ACTIVITY PROMOTES NEGATIVE ENERGY BALANCE 
 
Chapter Summary 
The adipocyte leptin, central to the homeostatic systems that regulate energy balance, 
activates the transcription factor STAT3 by binding to its receptor (LepRb) in the central 
nervous system to drive anorexia and weight loss. And, while the necessity of STAT3 in 
leptin action has been demonstrated, here we examine the sufficiency of STAT3 to 
normalize energy balance in the absence of other leptin-dependent signals. Using the 
enhanced STAT3 mutant (CASTAT3), we were able to further drive anorexia in already 
lean normoleptinemic chow-fed mice and found their sensitivity to exogenous leptin to 
remain intact. Moreover, our use of LepRb-specific TRAP-seq has identified a number 
of genes that may be responsible for mediating the observed weight loss and be the 
sought after signals downstream of STAT3 translocation that mediate its action. 
However, animals fed a high-fat diet became diet-induced obese (DIO) regardless of 
whether they had the enhanced STAT3 element or not. Therefore, there must exist a 
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block to leptin action downstream of STAT3 phosphorylation that prevents the anorexic 





Obesity, defined as a body mass index (BMI) of greater than 30kg/m2, results 
from an energy imbalance where energy stores from consumed calories outstrips the 
metabolic needs of the individual. In the last 50 years, obesity has dramatically 
increased in prevalence and incidence due to calorically dense diets.1 Today, over 70% 
of the US population is overweight (BMI>25kg/m2) and 37.7% is obese.2 
 Obesity results from a continued imbalance between intake and expenditure 
where the body’s homeostatic systems are unable to completely counter the shift in 
energy balance. And so, while obese individuals have increased basal metabolic rates 
compared to lean counterparts, their increased food intake continues, resulting in an 
ever-increasing positive energy surplus.3,4 Additionally, when obese individuals lose 
weight, the endogenous homeostatic systems promote an anabolic response (increase 
hunger and decrease energy expenditure) reminiscent of lean individuals losing weight.5 
Therefore, even when obese individuals are able to lose weight, homeostatic systems 
drive them to regain the lost weight. 
 The metabolic homeostasis our body maintains centers on the hormone leptin, 
which circulates in proportion to adipose mass and confers a snapshot of the 
individual’s energy stores when it binds to its receptor (LepRb) in the central nervous 
system.3,6,7 The type I cytokine receptor LepRb, when bound, activates Janus kinase 2 
(JAK2), resulting in a phosphorylation cascade, including Tyr1138, which recruits signal 
transducer and activator of transcription 3 (STAT3). This leptin activated JAK2→STAT3 
pathway mediates the majority of leptin’s anorectic action—mice with mutated Tyr1138 or 
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absent STAT3 in LepRb neurons demonstrate hyperphagic obesity similar to that of 
leptin deficient ob/ob animals.8,9 From these studies, it is clear that STAT3 is necessary 
in leptin action; however, its sufficiency in LepRb signaling to combat obesity has not 
been demonstrated. 
 Unlike leptin deficient or STAT3 ablated mutants, most individuals today are 
obese from the availability of cheap, calorically rich foods and sedentary lifestyles.1 
These diet-induced obese (DIO) individuals possess high circulating leptin 
concentrations (hyperleptinemia) expected of their elevated adiposity, instead of the 
absent leptin (hypoleptinemia) seen in leptin deficient obese indivdiuals.10 The success 
of exogenous leptin to treat hypoleptinemic obesity and its failure to treat 
hyperleptinemic DIO have promulgated the theory of “leptin resistance” in DIO.11 And, 
due to the importance of leptin→STAT3, leptin resistance is further supported by the 
absent pSTAT3 response to exogenous treatment in DIO animals.12 Therefore, using an 
enhanced STAT3 mutant, we investigated whether STAT3 signaling in the absence of 
all other leptin signals is sufficient to mediate leptin action. Furthermore, this 
constitutively active STAT3 mutant would determine whether the blockade of leptin 
action is upstream of STAT3 translocation/activity and whether obesity would be cured if 
exogenous leptin were able to expectedly increase STAT3 translocation. 
Results 
LepRCASTAT3 mice have enhanced STAT3 activity 
A constitutively active STAT3 mutant (CASTAT3) on the Rosa 26 locus was 
crossed with the LepRcre and Rosa26eGFP-L10a mice to generate 
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LepRcre/creRosa26CASTAT3/eGFP-L10a (LepRCASTAT3) and LepRcre/creRosa26eGFP-L10a/+ 
(LepReGFP) control mice (Figure 4.1A). To confirm the expression of the Stat3-C 
transgene in CASTAT3 mice, anti-eGFP translating ribosome affinity purification (TRAP) 
against hypothalamic material from LepRCASTAT3 and LepReGFP (both of which have one 
copy of the eGFP-L10a fusion protein) resulted in the sequencing of the actively 
translating messenger RNA. Sequenced reads that were perfectly matched to unique 
regions of the Stat3-C transgene or the endogenous Stat3 gene were aligned and 
quantified (Figure 4.1B-C, Figure 4.6). This confirmed the active translation of the Stat3-
C transgene previously shown to result in transcriptional activity and function.13,14 
Anorexia in LepRCASTAT3 mice on chow 
Weekly body weight measurements of male LepRCASTAT3 and LepReGFP mice 
revealed a lower body weight in LepRCASTAT3 mice due largely to decreased food intake 
(Figure 4.2A, 4.2B). The lower body weight was due to a significant decrease in adipose 
mass, both in grams and proportionally (Figure 4.2C, 4.2D). This decreased body 
weight did not affect blood glucose, serum leptin, serum insulin, or crown-rump length 
(Figure 4.2E, 4.2F, 4.2G, Figure 4.7A). Maximal oxygen consumption (VO2), both 
adjusted to body weight and to lean body mass, and total locomotor activity are also 
comparable between LepRCASTAT3 and LepReGFP mice (Figure 4.2H, 4.2I, Figure 4.7B-
4.7E). Thus, these results indicate that enhanced STAT3 in LepRb neurons results in 
decreased body weights due to anorexia. In females, however, body weight and food 
intake remain largely unchanged between LepRCASTAT3 and LepReGFP mice (Figure 4.9A, 
4.9B). And, while female LepRCASTAT3 mice did have significantly less fat and fluid mass, 
when compared by percentage, there was no significant difference in percent adiposity 
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or fluid (Figure 4.9C, 4.9D). Additionally, glycemic parameters and body length similarly 
remained comparable (Figure 4.9E-H). 
Leptin sensitivity remains intact in LepRCASTAT3 mice 
To investigate leptin sensitivity in mice with enhanced STAT3 activity, 10-week-
old male LepRCASTAT3 and control LepReGFP mice were injected twice daily for 3 days 
with 0.9% sodium chloride, then twice daily for 3 days with metreleptin (5mg/kg; i.p.), 
followed by twice daily for 2 days with 0.9% sodium chloride. Leptin treatment 
significantly decreased body weight and food intake in both LepRCASTAT3 and LepReGFP 
mice (Figure 4.3). This suggests that despite the augmented STAT3 signaling that 
drives anorexia, exogenous boli of leptin is effective in further decreasing food intake 
and body weight to a comparable extent in LepRCASTAT3 mice versus littermate controls. 
Transcriptional profiling of enhanced STAT3 animals 
Mice on the eGFP-L10a background were in one of six conditions: 1. 
LepRCASTAT3 ,2. LepReGFP treated with PBS 10-hours prior to sacrifice, 3. LepReGFP 
treated with leptin (5mg/kg, i.p.) 3-hours prior to sacrifice, 4. LepReGFP treated with leptin 
(5mg/kg, i.p.) 10-hours prior to sacrifice, 5. LepReGFPob/ob (on the ob/ob background) 
treated with PBS 10-hours prior to sacrifice, and 7. LepReGFPob/ob treated with leptin 
(5mg/kg, i.p.) 10-hours prior to sacrifice. 5-7 hypothalami from each of the groups were 
pooled and 3-4 of the independently pooled samples for each of the conditions were 
sequenced and the differential expressed genes were analyzed. Gene expression 
comparisons were analyzed between the LepRb neuron fraction (pull-down) and the 
non-LepRb cell fraction (supernatant) to generate a list of enriched genes. Additional 
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comparisons were performed between the gene expression values from the various 
conditions against the control PBS-treated LepReGFP condition to identify the genes that 
were differentially regulated (the leptin-treated LepReGFPob/ob condition was the only 
one not compared to the PBS-treated LepReGFP sample; rather, it was compared to the 
PBS-treated LepReGFPob/ob condition). The over 150 genes that were differentially 
regulated and enriched in LepRb neurons are shown in the heatmap, which highlights 
the clear dichotomy between the transcriptome of leptin deficient ob/ob mice and the 
transcriptome of the other 4 states of leptin action (Figure 4.4). Even though the leptin-
treated ob/ob (vs PBS-treated ob/ob) should be most similar to the 10h leptin v PBS 
condition, it is instead most closely coupled to the LepRCASTAT3 condition. This suggests 
that the profound metabolic normalization seen with leptin-treated ob/ob animals may 
be driven partly by enhanced STAT3 activity. Under the LepRCASTAT3 condition, those 
genes that were enriched in LepRb neurons and that experienced differential 
expression changes when compared to LepReGFP controls are listed in Table 4.1. 
LepRCASTAT3 is sufficient to partially normalize leptin-deficient hyperphagic 
obesity 
Whereas the hyperphagic obesity in STAT3 null mice in LepRb neurons 
demonstrates the necessity of STAT3 in leptin action, the sufficiency of STAT3 to 
mediate leptin action in the absence of other LepRb signals has not previously been 
demonstrated. To investigate this, LepRCASTAT3 mice were bred onto the ob/ob 
background. LepRCASTAT3;ob/ob mice gained significantly less weight versus their ob/ob 
littermate controls (Figure 4.5A). This weight loss is reflected in less adiposity and 
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increased lean body mass (Figure 4.5B, 4.5C). Furthermore, unfasted blood glucose 
values in LepRCASTAT3;ob/ob mice are lower than in ob/ob controls (Figure 4.5D). 
Enhanced STAT3 is ineffective in diet-induced obesity 
LepRCASTAT3 is effective in driving anorexia in both lean chow-fed animals and 
obese leptin-deficient animals, so we next investigated its effectiveness in diet-induced 
obesity (DIO). Male and female LepRCASTAT3 mice had comparable weights and food 
intakes to control LepReGFP mice when weaned onto a high-fat diet (Figure 4.8A, 4.8B; 
Figure 4.10A, 4.10B). Their body compositions, unfasted glucose, serum leptin and 
serum insulin values likewise remained comparable (Figure 4.8C-4.8G; Figure 4.10C-
4.10G). This suggests that the enhanced STAT3 action that suffices to drive weight loss 
in lean chow-fed animals and leptin deficient ob/ob mice may be insufficient to drive 
weight loss in DIO animals. 
Discussion 
The world-wide obesity epidemic is only growing as more and more individuals 
are exposed to cheap, calorically-rich foods. Today’s obesogenic environment is 
effective in overcoming individuals’ endogenous homeostatic systems meant to protect 
them from transient fluctuations in food intake. The inability of leptin, a major anorectic 
driver of these systems, to combat diet-induced obesity (DIO) has warranted continued 
investigation in the notion of leptin resistance. Indeed, DIO animals share many 
characteristics with STAT3 null mice: both are obese, hyperleptinemic, and do not 
respond phenotypically to exogenous leptin, presumably due to an absence of pSTAT3 
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activation. We, therefore, sought to determine whether enhanced STAT3 activity can 
drive the system towards negative energy balance during obesity. 
Previously, a mutant transcriptionally active form of STAT3 (CASTAT3) was 
found to promote leanness or mild obesity when placed in AgRP or POMC neurons, 
respectively.13,14 And while many AgRP and POMC neurons express LepRb, we found 
LepRCASTAT3 mice experienced anorexia and decreased adiposity compared to controls, 
suggesting that chronically augmented STAT3 activity results in additional negative 
energy balance in already-lean animals. This finding, coupled with previous work 
demonstrating effective anorexia from DIO hyperleptinemia, is further evidence that 
chronically enhanced STAT3 action (i.e. hyperleptinemia) is effective in driving 
additional weight loss.15 
Surprisingly, these CASTAT3 animals have intact leptin sensitivity when given 
exogenous leptin, intimating that increased STAT3 activity alone does not prohibit 
further exogenous leptin induced anorexia. These findings suggest that the increased 
STAT3 action during DIO-hyperleptinemia should not alone prohibit effective exogenous 
leptin treatment. There may therefore be other signals, perhaps leptin dependent, that 
block the effectiveness of exogenous leptin therapy. Furthermore, our DIO animals with 
the enhanced STAT3 action exhibited the same levels of adiposity and food intake 
compared to controls, suggesting that during DIO-induced hyperleptinemia either 
STAT3 activity is already exhausted or there exists a blockade of STAT3-induced 
anorexia downstream of its translocation. 
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Our data show that STAT3 action is sufficient to normalize much of the metabolic 
dysfunction in leptin deficient ob/ob animals. Therefore, leptin therapy in leptin deficient 
patients must be mediated primarily by leptin→STAT3 action. Obesity, strictly speaking, 
is then not what limits leptin therapy in DIO patients. Knight et. al. also recently 
demonstrated that high-fat diet itself does not dampen the effectiveness of leptin 
therapy in DIO mice.16 All together, it would seem that obesity, high-fat diet, and 
enhanced STAT3 activity (like under hyperleptinemia) are not responsible for the failure 
of exogenous leptin to provoke weight loss in DIO individuals. Perhaps other leptin-
dependent signals (e.g. negative regulators) during DIO-hyperleptinemia are 
responsible. Regardless, it is clear that further examination of hyperleptinemia and its 
functional and transcriptional consequences is necessary to inform the development of 
new targets in the battle against obesity. 
Materials and Methods 
Mice.  
Mice were bred in our colony in the Unit for Laboratory Animal Medicine at the 
University of Michigan; these mice and the procedures performed were approved by the 
University of Michigan Committee on the Use and Care of Animals and in accordance 
with AALAC and NIH guidelines. We purchased male and female C57BL/6 mice 
(Jackson stock #000664) and ob/ob mice (Jackson stock #000632) for experiments and 
breeding studies from Jackson Labs. Rosa26-CASTAT3-eGFP mice were generously 
provided by Sergei Koralov.13 Mice were bred at the University of Michigan and 
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provided with food and water ad libitum in temperature controlled rooms on a 12-hour 
light-dark cycle. 
LepRcre mice17 were crossed with Rosa26-loxSTOPlox-eGFP-L10a and Rosa26-
CASTAT3-eGFP to generate LepRcre/cre;RosaeGFP-L10a/CASTAT3 mice,18 which were then 
crossed with LepRcre mice to generate LepRcre/cre;RosaeGFP-L10a/CASTAT3 (LepR eGFP-
L10a/CASTAT3) and LepRcre/cre;RosaeGFP-L10a/+ (LepR eGFP-L10a/+) study animals. LepRcre and 
LepRcre/cre;RosaeGFP-L10a/CASTAT3 mice were backcrossed to ob/ob mice until LepRcre/cre; 
ob/+ mice and LepRcre/cre;RosaeGFP-L10a/CASTAT3;ob/+ were obtained, which were crossed 
to obtain LepRcre/cre;RosaeGFP-L10a/CASTAT3;ob/ob and LepRcre/cre;RosaeGFP-L10a/+;ob/ob 
study animals. 
Leptin sensitivity. 
10-month-old male LepRCASTAT3 and LepReGFP mice were injected twice daily for 
three days with 0.9% soldium chloride (Hospira; i.p.), followed with metreleptin (5mg/kg, 
i.p.) (a generous gift from AstraZenica, Inc.), then again with 0.9% sodium chloride 
(Hospira; i.p.) for 2 days. Body weight and food were measured twice per day during the 
injection period. 
Phenotyping of LepR eGFP-L10a/CASTAT3 and control mice.   
LepR eGFP-L10a/CASTAT3 and control LepR eGFP-L10a/+ were weaned into individual 
housing at 21 days and fed normal chow (Purina Lab Diet 5001) or 60% high-fat diet 
(Research Diets D12492, 60% kcal from fat). Similarly LepRcre/cre;RosaeGFP-
L10a/CASTAT3;ob/ob and LepRcre/cre;RosaeGFP-L10a/+;ob/ob study animals were weaned into 
individual housing at 21 days and fed normal chow (Purina Lab Diet 5001). Weekly 
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body weight and food intake were monitored. Unfasted blood glucose was take every 
other week from 4-20 weeks of age. Analysis of body fat and lean mass was performed 
at 21-22 weeks of age using NMR-based analyzer (Minispec LF90ll, Bruker Optics). 
Leptin and insulin were assayed by commercial ELISA with serum collected in 14-week 
old animals (Crystal Chem). One subset of male mice (10 weeks old) were analyzed for 
oxygen consumption (VO2) and locomotor activity using the Comprehensive Laboratory 
Animal Monitoring System (CLAMS, Columbus Instruments). 
Hypothalamic dissections for TRAP-seq. 
At the midpoint of the light cycle, 13- to 15-week-old adult homozygous mice 
were anesthetized with isoflurane, had their brains removed and placed onto a mouse 
coronal brain matrix (1mm sections). A 3x3x3 mm block was dissected from the ventral 
diencephalon immediately caudal to the optic chiasm and immediately homogenized for 
TRAP-seq analysis.  
Translating Ribosome Affinity Purification with deep sequencing (TRAP-seq). 
We employed anti-eGFP Translating Ribosome Affinity Purification (TRAP) using 
hypothalamic material from PBS or leptin treated LepReGFP, LepRLepRob/ob, LepRCASTAT3 
mice (which all express an eGFP-tagged ribosomal subunit in LepR cells). Messenger 
RNA isolated from eGFP-tagged ribosomes and from the eGFP-depleted was assessed 
for quality using TapeStation (Agilent, Santa Clara, CA) and samples with RNA Integrity 
Numbers (RINs) of 8 or greater were prepared using the Illumina TruSeq mRNA 
Sample Prep v2 kit (Catalog # RS-122-2001 and #RS-122-2002) (Illumina, San Diego, 
CA), where 0.1-3ug of RNA was converted to mRNA using a polyA purification. The 
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mRNA was chemically fragmented and copied into first strand cDNA using reverse 
transcriptase and random primers. The 3’ ends of the cDNA were adenylated and the 6-
nucleotide-barcoded adapters ligated. These products were then purified and enriched 
by PCR to create the cDNA library, which were checked for quality and quantity by 
TapeStation (Agilent) and qPCR using Kapa’s library quantification kit for Illumina 
Sequencing platforms (catalog #KK4835) (Kapa Biosystems, Wilmington MA). They 
were clustered on cBot (Illumina) and sequenced 4 samples per lane on a 50 cycle 
single end run on a HiSeq 2000 (Illumina) using version 2 reagents according to 
manufacturer’s protocols. 
RNA-seq analysis. 
50 base pair single end reads underwent QC analysis prior to alignment to 
mouse genome build mm10 using TopHat and Bowtie alignment software.19 Differential 
expression was determined using Cufflinks Cuffdiff analysis, with thresholds for 
differential expression set to fold change >1.5 or <0.66 and a false discovery rate of 
<0.05.20 Lists of differentially expressed genes were then queried against the Uniprot 
Database for gene ontology and protein class analysis.21 
Statistics. 
Data are reported as mean +/- SEM. RT-qPCR data are reported as mean fold 
change compared to normalized vehicle. Statistical analysis of physiological data was 
performed with Prism software (version 7). Unpaired t-test was used to compare results 
between two groups. Body weight gain, cumulative food intake and body length, were 






Figure 4.1: Enhanced STAT3 activity in LepRb neurons. (A) Schematic diagram 
showing the cross of LepRcre with Rosa26-CASTAT3-eGFP and Rosa26-loxSTOPlox-
eGFP-L10a to generate LepRCASTAT3/eGFP-L10a (LepR CASTAT3) and LepReGFP-L10a/+ (LepR 
eGFP) mice through excision of loxP-flanked NeoR, Neo, and Stop sequence only in cell 
types expressing LepRb. IRES: internal ribosome entry site; filled triangles: loxP sites; 
NeoR: neomycin resistance gene driven by the TK promoter; WSS: Westphal stop 
sequence; Stat3-C: constitutively active STAT3. (B) RNA sequencing percent reads of 
the inserted Stat3-C (Stat3-C divided by total Stat3-C and endogenous Stat3) in 
LepRCASTAT3 and control LepR eGFP. (C) The number of perfectly mapped reads at the 
unique sites for STAT3-C and endogenous STAT3 in both LepR CASTAT3 and LepReGFP 
controls.  n=3-4 per group. Mean +/- SEM; *p<0.05 by unpaired t-test; **p<0.01 by 






Figure 4.2: Constitutive STAT3 activity in LepRb neurons decreases body weight 
and adiposity. Male LepRCASTAT3/eGFP-L10a and LepReGFP-L10a/+ mice were placed on 
chow and body weight (A) and food intake (B) were measured weekly. At 21-22 weeks 
of age, animals underwent body composition analysis (C-D) by NMR spectroscopy. (E) 
Unfasted blood glucose was measured biweekly. Serum from 16-week-old mice were 
assayed for leptin (F) and insulin (G). 10-12 week-old mice were subjected to CLAMS 
analysis to determine VO2 normalized to total body mass (H), and locomotor activity (I) 
over a 72-hour period. n=15-20 for (A, B), n=8-14 for (C-I). Mean +/- SEM is shown; 
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Figure 4.3: Effect of exogenous leptin in already enhanced STAT3-expressing 
animals. Eight-week-old male LepRCASTAT3/eGFP-L10a and LepReGFP-L10a/+ mice fed normal 
chow were injected twice daily (at 8:30AM and 4:30PM) with PBS for 3 days, with leptin 
for 3 days (5mg/kg; i.p.), and then with PBS for 2 days. (A) Body weight was measured 
twice per day during the injection period; arrows indicate times of leptin injections. (B) 
Food intake was measured daily and compiled for the initial PBS period, the leptin 
period, and the second PBS period. n=9-12 per genotype. **p<0.01 for a to b, no 











Figure 4.4: TRAP-seq reveals similarities between LepRCASTAT3 and leptin treated 
ob/ob animals. Translating ribosome affinity purification (TRAP) was performed in 
LepReGFPob/ob, LepRCASTAT3 and LepReGFP mice treated with PBS or leptin and 
compared to the control PBS treated LepReGFP group. Fold change values for each of 
the groups were calculated and compared to littermate control PBS-treated LepReGFP or 
PBS-treated LepReGFPob/ob mice. Each sample comprised of pooled hypothalamic for 







Figure 4.5: LepRCASTAT3 partially normalizes ob/ob mice. Male LepRCASTAT3;ob/ob 
and LepReGFP;ob/ob mice were placed on chow and body weight (A) was measured 
weekly. At 14-15 weeks of age, animals underwent body composition analysis (B-C) by 
NMR spectroscopy. (D) Unfasted blood glucose was measured biweekly. Mean +/- SEM 















Figure 4.6: Enhanced STAT3 activity in LepRb neurons (females). (A) RNA 
sequencing percent reads of the inserted Stat3-C (Stat3-C divided by total Stat3-C and 
Stat3) in female LepRCASTAT3 and control LepReGFP. (B) The number of perfectly mapped 
reads at the unique sites for STAT3-C and endogenous STAT3 in female LepRCASTAT3 






Figure 4.7: Male LepRCASTAT3 body length and energy expenditure. (A) Body lengths 
of male mice were measured at 12 weeks. 10-week old LepReGFP and LepRCASTAT3 mice 
were placed in CLAMS and locomotor activity (B), VO2 normalized to total body mass 
(C, D), and VO2 adjusted to lean body mass (E) were measured. Data are shown for the 
dark cycle (Dark), light cycle (Light), and 24 hour (Total) period. *p<0.05 by unpaired t-









Figure 4.8: Enhanced STAT3 activity does not counter high-fat diet-induced 
obesity. Male LepRCASTAT3 and LepReGFP mice were placed on 60% high-fat diet and 
body weight (A) and food intake (B) were measured weekly. At 21-22 weeks of age, 
animals underwent body composition analysis (C-D) by NMR spectroscopy. (E) 
Unfasted blood glucose was measured biweekly. Serum from 16-week-old mice were 
assayed for leptin (F) and insulin (G). No significance was found by ANOVA or unpaired 










Figure 4.9: Constitutive STAT3 activity in LepRb neurons does not affect energy 
expenditure (females). Female LepRCASTAT3 and LepReGFP mice were placed on chow 
and body weight (A) and food intake (B) were measured weekly. At 21-22 weeks of 
age, animals underwent body composition analysis (C-D) by NMR spectroscopy. (E) 
Unfasted blood glucose was measured biweekly. Serum from 16-week-old mice were 
assayed for leptin (F) and insulin (G). (H) Body length was measured in 12-week-old 
female mice. N=16-20 per group (A, B); n=10-12 per genotype (C-H). Mean +/- SEM is 


















Figure 4.10: Enhanced STAT3 activity does not counter high-fat diet-induced 
obesity (females). Female LepRCASTAT3 and LepReGFP mice were placed on high-fat 
diet and body weight (A) and food intake (B) were measured weekly. At 21-22 weeks of 
age, animals underwent body composition analysis (C-D) by NMR spectroscopy. (E) 
Unfasted blood glucose was measured biweekly. Serum from 16-week-old mice were 
assayed for leptin (F) and insulin (G). No significance was found by ANOVA or unpaired 














Aldh1a1	 26.00	 1.34	 2.33	
Aldh1a7	 0.82	 2.81	 2.06	
Atf3	 1.53	 3.72	 1.84	
C130021I20Rik	 6.28	 2.52	 1.63	
Ccnb1ip1	 0.28	 0.97	 1.90	
Chrna6	 2.74	 2.39	 2.54	
Chrnb3	 0.85	 2.14	 2.86	
Crhbp	 12.94	 1.70	 1.58	
Cubn	 0.10	 0.89	 1.67	
Ddc	 102.09	 2.98	 1.53	
Egflam	 1.13	 2.17	 1.58	
En1	 3.13	 3.91	 3.39	
Fgf20	 0.21	 1.64	 2.76	
Foxa1	 6.88	 4.20	 1.70	
Foxa2	 0.79	 2.49	 2.19	
Gbp6	 0.68	 1.82	 1.58	
Gm5105	 0.13	 1.29	 1.92	
Gucy2c	 1.30	 6.66	 1.96	
Gzmk	 1.07	 1.16	 1.62	
H2-Q6	 0.36	 2.56	 3.11	
Ifi47	 0.20	 0.77	 1.96	
Igtp	 1.57	 1.65	 1.65	
Irgm2	 0.66	 0.95	 2.05	
Irx5	 2.82	 2.25	 1.68	
Irx6	 2.60	 4.08	 1.50	
Lmx1a	 2.85	 1.84	 1.61	
Myh6	 0.43	 1.35	 1.53	
Nr4a2	 12.80	 3.10	 1.52	
Ntf3	 0.65	 1.97	 1.75	
Ntn1	 2.27	 1.13	 1.89	
O3far1	 0.11	 3.03	 2.17	
Pitx3	 0.88	 2.24	 3.13	
Psmb8	 3.19	 1.60	 1.83	
Ret	 9.81	 2.50	 1.97	
Rnase6	 3.03	 1.32	 0.64	
Serpina3h	 0.34	 3.09	 2.74	
Serpina3m	 0.24	 2.42	 2.51	
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Slc10a4	 15.05	 2.19	 2.26	
Slc18a2	 5.89	 1.63	 2.06	
Slc6a3	 14.53	 3.65	 2.88	
Spink8	 0.40	 0.67	 2.24	
Sprr1a	 0.37	 2.60	 2.11	
Tap1	 0.86	 1.47	 1.52	
Th	 74.98	 2.66	 2.01	
Ucn	 2.00	 5.22	 0.39	
Usp18	 0.40	 0.87	 1.97	
 
Table 4.1: Fold change in LepRb enriched genes in LepRCASTAT3 mice. TRAP-Seq 
was performed on LepRCASTAT3 and littermate control LepRbeGFP mice. Genes enriched 
(FPKM in TRAP/FPKM in TRAP-depleted >1.5) at baseline or that became enriched in 
the CASTAT3 condition were included in this analyses. Enrichment and expression 
(FPKM) values displayed are from LepRbeGFP mice. Fold change values for LepRCASTAT3 
mice were compared to LepReGFP controls (Column 4). n=3-4 samples per treatment 
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LEPTIN ACTION THROUGH HYPOTHALAMIC CALCITONIN RECEPTOR-
EXPRESSING NEURONS CONTROLS ENERGY BALANCE 
 
Chapter Summary 
Obesity, and its vast negative implications on health, is an epidemic only growing 
in incidence. Central to our understanding of obesity is the adipocyte leptin, which binds 
to its receptor (LepRb) in the hypothalamus to provide a snap shot of fat stores and to 
drive anorexia. Unfortunately, leptin therapy is ineffective in promoting weight loss in 
diet-induced obese (DIO) individuals. However, leptin-amylin combination treatment is 
effective. Here, we explore the hypothalamic neurons that express both LepRb and 
amylin’s cognate receptor, calcitonin receptor (CalcR), by conditionally deleting LepRb 
in CalcR-expressing neurons. Not only are these mice obese from hyperphagia and 
decreased energy expenditure, but these LepRb- and CalcR-expressing neurons are a 
previously unstudied subpopulation of LepRb neurons. Thus, the regulation of energy 




Obesity is a growing epidemic in the United States and accounted for over $147 
billion of total health care costs in 2008.1 The adipocyte leptin is produced in proportion 
to triglyceride content and binds to its receptors (LepRb) to not only provide a summary 
of the body’s energy stores, but to also regulative energy balance.2–4 These LepRb-
expressing neurons are located throughout the brain and are heterogeneous in nature; 
those in the hypothalamus are perhaps the most involved in energy balance, for their 
ablation results in profound obesity and metabolic dysfunction.5 
 Of the many subpopulations of LepRb neurons in the hypothalamus, those 
located in the arcuate nucleus (ARC), which lies adjacent to the median eminence (a 
circumventricular organ that permits passage of circulating factors like leptin), are best 
characterized. Many of these ARC LepRb neurons express the melanocortin precursor 
POMC (termed POMC neurons) or the inhibitory hormone neuropeptide Y (NPY), the 
melanocortin antagonist agouti-related protein (AgRP), and the inhibitory 
neurotransmitter GABA. Partially through the melanocortin system, POMC neurons 
drive a negative energy balance while NAG (NPY, AgRP, GABA) neurons promote a 
positive energy balance.6 Leptin thereby promotes negative energy balance by 
increasing POMC neuronal activity while decreasing NAG action.6 Despite the central 
roles POMC and NAG neurons play in leptin action, deletion of LepRb from POMC 
and/or NAG neurons only modestly affect energy balance.7 Recent single-cell 
sequencing of ARC cells reveals the existence of other non-POMC and non-NAG 




The hormone calcitonin and its family of structurally and functionally related 
neuropeptides, including amylin, calcitonin gene-related peptide (CGRP), and 
adrenomedullin, all bind to CalcR in the brain to promote satiety, glycemic control and 
slowing of gastric empyting.9–12 In the context of the obesity epidemic, the interaction 
between leptin and CalcR agonists has been a promising area of research: combination 
leptin-amylin therapy is effective in producing synergistic and consistent weight loss in 
diet-induced obese (DIO) humans and rodents.13–15 Recently, Li et. al. demonstrated 
that the precursor to amylin is secreted in hypothalamic neurons and may synergize 
with LepRb-expressing neighboring neurons.16 This, coupled with the high expression 
and fold enrichment of CalcR in hypothalamic LepRb neurons, underscores not only the 
importance of these dual-expressing neurons on energy balance, but also highlights a 
new population of LepRb neurons that may mediate a portion of leptin signaling in the 
hypothalamus.17 Therefore, we conditionally ablated LepRb in CalcR-expressing 
neurons to determine whether those LepRbCalcR neurons are important in energy 
balance. Additionally, we aimed to identify this subpopulation of LepRb neurons that 
also express CalcR and genes that may be involved in their activity. 
Results: 
Calcitonin activates LepRb neurons in the ARC 
Salmon calcitonin (sCT), a powerful calcitonin receptor (CalcR) agonist, has 
particularly effective anorexigenic properties in the state of diet-induced obesity (DIO) 
and leptin resistance.18 Intraperitoneal injection of sCT resulted in the activation of 
CalcR neurons using immunohistochemically detectable cfos induction as marker in 
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CalcR;Rosa26L10a-eGFP (CalcReGFP) mice that express an L10a-GFP fusion protein in 
CalcR neurons (Figure 5.8). As suggested by previous in-situ hybridization 
experiments,19 many of these cfos-induced regions are in leptin receptor- (LepRb) rich 
regions of the hypothalamus. Indeed, cfos induction with sCT injection was found in 
neurons that not only express CalcR, but also express LepRb—specifically NPY 
expressing LepRb neurons (Figure 5.1). Quantification reveals that approximately 60% 
of cfos-positive neurons also express NPY, 2% express POMC, and the remaining 37% 
are arcuate neurons that express neither NPY or POMC (Figure 5.1e). In addition, there 
was no colocalization between CalcR and POMC when CalcReGFP mice were crossed to 
POMCsdred mice (Figure 5.12). Thus, the existence of these hypothalamic neurons 
expressing both LepRb and CalcR may impart clues on the synergistic weight loss 
demonstrated with amylin-leptin combination therapy in diet-induced obesity 20. 
Generation and characterization of CalcR-cre mice 
To study LepRb and CalcR dual expressing neurons, we inserted a 2a element 
plus the coding sequences for Cre recombinase into the 3’untranslated region of CalcR 
in mice to promote CalcR-restricted Cre expression (CalcRcre mice) (Figure 5.2a). We 
verified that this cre expression overlaps with CalcR mRNA by ISH (Figure 5.7). These 
CalcRcre mice were then bred to R26-loxSTOPlox-eGFP-L10a and LepRflox/flox mice to 
generate CalcRcre/cre;LepRflox/flox;Rosa26eGFP-10a/eGFP-10a (LepRCalcRKO) mice and 
littermate control CalcRcre/cre;RosaeGFP-10a/eGFP-L10a (CalcReGFP) mice (Figure 5.2a). 
Analysis of CalcReGFP and LepRCalcRKO mice show an absence of pSTAT3 in the CalcR 
neurons of LepRCalcRKO with leptin treatment compared to littermate controls (Figure 
5.2b, 5.2c, and Figure 5.9). We quantified the conditional ablation of LepRb in CalcR 
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neurons with pSTAT3 immunoreactivity (compared to control mice) in regions where 
there was potential overlap between pSTAT3 and CalcR expression: the arcuate 
nucleus (ARC), dorsomedial hypothalamus (DMH), lateral hypothalamic area (LHA) and 
nucleus of the solitary tract (NTS) (Figure 5.2d, 5.2e, and Figure 5.9). 
Leptin receptors in calcitonin receptor expressing neurons regulate energy 
balance 
Both male and female LepRCalcRKO mice have higher body weights and food 
intakes compared to control CalcReGFP mice (Figure 5.3a, 5.3f, and Figure 5.10a, 10f). 
The excess weight in LepRCalcRKO mice was largely due to elevated adipose mass 
(Figure 5.3c, 5.3d, and Figure 5.10c, 5.10d), and is reflected in elevated serum leptin 
levels (Figure 5.3e, and Figure 5.10e). LepRCalcRKO mice have unchanged crown to 
rump lengths when compared to CalcReGFP mice (Figure 5.3b, and Figure 5.10b). 
Interestingly, while LepRCalcRKO mice have more absolute adipose tissue, lean mass, 
and fluid; in percentage terms, LepRCalcRKO mice are less lean, more obese, and have 
comparable fluid levels (Figure 5.3c, 5.3d, Figure 5.10c, 5.10d). The maximal oxygen 
consumption (VO2) in male LepR
CalcRKO mice was lower than in CalcReGFP mice (Figure 
5.4a, 5.4b), but when VO2 was adjusted to lean body mass, VO2 was comparable 
between LepRCalcRKO and CalcReGFP mice (Figure 5.4c, 5.4d). A decrease in dark and 
total locomotor activity was also observed in LepRCalcRKO mice when compared to 
CalcReGFP control mice (Figure 5.4e, 5.4f). Thus, leptin action in LepRCalcR neurons is 
crucial for regulation of feeding and the control of body weight and adiposity. 
Glucose homeostasis is not disrupted in LepRCalcRKO animals 
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To determine the potential role for leptin action through LepRCalcR neurons on 
glucose homeostasis, unfasted serum glucose levels were measured biweekly from 4-
12 weeks of age in LepRCalcRKO and CalcReGFP control mice and were comparable 
(Figure 5.5a, and Figure 5.11a). 10-week-old LepRCalcRKO mice were found to have 
higher serum insulin levels when compared to 10-week-old littermate controls (Figure 
5.5b, and Figure 5.11b). Glucose tolerance and insulin tolerance test were performed 
but neither were altered in LepRCalcRKO mice (Figure 5.5c, 5.5d; Figure 5.11c, 5.11d). 
Gene expression, enrichment and regulation of CalcR neurons. 
We employed translating ribosome affinity purification (TRAP) using 
hypothalamic material from both CalcReGFP and LepRCalcRKO mice (which both express 
an eGFP-tagged ribosomal subunit fusion protein in CalcR neurons) to separate 
hypothalamic CalcR cell transcripts from non-CalcR expressing cell mRNA. The 
expression levels of key genes involved in regulation of food intake were measured and 
fold changes are detailed for enrichment (between CalcR and non-CalcR cells) and 
expression (between CalcR cells in control CalcReGFP and CalcR cells in LepRCalcRKO 
mice) (Figure 5.6a, 5.6b). Corroborating our finding of cfos expression with sCT 
injection seen in many NPY neurons (Figure 5.1c-e), AgRP and Npy are highly enriched 
in both CalcReGFP and LepRCalcRKO mice, while Pomc is de-enriched (Figure 5.6a). As 
expected, CalcR is highly enriched in CalcR neurons, although Sst was also found to be 
highly enriched in both CalcReGFP and LepRCalcRKO mice (Figure 5.6a). Socs3, Cartpt, 
and Serpina3N were all enriched in CalcReGFP but not in LepRCalcRKO mice (Figure 
5.6a). Examination of relative expression differences between control CalcReGFP to 
LepRCalcRKO mice reveal a significant decrease in expression of Socs3 (a surrogate for 
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LepRb action) and Serpina3N (Figure 5.6b). Deletion of LepRb from LepRCalcR neurons 
also resulted in increased expression of Pomc (although Pomc still remains de-enriched 
in CalcR neurons), AgRP and Npy (Figure 5.6a, 5.6b). Together, these data reveal a 
population of LepRb neurons that express CalcR/AgRP/Npy/Sst critical for leptin action 
and energy balance. Furthermore, given the severe metabolic phenotype of 
LepRCalcRKO mice, the differential expression of certain genes like SERPINA3N may 
underlie mechanisms responsible for the obesity. 
Discussion 
Previous studies have examined the phenotypic significance of amylin-leptin 
combination treatment in obese individuals, and the synergistic weight loss seen 
suggests the existence of interactions between the two hormones.13,15 Consistent with 
previous TRAP-seq and single-cell sequencing analyses, we found that LepRb is 
expressed in a number of CalcR neurons throughout the hypothalamus including the 
ARC, DMH and LHA.8,17 Unexpectedly, even though LepRb neurons and CalcR 
neurons are both expressed in the hindbrain and both mediate satiety, there is no 
overlap between the two. We found that most of the dual LepRb- and CalcR-expressing 
neurons are located in the ARC, which was confirmed with salmon calcitonin (sCT) 
treatment. Interestingly, many of these LepRb- and CalcR-expressing neurons in the 
ARC are NAG neurons and genetic ablation of LepRb from CalcR neurons resulted in a 
obesity from increased food intake and decreased energy expenditure. This would point 
to the importance of these CalcR-expressing LepRb neurons in the arcuate and 
identifies a population of non-Npy non-Pomc LepRb neurons that mediates a significant 
degree of leptin action, given the modest effects seen with LepRb ablation in AgRP/Npy 
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expressing neurons.7 Worthy of further investigation is the role sCT-activated NAG 
neurons play in satiety. Because NAG neurons promote a positive energy balance and 
sCT is a potent satiety compound, it should be explored whether directed delivery of 
sCT to non-NAG areas can amplify the satiety experienced. 
Clearly, leptin action through LepRCalcR neurons is important for energy balance. 
Gene expression analysis of these CalcR neurons demonstrate the enrichment of a 
number of genes that may mediate part of the demonstrated metabolic effects of LepRb 
ablation. Specifically, the enrichment of Sst is an interesting candidate for mediating 
leptin action; even more exciting is the significant decrease in expression of Serpina3N 
with LepRb deletion. Previous studies have identified SERPINA3N as a gene 
downstream of leptin action that may be an important enzyme in the regulation of leptin 
action and body weight homeostasis.8,17 Together, this work demonstrates the 
heterogeneous nature of LepRb neurons and the role leptin action plays in multiple 
homeostatic systems involved in energy balance. Given the promise of dual therapy in 
the treatment of obesity, the continued investigation of complementary hormones may 
reveal novel therapeutic targets to cure obesity. And while these studies demonstrate 
the importance of LepRbCalcR neurons, additional research on the deletion of CalcR from 
LepRb-expressing neurons need to be performed to strengthen the idea that the amylin-
leptin synergistic weight loss occurs in these CalcR- and LepRb-expressing neurons. 
Specifically, the question of whether DIO CalcRLepRKO mice responds to amylin-leptin 
therapy like their littermate DIO controls needs to be answered. Furthermore, while we 
point to SERPINA3N and SST as genes of interest in these neurons, TRAP-seq on 
LepRflpCalcRcre mice with a flp and cre dependent eGFP-L10a fusion protein (especially 
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when comparing PBS treated DIO to amylin-leptin treated DIO animals) would really 
identify the genes and molecular mechanisms that may be responsible for the 
synergistic weight loss observed. 
Materials and Methods 
Mice. 
Mice were bred in our colony at the Unit for Laboratory Animal Medicine at the 
University of Michigan; these mice and the procedures performed were approved by the 
University of Michigan Committee on the Use and Care of Animals and in accordance 
with AALAC and NIH guidelines. We purchased male and female C57BL/6 mice for 
experiments and breeding studies from Jackson Labs. Mice were bred at the University 
of Michigan and provided with food and water ad libitum in temperature controlled 
rooms on a 12-hour light-dark cycle. 
We generated LepReGFP mice by crossing LepRcre mice21 onto the eGFP-L10a 
background to produce LepRcre/+;Rosa26eGFP-10a/+ mice,22 which we then intercrossed to 
generate double homozygous LepRcre/cre;RosaeGFP-10a/eGFP-L10a (LepReGFP) study animals. 
Pomc-dsRed transgenic mice (gift from Malcolm Low) and Npy-GFP transgenic mice 
(Jackson stock #006417) were crossed to generate PomcdsRedNpyGFP mice. 
To generate CalcR-2aCre mice, a selection cassette containing the porcine 
teschoviral 2A cleavage sequence linked to Cre recombinase and a Frt-flanked 
kanamycin resistance gene was targeted to replace the stop codon of the CalcR gene in 
a bacterial artificial chromosome (RP24-193M22; Children’s Hospital Oakland Research 
Institute). A targeting plasmid containing the Cre-containing selection cassette and ~4 
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kb genomic sequence upstream and downstream of the CalcR stop codon was isolated 
and used for embryonic stem cell targeting by the University of Michigan Transgenic 
Core. Correctly targeted clones were identified by loss of native allele quantitative PCR 
in blastocysts. Chimeric animals generated from blastocyst implantation were then bred 
for germline transmission of the CalcR-2aCre allele. Flp-deleter mice were then used to 
remove the neomycin selection cassette.  Mice were subsequently intercrossed to 
generate homozygous Cre reporter strains and bred to Cre-dependent reporter lines. 
CalcReGFP mice were produced by crossing CalcRcre mice onto the eGFP-L10a 
background to produce CalcRcre/+;Rosa26eGFP-10a/+ mice, which were then intercrossed 
to generated double homozygous CalcRcre/cre;RosaeGFP-10a/eGFP-L10a (CalcReGFP) study 
animals. LepRflox/flox mice23 were bred to CalcReGFP mice to generate 
CalcRcre/+;LepRflox/+;Rosa26eGFP-10a/+ mice, which were bred to CalcReGFP mice to 
produce CalcRcre/cre;LepRflox/+;Rosa26eGFP-10a/eGFP-10a mice. The intercross of 
CalcRcre/cre;LepRflox/+;Rosa26eGFP-10a/eGFP-10a mice resulted in 
CalcRcre/cre;LepRflox/flox;Rosa26eGFP-10a/eGFP-10a (LepRCalcRKO) mice and littermate control 
(CalcRcre/cre;LepR+/+;Rosa26eGFP-10a/eGFP-10a (CalcReGFP)) mice for study. 
PomcdsRedCalcReGFP were generated by crossing CalcRcre onto the eGFP-L10a 
background then crossing with the Pomc-dsRed transgenic mice. We genotyped 
offspring using PCR. 
Leptin treatment, salmon calcitonin treatment and immunohistochemistry. 
Mice had food removed at the onset of the light cycle and were treated four hours 
later with metreleptin (5mg/kg; i.p.), salmon calcitonin (150ug/kg; i.p.), or vehicle and 
subsequently perfused 90 minutes later. Prior to perfusion, mice were anesthetized with 
152 
 
a lethal dose of pentobarbital and transcardially perfusion with phosphate buffered 
saline (PBS) followed by 10% buffered formalin. Brains were removed, placed in 10% 
buffered formalin overnight, and dehydrated in 30% sucrose for one week. Using a 
freezing microtome (Leica), brains were cut into 30 um sections. Sections were treated 
sequentially with 1% hydrogen peroxide/ 0.5% sodium hydroxide, 0.3% glycine, 0.03% 
sodium dodecyl sulfate, and blocking solution (PBS with 0.1% triton, 3% Normal Donkey 
Serum). Immunostaining was performed using primary antibodies for pSTAT3 (Cell 
Signaling #9145, rabbit, 1:1000), GFP (Aves Labs #GFP1020, chicken, 1:1000), c-fos 
(Santa Crus sc-52, rabbit, 1:1000), dsRed (Living Colors #632496, 1:1000). All 
antibodies were reacted with species-specific Alexa Fluor-488 or -568 conjugated 
secondary antibodies (Invitrogen, 1:200) or processed with the avidin-
biotin/diaminobenzidine (DAB) method (ABC kit, Vector Labs, 1:500; DAB reagents, 
Sigma). Images were collected on an Olympus BX53F microscope. DAB images were 
pseudocolored using Photoshop software. The number of c-Fos and pSTAT3 positive 
nuclei and those colocalizing with GFP and dsRed expressing cells were counted. 
In situ hybridization.  
For in situ hybridization (ISH), adult CalcR-Cre and wildtype control mice were 
anesthetized with isoflurane and then euthanized by decapitation. Whole brains were 
dissected, flash frozen in isopentane, chilled on dry ice and stored at -80°C. 16 μm-thick 
coronal sections were cut on a cryostat (Leica), thaw-mounted to SuperFrost Plus 
slides, allowed to dry at -20°C for one hour and then stored at -80°C. Slides were then 
processed for ISH using RNAScope technology per the manufacturer’s protocol 
(Advanced Cell Diagnostics). For all slides, the multiplex fluorescent assay (320850) 
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was used to visualize CalcR (477791) and Cre (312281-C3) probes using Amp 4 Alt-A. 
Images were obtained with an Olympus BX53F and QImaging Retiga 6000 
monochrome camera under 40X objective. All images were processed identically in 
CellProfiler (Lamprecht MR 2007 Biotechniques) to reduce nonspecific background. 
Serial images (16 per arcuate nucleus) were taken and stitched together using 
Photoshop (Adobe).    
Phenotyping of LepRCalcRKO and control mice.   
LepRCalcRKO and littermate control (LepRcre) mice were weaned into individual 
housed cages at 21 days and fed normal chow (Purina Lab Diet 5001). Weekly body 
weight and food intake were monitored. Unfasted blood glucose sample was take every 
other week from 4-12 weeks of age. Glucose tolerance test (2g/kg body weight, i.p.) and 
insulin tolerance test (1 unit/kg body weight, Humulin (Eli Lilly), i.p.) were performed in 
13 and 14 week old mice, respectively, after a 5-hour fast three hours after the start of 
the light-cycle. Analysis of body fat and lean mass was performed at 15 weeks of age 
using NMR-based analyzer (Minispec LF90ll, Bruker Optics). One subset of mice (9-11 
weeks old) were analyzed for oxygen consumption (VO2), food intake, and locomotor 
activity using the Comprehensive Laboratory Animal Monitoring System (CLAMS, 
Columbus Instruments). Leptin and insulin were assayed by commercial ELISA (Crystal 
Chem). 
TRAP RT-qPCR.   
At the midpoint of the light cycle, adult homozygous mice were anesthetized with 
isoflurane, had their brains removed and placed onto a mouse coronal brain matrix 
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(1mm sections). A 3x3x3mm block was dissected from the ventral diencephalon 
immediately caudal to the optic chiasm; this hypothalamic dissection was homogenized 
for TRAP-seq analysis. We employed anti-eGFP Translating Ribosome Affinity 
Purification (TRAP) using hypothalamic material from CalcReGFP and LepRCalcRKO mice 
(which both express an eGFP-tagged ribosomal subunit in CalcR cells). The messenger 
RNA isolated from eGFP-tagged ribosomes and from the eGFP-depleted was assessed 
for quality using the TapeStation (Agilent, Santa Clara, CA) and samples with RINs 
(RNA Integrity Numbers) of 8 or greater were converted to cDNA using iScript cDNA 
synthesis kit (Biorad #170-8891) for use in reverse transcription PCR. cDNA was 
analyzed in triplicate by quantitative real time PCR on an Applied Biosystems 
StepOnePlus Real-Time PCR System for GAPDH (endogenous control) and the 
following: AgRP, Pomc, Serpina3n, Socs3, Npy, Cartpt, Sst, and CalcR. All Taqman 
assays were acquired from Applied Biosystems (Foster City, CA). We calculated 
relative mRNA expression values using the 2-ΔΔCt method with normalization of each 
sample ΔCt value to the average ΔCt value from the control mice. 
Statistics. 
Data are reported as mean +/- SEM. Statistical analysis of physiological data was 
performed with Prism software (version 7). Unpaired t-test was used to compare results 
between two groups. Body weight gain, cumulative food intake, body length, GTT and 







Figure 5.1: Salmon calcitonin-stimulated cfos-IR in LepRb, POMC and NPY 
neurons.   (A-B) Representative images showing colocalization of cfos-IR (purple) with 
GFP-IR (green) in LepReGFP mice treated with salmon calcitonin (sCT; 150ug/kg, i.p.) or 
PBS vehicle. (C-D) Representative images showing colocalization of cfos-IR (blue) with 
dsRed-IR (red) and GFP-IR (green) in POMCdsredNPYGFP mice. (E) Counts of cfos-IR in 
the arcuate nucleus (Total), those dual-labeled with dsred-IR (POMC), those dual-
labeled with GFP-IR (NPY), and those not colocalized with either (Other). Arrows 





Figure 5.2: Generation of CalcRcre and the lack of LepRb in CalcR expressing 
neurons. (A) Schematic diagram showing the cross of CalcRcre with R26-loxSTOPlox-
eGFP-L10a (Rosa26eGFP-L10a) mice to generate CalcReGFP mice and the cross of 
CalcRcre with LepRflox/flox mice to generate LepRCalcRKO mice. pA: polyadenylation 
signal. (B-C) Representative images showing colocalization of pSTAT3-IR (purple) with 
GFP-IR (green) in the arcuate nucleus of four-week-old CalcReGFP and LepRCalcRKO 
(both of which are on the Rosa26eGFP-L10a background) mice treated with leptin (5mg/kg, 
i.p.) for 90 minutes. Arrows indicate colocalized neurons. (D-E) The number of cells 





Figure 5.3: LepRCalcR neurons regulate energy balance. (A) Male LepRCalcRKO and 
CalcReGFP (littermate control) mice were placed on chow and body weight (A) measured 
weekly (****p<0.0001 by ANOVA), and crown-rump length (B) measured biweekly. At 
14-15 weeks of age, animals underwent body composition analysis (C-D) by NMR 
spectroscopy (***p<0.001; ****p<0.0001 by unpaired t-test). Serum from 10-week-old 
mice were assayed for leptin (E) (****p<0.0001 by unpaired t-test). Cumulative food 





Figure 5.4: Leptin acts on LepRCalcR neurons to regulate VO2 and locomotor 
activity. 9-11 week-old male CalcReGFP (n=12) and LepRCalcRKO (n=8) mice were 
subjected to CLAMS analysis to determine (A-B) VO2 normalized to total body mass, 
(C-D) VO2 adjusted to lean body mass, and (E-F) locomotor activity. Data are shown for 
dark cycle (Dark), light cycle (Light), 24 hours (Total), and the entire hour-by-hour 72-






Figure 5.5: Glycemic indices are unaffected by LepRCalcR neurons. (A) Biweekly 
blood glucose concentrations for male CalcReGFP (control) and LepRCalcRKO mice at 4-
12 weeks of age. (B) Serum insulin concentrations for 10-week-old mice (*p<0.05 by 
unpaired t-test). Mice at 12-14 weeks of age were treated with (C) glucose (2g/kg; i.p.) 












Figure 5.6: Gene expression and fold change in the hypothalamus of CalcReGFP 
and LepRCalcRKO mice. Translating ribosome affinity purification (TRAP) was 
performed on CalcReGFP (n=11) and LepRCalcRKO mice (n=16). Changes in transcript 
expression were assayed by RT-qPCR using ABI Taqman assays for the listed genes 
and for GAPDH as the control. Transcript expression in CalcR-expressing neurons and 
nonCalcR neurons in the hypothalamus was measured and (A) mean enrichment 
(Enrichment) with standard error (SEM) are detailed with enrichment values >1.5 
bolded. (B) Relative expression of genes are plotted for both genotypes (*p<0.05; 













Figure 5.7: Verification of CalcR-Cre mouse strain. Representative ISH images 
showing Calcr mRNA (green) and Cre mRNA (red) signal in the arcuate nucleus of 
wildtype (A) and CalcR-Cre (B) mice. A’ and B’ are more magnified images of the area 
indicated by the dotted rectangles in A and B. Blue is DAPI. Scale bar = 50 µm (A,B) 














Figure 5.8: Salmon calcitonin-stimulated cfos-IR in CalcReGFP mice. Representative 
images show colocalization of cfos-IR (purple) with GFP-IR (green) in CalcReGFP mice 















Figure 5.9: Conditional ablation of LepRb in CalcR neurons. Representative images 
showing colocalization of pSTAT3-IR (purple) with GFP-IR (green) in the dorsomedial 
hypothalamus (DMH), lateral hypothalamic area (LHA) and nucleus of the solitary tract 
(NTS) of four-week-old CalcReGFP and LepRCalcRKO (both of which are on the 
Rosa26eGFP-L10a background) mice treated with leptin (5mg/kg, i.p.) for 90 minutes. 





Figure 5.10: LepRCalcR neurons regulate energy balance (females). (A) Female 
LepRCalcRKO and CalcReGFP (littermate control) mice were placed on chow and body 
weight (A) was measured weekly (****p<0.0001 by ANOVA), and crown-rump length (B) 
was measured biweekly. At 14-15 weeks of age, animals underwent body composition 
analysis (C-D) by NMR spectroscopy (***p<0.001; ****p<0.0001 by unpaired t-test). 
Serum from 10-week-old mice were assayed for leptin (E) (****p<0.00001 by unpaired t-
test). Cumulative food intake (F) was measured weekly for mice at 4-12 weeks of age 





Figure 5.11: Glycemic indices are controlled by LepRCalcR neurons (females). (A) 
Biweekly blood glucose concentrations for female CalcReGFP (control) and LepRCalcRKO 
mice at 4-12 weeks of age. (B) Serum insulin concentrations for 10-week-old mice 
(**p<0.01 by unpaired t-test). Mice at 12-14 weeks of age were treated with (C) glucose 
(2g/kg; i.p.) or (D) insulin (1 U/kg; i.p.) and blood glucose concentrations were 
measured (*p<0.05 by ANOVA). (E) Area under the curve analysis was performed for 






Figure 5.12: Lack of colocalization between ARC CalcR and POMC neurons. 
Representative images from the ARC of CalcReGFP mice crossed with POMCdsred to 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Leptin and diet-induced obesity 
 Chapter 2 of this dissertation explores the transcriptional state of high-fat diet-
induced obesity (DIO) in leptin receptor (LepRb) neurons and compares it to conditions 
of leptin deficiency and leptin activity. Through the TRAP-seq approach, we are able to 
evaluate the relationships between seemingly similar (or dissimilar) conditions by 
examining the translatome of LepRb neurons in the hypothalamus of mice. This 
approach has revealed the similarity in the expected conditions of leptin deficient ob/ob 
mice and mice treated with leptin antagonist SMLA; however, a more surprising 
relationship was discovered between the seemingly disparate conditions of high-fat DIO 
and leptin-injected lean mice. Far from the postulated “leptin resistance” that occurs in 
diet-induced obesity, these data suggest that DIO is a leptin active state more similar to 
a 10-hour intraperitoneal injection of exogenous leptin than any other condition.  
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 Because “leptin resistance” is thought to mostly occur in the arcuate nucleus 
(ARC) of the hypothalamus,1 further clarification of the relationship between leptin 
treatment and DIO in the ARC was necessary. One advantage of the TRAP-seq 
technique is the ability to micro-dissect any area of interest and examine the 
transcriptional profile compared across various conditions. Thus, ARC-specific TRAP-
seq analysis reveals that DIO is indeed similar to 10-hour leptin treatment. This finding 
further confirms the finding that the hyperleptinemia in DIO does not denote “resistance” 
and inactivity of leptin; instead, it effectively decreases energy balance (to an extent).2  
But, this does not mean that leptin “resistance” is entirely incorrect in DIO. The 
ARC TRAP-seq analysis further reveals that DIO is more similar to leptin treated DIO 
mice than any other condition. Given the previous findings that exogenous leptin 
therapy is an ineffective weight-loss treatment in DIO, it is unsurprising that 
transcriptionally, the ARC remains unchanged with leptin injection on the background of 
DIO. What this may suggest, however, is that while the hyperleptinemia in DIO is 
euleptinemic (in proportion to the individual’s fat stores) and effective, further exposure 
to exogenous leptin treatment results in an ineffective level of additional leptin past that 
euleptinemic level. One potentially important avenue for further exploration is whether 
an individual’s euleptinemic level can be artificially manipulated. Indeed, if in the DIO 
setting, the euleptinemic level were reset to normoleptinemic levels (leptin levels 
expected of lean individuals), the excess endogenous leptin may be even more potent 
in exerting negative energy balance.3 Another possibility is that there is an innate ceiling 
of leptin action where additional leptin is ineffective. This warrants careful investigation, 
however, for obese individuals do not exponential gain weight—if there indeed is a firm 
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threshold of leptin action, then the endogenous leptin action of an obese individual 
(BMI=30kg/m2) should be similar to that of super obese individual (BMI=50kg/m2). While 
super obesity is not uncommon, the vast majority of overweight individuals do not 
proceed to super obesity despite their continued positive energy balance.4 A third 
possibility is that high-fat diet itself may have effects on energy homeostasis and short 
circuit LepRb neurons from responding appropriately to the hyperleptinemia and 
exogenous leptin. While a previous publication would argue against this,3 our 
understanding of this possibility is still lacking. Last, excess leptin action may 
overwhelm LepRb neurons such that they are constantly activated to the point of 
exhaustion. I will expound upon this last possibility later in this chapter. Regardless of 
what may truly be occurring, if leptin is the means by which our adipocytes 
communicate the status of our energy stores, understanding LepRb neurons and their 
response in various conditions is critical.  
A current area of investigation that ties in these possibilities is the finding of 
gliosis in the ARC of DIO animals.5 Our findings of gliosis under chronic leptin infusion 
(and lack there of in leptin deficient animals) suggest that the gliosis seen in DIO is a 
consequence of hyperleptinemia, rather than a marker (or driver) of obesity. This 
suggests that gliosis may serve as a useful surrogate of LepRb neuronal (over)activity. 
However, gliosis is also involved in inflammation and many reports have categorized 
DIO as a state of low-grade hypothalamic inflammation, perhaps as a consequence of 
the saturated fatty acids in the high-fat diets (HFD) consumed to cause DIO.6,7 The most 
provocative interpretation of gliosis (whose presence in the ARC precedes obesity in the 
body) causing obesity warrants further attention due to the paradigm-shifting nature of 
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this idea, if true.5 Experiments eliciting gliosis (through viral or optogenetic means) 
independent of body weight, inflammation state or fatty acid intake would help 
disentangle this hypothesis. Thus, the role of gliosis in the genesis of obesity is a 
complicated one and requires further investigation. 
We have used TRAP-seq to untangle some of these different metabolic 
phenomena by identifying and comparing the relative expression of genes responsive to 
leptin action, obesity, and inflammation. Furthermore, we have used sex-specific TRAP-
seq to understand the sex differences in DIO gliosis (i.e. the absence of gliosis in 
female DIO mice). Fractalkine has recently been implicated; however, while our sex-
specific TRAP-seq analysis does show a demonstrable difference in expression levels 
between male and female DIO animals, the absolute expression levels (FPKM) are 
extremely low and fractalkine was not significantly enriched in LepRb neurons for any of 
the conditions.8 Instead, our sex-specific experiments suggest that the gliosis difference 
may not contribute much to the activity of LepRb neurons. It is worth noting that much of 
our efforts here have focused exclusively on LepRb neurons and the transcriptional 
changes unique to that population. While we have analyzed transcriptional changes in 
non-LepRb cells, those analyses have not been cell-type specific. Therefore, to further 
elucidate the phenomena occurring, future investigators should identify the 
transcriptional changes of other cells involved in metabolism in the hypothalamus (e.g. 
microglia, astrocytes, tanycytes, etc). Moreover, given the cross-talk and interactive 
nature of glia, it is critical to investigate the relationships among cells. 
Leptin is, without a doubt, important in obesity. However, the heterogeneity of 
LepRb neurons and their interactions with neighboring cells complicate our 
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understanding of DIO. And, while our efforts to profile the transcriptional changes 
exclusively in LepRb neurons through TRAP-seq has reveals new insights in DIO, more 
needs to be done. LepRb neurons do not exist in a vacuum. They are constantly 
interacting, modifying and being modulated by neighboring (and not so neighboring) 
neurons, glia, and cells. Our analyses of the transcriptional changes in non-LepRb cells 
provide a gestalt that requires more detailed investigation. It is my hope that when the 
data here in this dissertation is combined with other sequencing data (microglial TRAP-
seq, single-cell sequencing, etc.), new hypotheses and interpretations will be generated 
and tested. Indeed, while our sex-specific LepRb and non-LepRb TRAP-seq data may 
be insufficient to understand the sex differences in DIO gliosis, a more complete 
depiction of how various cells respond to different conditions may inform our thinking of 
whether gliosis is a potential therapeutic target for obesity, or whether it is an artifact. 
STAT proteins in leptin action 
The work in Chapter 2 identified expected and novel gene patterns in LepRb 
neurons in a variety of metabolic insults; one of these unexpected findings is the 
transcriptional differences of leptin deficient ob/ob mice and STAT3 ablated mice. 
STAT3 is the major anorectic signal of leptin, and both ob/ob and STAT3LepRKO mice 
manifest hyperphagic obesity. Yet, their transcriptional profiles are quite dissimilar. 
Much of this dissimilarity is due to STAT1 compensation/upregulation (and the genes 
downstream of it) in STAT3-deficient mice. The TRAP-seq data, coupled with previous 
studies showing leptin activating STAT1 cell lines, implicates STAT1 as an important 
signal of leptin action. 
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 However, our finding that ablation of STAT1 in LepRb neurons does not result in 
obesity or phenotypically exacerbate the obesity in STAT3LepRKO mice partially rebukes 
the importance of the transcriptional analyses. This illustrates a limitation of TRAP-seq: 
the transcriptional patterns of neurons may change under various conditions, but it may 
not be functionally/phenotypically relevant. It is, therefore, unclear how to prioritize the 
changing gene patterns under the various conditions: whether by directionality, 
amplitude or number of genes. Despite this drawback, the extensive transcriptional data 
do provide novel targets to explore (even if many are red herrings) and perhaps with 
collaboration and new perspectives, new insights can be gleaned. 
 Additionally, if diet-induced obesity is a state of “leptin resistance”, the 
STAT3LepRKO model would most mimic it: it is hyperleptinemic, obese, and 
unresponsive to exogenous leptin injections. Despite the transcriptional dissimilarity 
between DIO and STAT3LepRKO mice under TRAP-seq, the TRAP-seq data does 
identify a number of STAT3 independent leptin signals elevated in DIO that may be 
responsible for the failure of exogenous leptin to promote weight loss in DIO. 
 The upregulation of STAT1 in tanycytes with its deletion from LepRb neurons 
and the ARC gliosis seen in STAT1LepRKO mice demonstrate the importance of 
understanding the interaction between neurons and glia. Metabolically, these mice are 
comparable to littermate controls; however, the brain does much more than regulate 
metabolism. The brain is the most complex organ and compared to other organs, we 
know relatively little. Given its complexity and the multitude of diseases that affect it, 
these negative metabolic findings and the available transcriptional data may be 
informative to other neuroscientists examining STAT proteins in different cell types. The 
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differential expression of STAT1 from different cells when it is deleted from one cell type 
underscores the importance of investigation into how various cells communicate and 
interact. Therefore, in addition to the cell-autonomous transcriptional regulation revealed 
through sequencing techniques, additional methods delineating how the differential 
expression of genes like STAT1 modulate and influence other cells in the CNS milieu 
should be pursued. 
Enhanced STAT3 and leptin action 
 Chapter 3 highlighted the necessity of STAT3 in metabolism; chapter 4 examines 
the sufficiency of STAT3 in leptin action. STAT3 mediates the majority of leptin’s 
anorexic action and immunohistochemical staining for pSTAT3 is regularly used as a 
proxy for leptin action. Using a constitutively active STAT3 (CASTAT3) mutant, we 
enhanced STAT3 action in LepRb neurons, causing decreased food intake and body 
weight. On the leptin deficient ob/ob background, LepRCASTAT3 normalized metabolic 
parameters; however, on high-fat diet (HFD), LepRCASTAT3 were similarly obese 
compared to littermate controls. Therefore, STAT3 signaling in LepRb neurons suffices 
to mediate part of physiologic leptin action in the absence of other leptin signals; 
however, enhanced STAT3 signaling is unable to suppress body weight in DIO. This is 
reminiscent of our findings where chronic leptin (leptin minipump) significantly 
decreased adiposity and body weight in lean animals and previous studies 
demonstrating exogenous leptin treatment’s ineffectiveness in diet-induced obese 
animals and patients. Again, the concept of “leptin resistance” arises where while lean 
normoleptinemic animals lose adiposity when their effective leptin action is increased 
(through minipumps or LepRCASTAT3), DIO animals, which are hyperleptinemic (though in 
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proportion to their elevated adiposity), do not lose weight when leptin action is increased 
(hence they are leptin “resistant”). Because LepRCASTAT3 and leptin are effective weight 
loss therapies for leptin deficient animals, it is not obesity that prohibits leptin sensitivity; 
rather, it must be, leptin, fatty acids or something else that is responsible for the 
difference in leptin therapy between DIO and ob/ob animals. Knight et. al. demonstrated 
that ob/ob mice clamped to different leptin levels and fed HFD are still responsive to 
leptin when going from a normoleptinemic (hypoleptinemic relative to fat stores) to a 
hyperleptinemic (euleptinemic relative to fat stores) state, suggesting that leptin action 
(at least from normoleptinemia to hyperleptinemia levels) is not curbed by HFD. Thus, 
endogenous leptin levels may determine the effectiveness of leptin therapy. 
 The immunohistochemical evidence for “leptin resistance” is the absence of an 
exogenous leptin-induced pSTAT3 response; however, it is worth noting that the 
baseline (not treated with exogenous leptin) levels of pSTAT3 are elevated in DIO 
animals compared to chow-fed controls. If DIO results from the absence of an 
appropriate elevation of pSTAT3 activity from the hyperleptinemia, an attractive therapy 
is to enhance STAT3 activity; however, our findings would argue that even with 
constitutive STAT3 activity, DIO persists to the same degree as DIO controls. The 
blockade to an acute anorectic response to exogenous leptin may, therefore, be 
downstream of STAT3 translocation. Further exploration into transcriptional outcomes of 
STAT3 in DIO may yield new insights into a feasible leptin therapy for DIO. 
A separate, but related, aspect of leptin resistance is the elevated endogenous 
pSTAT3-IR observed in DIO.1,2 While there is a preoccupation with DIO pSTAT3-IR not 
exactly mirroring the extent of expression in 1-hour leptin treated chow-fed animals, a 
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more apt comparison would be to compare DIO pSTAT3 expression at baseline with 
chronic (or 10-hour) leptin treatment. This comparison not only aligns 
immunohistochemically, but is also more similar transcriptome-wise when compared to 
a short-term leptin treatment (i.e. the 3-hour leptin treated condition). This shift of 
examining DIO as a condition of leptin resistance to one of constant leptin 
bombardment raises a few questions. The most prominent of which is whether leptin 
(over)activity is detrimental or beneficial. Clearly, endogenous leptin action in DIO has 
negative energy balance effects; however, the level of anorectic control falls short of our 
(perhaps unrealistic) expectations. To illustrate this, I cannot help but draw a 
comparison to neuronal membrane potentials. Leptin treatment in chow-fed animals 
elicits an impressive anorexia, much like how a depolarization event results in an 
exaggerated action potential. The excess of leptin action in DIO may then be analogous 
to a membrane potential that is unable to repolarize, where the leptin bombardment 
may still elicit smaller “graded potentials” but it is unable to continually induce large 
action potentials. This analogy may help explain the perplexing phenomenon of weight 
rebound after weight loss. The textbook 72kg man who has been the same weight for 
decades can eat significantly more than a similar 72kg man who just lost 80kg of 
weight, all else being equal. The normoleptinemic states of both these 72kg men cannot 
explain this disparity; additional studies examining whether the latter’s bombardment of 
leptin from his recent hyperleptinemia may be preventing his ability to mount 
exaggerated “action potential” level responses to leptin are necessary. This 
phenomenon of homeostatic systems responding to weight loss by mounting an 
anabolic response (increased food intake and decreased energy expenditure) often 
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results in rebound weight-gain. Interestingly, this phenomenon coincides with the 
continued existence of gliosis months after DIO mice have normalized their weights 
switching from a high-fat diet to a normal chow diet.9 So, if gliosis is a marker of LepRb 
neuronal activity, the gliosis, weight rebound and inability to mount “action potential” 
level responses to leptin could be manifestations of the same condition. Because LepRb 
neurons do recover/repolarize (at least in some individuals) and individuals who lose 
weight eventually do mostly normalize energy balance, weight gain in DIO appears 
reversible; additional research in this area would further our understanding of 
sustainable weight loss. 
The over-activity of LepRb neurons can itself drive gliosis in the area, which 
would explain why the ARC is the only area to experience the gliosis (it is adjacent to 
the median eminence and so constantly exposed to the elevated circulating leptin levels 
in hyperleptinemia). Interestingly, the absence of gliosis in other LepRb hypothalamic 
populations like the DMH or LHA correlates with the pSTAT3 responsiveness of those 
regions as well.1,5 The lack of a phenotypic response from exogenous leptin, instead of 
demonstrating leptin resistance, illustrates the importance of ARC LepRb neurons in 
mediating leptin’s anorectic effects. There has been some evidence suggesting that 
leptin exposure in the hypothalamus begins in the ARC and then spreads laterally into 
the rest of the hypothalamus. Indeed, an experiment that needs to be performed is one 
that clamps leptin levels to ever-increasing levels of hyperleptinemia and examines the 
gliosis and pSTAT3-IR response to exogenous leptin. This study would help determine 
if the ARC is unique or if other regions can also be made unresponsive and experience 
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gliosis. My expectation is that the level of hyperleptinemia in DIO is just enough to 
induce leptin over-activity in the ARC (and not in other regions).  
Furthermore, the absence of gliosis in females may be due to the exclusively 
female experience of pregnancy. During pregnancy, adiposity and leptin levels increase 
significantly and from a teleological perspective, it would follow that females have an 
imbedded capacity and expectation to experience fluctuations in adiposity and leptin 
levels. An interesting study that should be performed is the examination of whether 
female DIO animals experience rebound weight-gain to the same extent as their male 
counterparts. The sex differences observed may be the perfect lens by which to link 
endogenous leptin inactivity, gliosis, and rebound weight-gain together. 
If this recovery period (i.e. repolarization of LepRb neurons) were shortened and 
rebound weight gain were eliminated, the tide of the battle against obesity may finally 
turn. Then, the cure to obesity would not lie in identifying new weight loss drugs, for we 
have very effective therapies already in diet and exercise; rather, it may be in the 
pharmacologic targeting of LepRb neurons to allow individuals to sustain their weight 
loss. Thus, the exploration and use of leptin and LepRb antagonists like SMLA may 
reveal the development of an approachable regimen to effectively combating obesity. 
LepRb- and CalcR-expressing neurons 
Whereas the previous Chapters 2-4 focus exclusively on leptin signaling, Chapter 
5 examines the existence of hypothalamic neurons that express both LepRb and 
calcitonin receptor (CalcR). Not only is CalcR the cognate receptor for salmon calcitonin 
(sCT), a potent anorectic agent, but it is also the receptor for amylin, a hormone that 
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promotes satiety. Additionally, many previous studies have demonstrated effective 
synergistic weight loss in DIO humans and rodents with dual therapy of leptin and 
amylin; therefore, the identification of the locations and molecular interactions between 
leptin and amylin may uncover the mechanisms responsible for a proven treatment to 
DIO.10–12 Our data reveal the significance of LepRb neurons on energy balance that 
also express CalcR, which supports the possibility of these LepRb- and CalcR-
expressing neurons as the site of synergistic weight loss. The complimentary set of 
experiments that need to be performed is the deletion of CalcR in LepRb neurons; if 
leptin-amylin dual therapy on CalcRLepRKO DIO mice is ineffective compared to DIO 
controls, then these hypothalamic LepRb- and CalcR-expressing neurons may indeed 
be the location of the synergy. 
Understanding the molecular underpinnings of leptin-amylin synergistic weight 
loss would identify pharmacological targets that could treat DIO. To accomplish this 
feat, multiple recombinase systems (i.e. LepRb- FLP/FRT and CalcR- cre/lox) should be 
combined with a FLP- and cre-dependent eGFP-L10a element that would enable 
TRAP-seq of neurons that only express both LepRb and CalcR. Characterizing the 
transcriptome of these neurons under the conditions of DIO and DIO treated with leptin 
and/or amylin would produce a target list of genes and molecular mechanisms that may 
be responsible for the synergistic weight loss demonstrated.  
The other avenue worth investigating is the finding that sCT activates CalcR 
neurons that also express NPY, AgRP and GABA (NAG neurons), which are known to 
drive positive energy balance. This is surprising because sCT is a potent satiety drug. 
Therefore, a deeper understanding and investigation of sCT-driven NAG neuronal 
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activation would have implication on energy homeostasis, regardless of the outcome. 
These possible outcomes are: 1. hunger, 2. satiety, or 3. no observable metabolic 
effect. If sCT-dependent NAG activity results in hunger, then the overall satiety 
experienced with sCT therapy could be amplified by silencing NAG neurons or directing 
the sCT activity only to non-NAG neuronal sites (presumably in the hindbrain). If, 
however, NAG neurons cause satiety, the current understanding of NAG neurons 
exclusively driving hunger would need re-evaluation. Finally, if there is no observed 
metabolic impact, this may provide a system to study the negative valence of NAG 
neurons uncoupled from hunger.13 Clearly, these questions need to be answered with 
viral, DREADD, optogenetic and localized injection approaches. 
The continued characterization of the many homeostatic systems responsible for 
energy balance and leptin’s roles in them is the next step in understanding the 
neurobiology of obesity. For me, this has demonstrated the hidden synergy in multiple 
complementary systems, whose investigation may reveal an approachable 
pharmaceutical cure to obesity. 
Conclusions 
 Twenty years ago, leptin fell short of expectations as the cure to all obesity. 
Since then, a deeper and more nuanced understanding of the neuroendocrine 
regulation of obesity and leptin has developed. Innovations in deep sequencing 
technologies have begun to reveal the transcriptome of cells responsive to leptin, and 
ongoing efforts to identify how cells communicate with one another in response to leptin 
and other metabolic insults are developing. Many exciting findings (like the synergistic 
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weight loss with amylin-leptin therapy) provide new evidence that leptin signaling may 
hold the key after all to curing obesity even if the mechanisms remain opaque. 
Moreover, the advent and utilization of new technologies have afforded researchers the 
opportunity to test hypotheses and to further the understanding of the field. There has, 
therefore, never been a more exciting time to investigate the nuances of leptin action. 
 The data and chapters presented in this dissertation represent only a portion of 
the many and varied approaches investigators can take in solving the mystery of 
obesity. The 21st century in research has been marked with the importance of genes; 
consequently, genetic techniques have been instrumental tools in the investigation of 
obesity. In line with this, much of the data detailed in this dissertation revolves around 
transcriptional analyses and the role LepRb-expressing neurons play in these various 
metabolic conditions. Our use of these genetic techniques have allowed us to better 
characterize diet-induced obesity as a state of leptin over-activity (instead of one of 
leptin deficiency/resistance). Additionally, the identification and investigation of novel 
genes like calcitonin receptor (CalcR) in leptin action have begun to complete our 
understanding of previously discovered interactions between leptin and amylin that may 
hold the key to treating diet-induced obesity. Furthermore, the finding that STAT3 is 
sufficient to mediate leptin action is thanks to the genetic manipulations that allow many 
of these hypotheses to be tested. 
 Despite these findings, it is clear that these genetic data need to be anchored to 
physiological studies and examined carefully. The importance of the transcriptional data 
generated in Chapter 2 cannot be understated; however, it also highlights the 
importance of examining other cell types like glia. The interactions among cells in the 
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CNS milieu are necessary to contextualize the transcriptional findings from sequencing 
techniques. The interaction between neurons and glia is exemplified in Chapter 3, which 
additionally provides a cautionary tale of relying too heavily on transcriptional analyses. 
Therefore, while genetic techniques are extraordinary powerful, they are insufficient to 
fully inform our understanding of physiology. 
 Research has become increasingly collaborative. This has been necessary with 
the explosion of technologies and our ever-increasing complex understanding of the 
natural world. Additionally, the sharing of data and expertise has allowed for the rapid 
progress in all fields. One of the many valuable lesson I will take with me is the 
importance of the re-examination and re-interpretation of previous data contextualized 
to the ever-evolving understanding of the field. I hope that the data generated in this 
dissertation will help inform and guide investigators in their research to improve the 
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